 AGREEMENT AND PLAN OF MERGER       

Exhibit 10.1

 



 

 



  

 

 

AGREEMENT AND PLAN OF MERGER 

 

 

 

BY AND AMONG 

 

 

 

ENDO PHARMACEUTICALS HOLDINGS INC.

 

 

BTB PURCHASER INC.

 

 

AND

 

 

INDEVUS PHARMACEUTICALS, INC.

 



 

 

 

DATED AS OF JANUARY 5, 2009

 

 

 



 

   

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 



 

TABLE OF CONTENTS

 

 

 

          |     |  

PAGE

    
---|---|--- 
        |     |     
        |  

ARTICLE  I

 

 

THE  OFFER

    |     
        |     |     
     

Section  1.1

    |  

The  Offer

    |  

2

    
     

Section  1.2

    |  

Company  Actions.

    |  

5

    
     

Section  1.3

    |  

Directors.

    |  

6

    
     

Section  1.4

    |  

Top-Up  Option.

    |  

7

    
        |     |     
        |  

ARTICLE  II

 

 

THE  MERGER

    |     
        |     |     
     

Section  2.1

    |  

The  Merger

    |  

8

    
     

Section  2.2

    |  

Closing;  Effective Time

    |  

8

    
     

Section  2.3

    |  

Effect  of the Merger

    |  

9

    
     

Section  2.4

    |  

Organizational  Documents of the Surviving Corporation

    |  

9

    
     

Section  2.5

    |  

Directors  and Officers of the Surviving Corporation

    |  

9

    
        |     |     
        |  

ARTICLE  III

 

 

EFFECTS  OF THE MERGER;

 

EXCHANGE  OF CERTIFICATES

    |     
        |     |     
     

Section  3.1

    |  

Effect  on Capital Stock

    |  

9

    
     

Section  3.2

    |  

Exchange  of Shares and Certificates

    |  

12

    
     

Section  3.3

    |  

Dissenting  Shares

    |  

14

    
     

Section  3.4

    |  

Nebido  CCP Escrow

    |  

14

    
        |     |     
        |  

ARTICLE  IV

 

REPRESENTATIONS  AND WARRANTIES OF COMPANY

    |     
        |     |     
     

Section  4.1

    |  

Organization,  Standing and Corporate Power

    |  

15

    
     

Section  4.2

    |  

Capitalization

    |  

16

    
     

Section  4.3

    |  

Authority

    |  

17

    
     

Section  4.4

    |  

No  Conflict

    |  

18

    
     

Section  4.5

    |  

Required  Filings and Consents

    |  

19

    
     

Section  4.6

    |  

Compliance;  Regulatory Compliance

    |  

19

    
     

Section  4.7

    |  

SEC  Filings; Financial Statements

    |  

20

    
     

Section  4.8

    |  

Absence  of Certain Changes or Events

    |  

22

    
     

Section  4.9

    |  

FDA  and Related Matters

    |  

23

    
     

Section  4.10

    |  

Taxes

    |  

25

    
     

Section  4.11

    |  

Change  of Control Arrangements; No Excess Parachute Payment

    |  

26

    
   

 

 

 

 

 

 

 

 

 

 

 

i  

 

 

 

 

 

 

 

 

 

       

Section  4.12

    |  

Litigation

    |  

27

    
---|---|--- 
     

Section  4.13

    |  

Material  Contracts

    |  

28

    
     

Section  4.14

    |  

Employee  Benefit Plans

    |  

31

    
     

Section  4.15

    |  

Labor  and Employment Matters

    |  

33

    
     

Section  4.16

    |  

Environmental  Matters

    |  

34

    
     

Section  4.17

    |  

Intellectual  Property

    |  

35

    
     

Section  4.18

    |  

Stockholders\'  Rights Agreement

    |  

38

    
     

Section  4.19

    |  

Brokers;  Schedule of Fees and Expenses

    |  

38

    
     

Section  4.20

    |  

Insurance

    |  

38

    
        |     |     
        |  

ARTICLE  V

 

REPRESENTATIONS  AND WARRANTIES

 

OF  PARENT AND MERGER SUB

    |     
        |     |     
     

Section  5.1

    |  

Organization  and Good Standing

    |  

39

    
     

Section  5.2

    |  

Authority

    |  

39

    
     

Section  5.3

    |  

No  Conflict

    |  

40

    
     

Section  5.4

    |  

Required  Filings and Consents

    |  

40

    
     

Section  5.5

    |  

Compliance;  Regulatory Compliance

    |  

40

    
     

Section  5.6

    |  

SEC  Filings; Financial Statements

    |  

41

    
     

Section  5.7

    |  

Absence  of Certain Changes or Events

    |  

42

    
     

Section  5.8

    |  

Litigation

    |  

42

    
     

Section  5.9

    |  

Financing

    |  

42

    
     

Section  5.10

    |  

Brokers

    |  

42

    
        |     |     
        |  

ARTICLE  VI

 

COVENANTS

    |     
        |     |     
     

Section  6.1

    |  

Conduct  of Company\'s Business Pending the Merger

    |  

42

    
     

Section  6.2

    |  

Access  to Information; Confidentiality

    |  

46

    
     

Section  6.3

    |  

Notification  of Certain Matters; Regulatory Communications

    |  

47

    
     

Section  6.4

    |  

Antitrust  Filings; Reasonable Best Efforts

    |  

47

    
     

Section  6.5

    |  

No  Solicitation; Company Board Recommendation

    |  

49

    
     

Section  6.6

    |  

Stockholder  Litigation

    |  

51

    
     

Section  6.7

    |  

Indemnification;  Director and Officer Insurance

    |  

51

    
     

Section  6.8

    |  

Public  Announcements

    |  

52

    
     

Section  6.9

    |  

Preparation  of SEC Documents; Stockholders\' Meeting

    |  

52

    
     

Section  6.10

    |  

Employees

    |  

53

    
     

Section  6.11

    |  

Rule  16b-3

    |  

55

    
     

Section  6.12

    |  

Development  Drugs

    |  

56

    
     

Section  6.13

    |  

State  Takeover Laws

    |  

56

    
     

Section  6.14

    |  

Contingent  Stock Rights

    |  

56

    
     

Section  6.15

    |  

Voting  of Shares

    |  

57

    
     

Section  6.16

    |  

Conduct  of Business by Parent and Merger Sub Pending the Merger

    |  

57

    
     

Section  6.17

    |  

No  Control of Other Party\'s Business

    |  

57

    
        |     |     
   

 

 

 

 

 

 

 

 

 

 

ii  

 

 

 

 

 

 

 

 

 

          |  

ARTICLE  VII

 

CONDITIONS

    |     
---|---|--- 
        |     |     
     

Section  7.1

    |  

Conditions  to the Obligation of Each Party

    |  

57

    
     

Section  7.2

    |  

Failure  of Conditions

    |  

58

    
        |     |     
        |  

ARTICLE  VIII

 

TERMINATION,  AMENDMENT AND WAIVER

    |     
        |     |     
     

Section  8.1

    |  

Termination

    |  

58

    
     

Section  8.2

    |  

Effect  of Termination

    |  

60

    
     

Section  8.3

    |  

Amendments

    |  

61

    
     

Section  8.4

    |  

Waiver

    |  

62

    
        |     |     
        |  

ARTICLE  IX

 

GENERAL  PROVISIONS

    |     
        |     |     
     

Section  9.1

    |  

Nonsurvival  of Representations and Warranties

    |  

62

    
     

Section  9.2

    |  

Notices

    |  

62

    
     

Section  9.3

    |  

Interpretation

    |  

63

    
     

Section  9.4

    |  

Counterparts

    |  

63

    
     

Section  9.5

    |  

Entire  Agreement; No Third-Party Beneficiaries

    |  

63

    
     

Section  9.6

    |  

Governing  Law

    |  

64

    
     

Section  9.7

    |  

Assignment

    |  

64

    
     

Section  9.8

    |  

Consent  to Jurisdiction

    |  

64

    
     

Section  9.9

    |  

Headings,  etc.

    |  

64

    
     

Section  9.10

    |  

Severability

    |  

64

    
     

Section  9.11

    |  

Failure  or Indulgence Not Waiver; Remedies Cumulative

    |  

64

    
     

Section  9.12

    |  

Waiver  of Jury Trial

    |  

64

    
     

Section  9.13

    |  

Specific  Performance

    |  

65

    
     

Section  9.14

    |  

Certain  Definitions

    |  

65

    
   

 

 

 

 



 



 

EXHIBIT A \--  Conditions of the Offer

 

EXHIBIT B \-- Form of Nebido Contingent Cash Consideration Agreement

 

EXHIBIT C \-- Form of Octreotide Contingent Cash Consideration Agreement

 

 

 



 

 

 

 

 

 

 

iii  

 

 

 

 

 

 

 

INDEX OF DEFINED TERMS

 

 



 

       

2008  ESPP

    |  

10

    
---|--- 
     

409A  Authorities

    |  

32

    
     

Affiliate

    |  

68

    
     

Agreement

    |  

1

    
     

Associate

    |  

68

    
     

CERCLA

    |  

34

    
     

Certificate  of Merger

    |  

8

    
     

Certificates

    |  

12

    
     

Cleanup

    |  

64

    
     

Closing

    |  

8

    
     

Closing  Date

    |  

8

    
     

Code

    |  

4

    
     

Commonly  Controlled Entity

    |  

30

    
     

Company

    |  

1

    
     

Company  Adverse Recommendation Change

    |  

49

    
     

Company  Benefit Agreements

    |  

31

    
     

Company  Benefit Plans

    |  

31

    
     

Company  Board

    |  

1

    
     

Company  Bylaws

    |  

15

    
     

Company  Certificate of Incorporation

    |  

15

    
     

Company  Common Stock

    |  

1

    
     

Company  Disclosure Letter

    |  

14

    
     

Company  Filed SEC Report

    |  

20

    
     

Company  Financial Statements

    |  

20

    
     

Company  IP

    |  

64

    
     

Company  Licensed IP

    |  

64

    
     

Company  Material Adverse Effect

    |  

69

    
     

Company  Material Contract

    |  

27

    
     

Company  Notice of Adverse Recommendation

    |  

50

    
     

Company  Option

    |  

16

    
     

Company  Organizational Documents

    |  

15

    
     

Company  Owned IP

    |  

64

    
     

Company  Participant

    |  

26

    
     

Company  Partner

    |  

23

    
     

Company  Pension Plan

    |  

30

    
     

Company  Pension Plans

    |  

30

    
     

Company  Permits

    |  

20

    
     

Company  Preferred Stock

    |  

15

    
     

Company  SEC Reports

    |  

20

    
     

Company  Stock Plans

    |  

16

    
     

Company  Stock Rights

    |  

16

    
     

Company  Stockholder Approval

    |  

17

    
     

Company  Stockholders\' Meeting

    |  

52

    
     

Company  Subsidiaries

    |  

17

    
     

Company  Subsidiary

    |  

17

    
   

 

 

 

 

 

 

 

 

 

 

iv  

 

 

 

 

 

 

 

 

 

       

Company  Takeover Proposal

    |  

49

    
---|--- 
     

Company  Termination Fee

    |  

60

    
     

Company  Welfare Plan

    |  

30

    
     

Company  Welfare Plans

    |  

30

    
     

Competition  Laws

    |  

47

    
     

Confidentiality  Agreement

    |  

45

    
    Contingent  Cash Consideration Agreements   | 65  
     

Contingent  Cash Consideration Payments

    |  

65

    
     

Contract

    |  

65

    
     

Core  Product

    |  

65

    
     

Covered  Employees

    |  

53

    
     

DandO  Insurance

    |  

51

    
     

DGCL

    |  

1

    
     

Dissenting  Shares

    |  

14

    
     

Effective  Time

    |  

8

    
     

EMEA

    |  

19

    
     

Environmental  Laws

    |  

65

    
     

Environmental  Permits

    |  

65

    
     

ERISA

    |  

30

    
     

Exchange  Act

    |  

2

    
     

Exchange  Agent

    |  

12

    
     

Exchange  Fund

    |  

12

    
     

FDA

    |  

19

    
     

FDCA

    |  

20

    
     

FIRPTA  Certificate

    |  

65

    
     

GAAP

    |  

20

    
     

Good  Clinical Practices

    |  

65

    
     

Good  Laboratory Practices

    |  

66

    
     

Good  Manufacturing Practices

    |  

66

    
     

Governmental  Entity

    |  

19

    
     

Hazardous  Substances

    |  

66

    
     

HSR  Act

    |  

3

    
     

Hydron  Impeding Event

    |  

66

    
     

Hydron  Technology

    |  

66

    
     

IND

    |  

66

    
     

Independent  Directors

    |  

6

    
     

Intellectual  Property

    |  

67

    
     

IP  Contract

    |  

35

    
     

Judgments

    |  

57

    
     

known  to Company

    |  

69

    
     

known  to Parent

    |  

70

    
     

Law

    |  

18

    
     

Liability

    |  

21

    
     

Liens

    |  

17

    
     

Litigation

    |  

27

    
     

Merger

    |  

1

    
     

Merger  Consideration

    |  

9

    
   

 

 

 



 

 

 

 

 

 

 

v  

 

 

 

 

 

 



 

 

 

 

 

 

       

Merger  Sub

    |  

1

    
---|--- 
    Merger  Sub Common Stock  | 9  
     

Nasdaq

    |  

3

    
     

NDA

    |  

67

    
     

Nebido

    |  

67

    
     

Nebido  Contingent Cash Consideration Agreement

    |  

67

    
     

Nebido  Contingent Cash Consideration Payment

    |  

69

    
     

Nebido  Transition Team

    |  

53

    
    Nebido  Transition Team Employment Period  | 53  
     

New  Plan

    |  

54

    
     

Nonqualified  Deferred Compensation Plan

    |  

32

    
     

Octreotide

    |  

67

    
     

Octreotide  Contingent Cash Consideration Agreement

    |  

67

    
     

Octreotide  Contingent Cash Consideration Payment

    |  

67

    
     

Octreotide  Contingent Stock Rights Agreement

    |  

56

    
     

Offer

    |  

1

    
     

Offer  Closing

    |  

3

    
     

Offer  Closing Date

    |  

3

    
     

Offer  Conditions

    |  

2

    
     

Offer  Documents

    |  

4

    
     

Offer  Price

    |  

1

    
     

Order

    |  

18

    
     

Outside  Date

    |  

58

    
     

Parent

    |  

1

    
     

Parent  Filed SEC Report

    |  

40

    
     

Parent  Financial Statements

    |  

42

    
     

Parent  Material Adverse Effect

    |  

71

    
     

Parent  SEC Reports

    |  

42

    
    Paying  Agent   | 4  
    Per  Share Paid Value  | 68  
    Performance  Share Award  | 10  
     

Person

    |  

68

    
     

Primary  Company Executives

    |  

27

    
     

Product  IP

    |  

68

    
     

Products

    |  

68

    
     

Products  Contract

    |  

29

    
     

Proxy  Statement

    |  

52

    
     

Regulatory  Authority

    |  

19

    
     

Regulatory  Authorizations

    |  

68

    
     

Release

    |  

68

    
     

Representatives

    |  

68

    
     

Requisite  Short-Form Merger Shares

    |  

7

    
     

Sarbanes-Oxley  Act

    |  

20

    
     

Schedule  14D-9

    |  

5

    
     

Schedule  TO

    |  

4

    
     

SEC

    |  

3

    
     

Securities  Act

    |  

7

    
     

Stent  Contingent Stock Rights Agreement

    |  

55

    
     

Stockholder  Tender Agreements

    |  

2

    
     

Subsidiary

    |  

68

    
     

Superior  Proposal

    |  

49

    
   

 

 

 

 

 

 



 



 

 

 

 

 

 

 

vi  

 

 

 

 

 

 



 

 

       

Supprelin

    |  

68

    
---|--- 
     

Surviving  Corporation

    |  

8

    
     

Takeover  Statute

    |  

5

    
     

Tax  Return

    |  

26

    
     

Taxes

    |  

26

    
     

to  the knowledge of Parent

    |  

70

    
     

to  the knowledge of the Company

    |  

69

    
     

Top-Up  Option

    |  

7

    
     

Top-Up  Shares

    |  

7

    
     

Transaction  Agreements

    |  

2

    
     

Transition  Committee

    |  

46

    
     

Transition  Plan

    |  

46

    
     

Uncertificated  Shares

    |  

12

    
    Valuation  Point  | 68  
     

WARN  Act

    |  

54

    
   

 

 



 



 

 

 

 

 

 

 

vii  

 

 

 

 

 

 

 

 

 

AGREEMENT AND PLAN OF MERGER

 

 

THIS AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of January 5,
2009, is by and among Endo Pharmaceuticals Holdings Inc., a Delaware
corporation ("Parent"), BTB Purchaser Inc., a Delaware corporation and a
direct, wholly-owned Subsidiary of Parent ("Merger Sub"), and Indevus
Pharmaceuticals, Inc., a Delaware corporation (the "Company").

 

 

W I T N E S S E T H:

 

 

WHEREAS, Parent desires to acquire the Company on the terms and subject to
the conditions set forth in this Agreement;

 



 

WHEREAS in furtherance of the acquisition of the Company by Parent, Parent
proposes to cause Merger Sub to commence an offer (as it may be amended from
time to time as permitted under this Agreement, the \'\'Offer\'\') to
purchase all of the outstanding shares of common stock, par value $0.001
per share, of the Company ("Company Common Stock ") at a price per share of
Company Common Stock of (1) $4.50, net to the seller in cash, without
interest, (2) the contractual right to receive one or more Nebido Contingent
Cash Consideration Payments (as defined in Section 9.14(v)) and (3) the
contractual right to receive an Octreotide Contingent Cash Consideration
Payment (as defined in Section 9.14(x)) (the aggregate consideration referred
to in (1), (2) and (3), or any other consideration per share paid pursuant to
the Offer, the ("Offer Price"), upon the terms and subject to the conditions
set forth in this Agreement;

 



 

WHEREAS it is proposed that, on the terms and subject to the conditions set
forth in this Agreement, following the consummation of the Offer, Merger Sub
shall, in accordance with the General Corporation Law of the State of
Delaware (the "DGCL"), merge with and into the Company (the
"Merger"), pursuant to which each share of Company Common Stock, other than
(i) shares of Company Common Stock directly or indirectly owned by Parent,
Merger Sub or the Company and (ii) Dissenting Shares (as defined in Section
3.3), will be converted into the right to receive the Merger Consideration
(as defined in Section 3.1(a));

 



 

WHEREAS the board of directors of the Company (the "Company Board") has
unanimously (i) determined that the Offer, the Merger, this Agreement and the
other transactions contemplated hereby are advisable, fair to and in the best
interests of the stockholders of the Company, (ii) adopted and approved this
Agreement and determined the transactions contemplated hereby, including the
Offer and the Merger, are advisable, fair to and in the best interest of the
stockholders of the Company and (iii) resolved to recommend acceptance of the
Offer and, if required, approval of the Merger by its stockholders;

 

 

WHEREAS, the Board of Directors of Merger Sub has approved and declared it
advisable for Merger Sub to enter into this Agreement providing for the Offer
and the Merger, upon the terms and subject to the conditions set forth
herein;

 

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

WHEREAS, the Board of Directors of Parent has approved this Agreement, the
Offer and the Merger and Parent, in its capacity as the sole stockholder of
Merger Sub, has approved this Agreement, the Offer and the Merger upon the
terms and subject to the conditions set forth herein;

 

 

WHEREAS, concurrently with the execution and delivery of this Agreement,
Parent and Merger Sub have entered into an agreement with each of Glenn L.
Cooper, M.D., Michael W. Rogers, Noah D. Beerman, Mark S. Butler, Bobby W.
Sandage, Jr. Ph.D, Malcolm Morville, Ph.D, and Sanders Morris Harris,
pursuant to which each of them has irrevocably agreed to tender the shares of
Company Common Stock beneficially owned by such executive officer or director
in the Offer (constituting, in the aggregate, approximately 4.7% of the
outstanding shares of Company Common Stock (collectively, the
"Stockholder Tender Agreements,") and together with (i) the Nebido Contingent
Cash Consideration Payment Agreement and the Octreotide Contingent Cash
Consideration Agreement and (ii) this Agreement, collectively referred to as
the "Transaction Agreements");

 

 

NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements contained in this
Agreement and intending to be legally bound hereby, the parties hereto agree
as follows:

 

 

ARTICLE I

 

 

THE OFFER

 

 

Section 1.1 The Offer.

 

 

(a) Subject to the conditions of this Agreement, as promptly as practicable
(but in no event later than five business days) after the date of
this Agreement, Merger Sub shall, and Parent shall cause Merger Sub to,
commence, within the meaning of Rule 14d-2 under the Securities Exchange Act
of 1934, as amended (together with the rules and regulations promulgated
thereunder, the "Exchange Act"), the Offer to purchase all of the
outstanding shares of Company Common Stock; provided, that the Company agrees
that no shares of Company Common Stock owned by the Company or any Company
Subsidiary will be tendered pursuant to the Offer. The obligations of Merger
Sub to, and of Parent to cause Merger Sub to, accept for payment, and pay
for, any shares of Company Common Stock tendered pursuant to the Offer are
subject only to the conditions set forth in Exhibit A (as they may be amended
in accordance with this Agreement, the "Offer Conditions").

 

 

(i) The initial expiration date of the Offer shall be midnight, New York City
time, on the 45th calendar day following the commencement of the
Offer (determined pursuant to Rule 14d-1(g)(3) under the Exchange Act).
Merger Sub expressly reserves the right, at any time, to, in its
sole discretion, waive, in whole or in part, any Offer Condition or modify
the terms of the Offer; provided, however, that, without the prior written
consent of the Company, Merger Sub shall not (i) reduce the number of shares
of Company Common Stock subject to the Offer, (ii) reduce the Offer Price or
change the form of consideration payable in the Offer, (iii) change,
modify or waive the Minimum Tender Condition (as defined in Exhibit A), (iv)
add to the Offer Conditions, or (v) otherwise amend the Offer in any manner
adverse to the holders of Company Common Stock.

 

 

 

 

 

 

 

 

 

2  

 

 

 

 

 

 

 

 

(ii) Notwithstanding anything in this Agreement to the contrary, and without
limiting Parent\'s or Merger Sub\'s obligations under this
Section 1.1(a)(ii), Merger Sub (A) may, in its sole discretion, without
consent of the Company, extend the Offer on one or more occasions for any
period, if on any then-scheduled expiration date of the Offer any of the
Offer Conditions shall not be satisfied or, in Merger Sub\'s sole discretion,
waived, until such time as such condition or conditions are satisfied or
waived and (B) shall extend the Offer for any period required by any rule,
regulation, interpretation or position of the United States Securities and
Exchange Commission (the "SEC"), the staff thereof or the Nasdaq Stock Market
(the "Nasdaq") applicable to the Offer, and until any waiting period (and
any extension thereof) applicable to the consummation of the Offer under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the
"HSR Act") and any other applicable foreign antitrust, competition
or similar Law shall have expired or been terminated; provided, however, that
in no event shall Merger Sub be required to extend the Offer (1) beyond the
Outside Date (as defined in Section 8.1(b)(i)) or (2) at any time that Parent
or Merger Sub is permitted to terminate this Agreement pursuant to ARTICLE
VIII.

 

 

(iii) Parent and Merger Sub agree that if on any scheduled expiration date of
the Offer, the Minimum Tender Condition is not satisfied but all of the other
Offer Conditions set forth in Exhibit A are satisfied or, in Merger Sub\'s
sole discretion, waived, then Merger Sub shall, and Parent shall
cause Merger Sub to, extend the Offer for a ten calendar day period;
provided, however, that this provision shall not require Merger Sub to extend
the expiration of the Offer more than one time, and in no event shall Merger
Sub be required to extend the Offer (1) beyond the Outside Date or (2) at any
time that Parent or Merger Sub is permitted to terminate this Agreement
pursuant to ARTICLE VIII.

 

 

(iv) On the terms and subject to the conditions of this Agreement, Merger Sub
shall, and Parent shall cause Merger Sub to, accept and pay for (subject
to any withholding of tax pursuant to Section 1.1(d)) all shares of Company
Common Stock validly tendered and not validly withdrawn pursuant to the Offer
as soon as practicable after the expiration date of the Offer (as it may be
extended and re-extended in accordance with this Section 1.1(a)). Acceptance
for payment of shares of Company Common Stock pursuant to and subject to the
conditions of the Offer upon the expiration of the Offer is referred to in
this Agreement as the "Offer Closing", and the date on which the
Offer Closing occurs is referred to in this Agreement as the "Offer Closing
Date". Merger Sub expressly reserves the right to, in its sole discretion,
following the Offer Closing, extend the Offer for a "subsequent offering
period" in accordance with Rule 14d-11 under the Exchange Act, and the Offer
Documents (as defined below) may, in Merger Sub\'s sole discretion, provide
for such a reservation of right. Nothing contained in this Section 1.1(a)
shall affect any termination rights in ARTICLE VIII.

 

 

 

 

 

 

 

 

 

3  

 

 

 

 

 

 

 

 

(b) On the date of commencement of the Offer, Parent and Merger Sub shall
file with the SEC a Tender Offer Statement on Schedule TO with respect to
the Offer (together with all amendments and supplements thereto and
including exhibits thereto, the "Schedule TO"), which shall contain an offer
to purchase and a related letter of transmittal and summary advertisement and
other appropriate ancillary offer documents (such Schedule TO and the
documents included therein pursuant to which the Offer will be made, together
with any supplements or amendments thereto, the "Offer Documents"), and cause
the Offer Documents to be disseminated to the stockholders of the Company as
and to the extent required by Federal securities laws. Each of Parent, Merger
Sub and the Company shall promptly correct any information supplied by it for
inclusion or incorporation by reference in the Offer Documents if and to the
extent that such information shall have become false or misleading in any
material respect, and each of Parent and Merger Sub shall take all steps
necessary to amend or supplement the Offer Documents and to cause the Offer
Documents as so amended or supplemented to be filed with the SEC and
disseminated to the stockholders of the Company, in each case as soon as
reasonably practicable and as and to the extent required by
applicable Federal securities laws. Parent and Merger Sub shall promptly
notify the Company upon the receipt of any comments from the SEC, or any
request from the SEC for amendments or supplements, to the Offer Documents,
and shall promptly provide the Company with copies of all correspondence and
summaries of all material oral communications between them and their
representatives, on the one hand, and the SEC, on the other hand. Prior to
the filing of the Offer Documents (including any amendment or supplement
thereto) with the SEC or dissemination thereof to the stockholders of the
Company, or responding to any comments of the SEC with respect to the Offer
Documents, Parent and Merger Sub shall provide the Company and its counsel a
reasonable opportunity to review and comment on such Offer Documents or
response, and Parent and Merger Sub shall give reasonable consideration
to any such comments. In the event that Parent or Merger Sub receives any
comments from the SEC or its staff with respect to the Offer Documents, each
shall use its reasonable best efforts to (i) respond promptly to
such comments and (ii) take all other actions necessary to resolve the issues
raised therein.

 

 

(c) Parent shall provide or cause to be provided to Merger Sub on a timely
basis the consideration necessary to pay for any shares of Company
Common Stock that Merger Sub becomes obligated to accept for payment, and
pay for, pursuant to the Offer and shall cause Merger Sub to fulfill all of
Merger Sub\'s obligations under this Agreement.

 

 

(d) Parent, Merger Sub or the paying agent for the Offer (the "Paying
Agent") shall be entitled to deduct and withhold from the consideration
otherwise payable pursuant to the Offer to any holder of shares of Company
Common Stock such amounts as Parent, Merger Sub or the Paying Agent is
required to deduct and withhold with respect to the making of such
payment under the Internal Revenue Code of 1986, as amended, and applicable
Treasury Regulations issued pursuant thereto (the "Code"), or any provision
of state, local or foreign Tax law. To the extent that amounts are so
withheld and paid over by Parent, Merger Sub or the Paying Agent to the
appropriate taxing authority, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the holder of the
shares of Company Common Stock in respect of which such deduction and
withholding was made by Parent, Merger Sub or the Paying Agent.

 

 

Section 1.2 Company Actions.

 

 

 

 

 

 

 

 

 

4  

 

 

 

 

 

 

 

(a) The Company hereby approves and consents to the Offer, the Merger and the
other transactions contemplated by this Agreement and the Contingent Cash
Consideration Agreements and represents that the Board of Directors, at a
meeting duly called and held has unanimously

 

 

(i) determined that the Offer, the Merger, this Agreement, Contingent Cash
Consideration Agreements and the transactions contemplated hereby and
thereby are advisable, fair to and in the best interests of the Company and
its stockholders;

 

 

(ii) adopted this Agreement and approved the transactions hereby;

 

 

(iii) resolved to recommend acceptance of the Offer and, if required,
approval of the Merger by its stockholders; and

 

 

(iv) taken all other actions necessary to exempt the Offer, the Merger, this
Agreement, the Contingent Cash Consideration Agreements and the transactions
contemplated hereby and thereby from any "fair price", "moratorium", "control
share acquisition", "interested stockholder", "business combination" or other
similar statute or regulation ("Takeover Statute").

 

 

(b) On the date the Offer Documents are filed with the SEC, the Company shall
file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9
with respect to the Offer (such Schedule 14D-9, together with any supplements
or amendments thereto, the "Schedule 14D-9") containing, subject to Section
6.5(b), the recommendation described in Section 1.2(a)(iii) and shall mail the
Schedule 14D-9 to the stockholders of the Company as required by Rule 14d-9
under the Exchange Act. Each of the Company, Parent and Merger Sub shall
promptly correct any information supplied by it for inclusion or
incorporation by reference in the Schedule 14D-9 if and to the extent that
such information shall have become false or misleading in any material
respect, and the Company shall take all steps necessary to amend
or supplement the Schedule 14D-9 and to cause the Schedule 14D-9 as so
amended or supplemented to be filed with the SEC and disseminated to the
stockholders of the Company, in each case as soon as reasonably practicable
and as and to the extent required by applicable Federal securities laws. The
Company shall promptly notify Parent upon the receipt of any comments from
the SEC, or any request from the SEC for amendments or supplements, to the
Schedule 14D-9, and shall promptly provide Parent with copies of all
correspondence and summaries of all material oral communications between the
Company and its representatives, on the one hand, and the SEC, on the other
hand. Prior to the filing of the Schedule 14D-9 (including any amendment or
supplement thereto) with the SEC or mailing thereof to the stockholders of the
Company, or responding to any comments of the SEC with respect to the
Schedule 14D-9, the Company shall provide Parent and its counsel a
reasonable opportunity to review and comment on such Schedule 14D-9 or
response, and the Company shall give reasonable and good faith consideration
to any comments made by Parent, Merger Sub and their counsel. The Company
hereby consents to the inclusion in the Offer Documents of the recommendation
of the Board of Directors of the Company contained in the Schedule 14D-9.
In the event that the Company receives any comments from the SEC or its staff
with respect to the Schedule 14D-9, it shall use its reasonable best efforts
to (i) respond promptly to such comments and (ii) take all other actions
necessary to resolve the issues raised therein.

 

 

 

 

 

 

 

 

5  

 

 

 

 

 

 

 

 

 

(c) In connection with the Offer and the Merger, the Company shall cause its
transfer agent to furnish Parent and Merger Sub promptly (and no later than
the date hereof) with mailing labels containing the names and addresses
of the record holders of Company Common Stock as of the latest practicable
date and of those persons becoming record holders subsequent to such date,
together with copies of all lists of stockholders, security position listings
and computer files and all other information in the Company\'s possession or
control regarding the beneficial owners of Company Common Stock, and shall
furnish to Parent and Merger Sub such information and assistance (including
periodically updated lists of stockholders, security position listings
and computer files) as Parent may reasonably request in communicating the
Offer to holders of Company Common Stock.

 

 

Section 1.3 Directors.

 

 

(a) Effective upon the Offer Closing and from time to time
thereafter, Parent shall be entitled to designate the number of directors,
rounded up to the next whole number, on the Board of Directors that equals
the product of (i) the total number of directors on the Board of Directors
(giving effect to the election of any additional directors pursuant to this
Section 1.3) and (ii) the percentage that the number of shares of Company
Common Stock beneficially owned by Parent and/or Merger Sub (including shares
accepted for payment) bears to the total number of shares outstanding, and
the Company shall cause Parent\'s designees to be elected or appointed to
the Board of Directors, including by increasing the number of directors
and seeking and accepting resignations of incumbent directors. At such time,
the Company shall also cause individuals designated by Parent to constitute
the number of members, rounded up to the next whole number, on (A)
each committee of the Board of Directors and (B) as requested by Parent,
each board of directors of each Subsidiary of the Company (and each committee
thereof) that represents the same percentage as such individuals represent on
the Board of Directors. 

 

 

(b) The Company\'s obligations to appoint Parent\'s designees to the Board of
Directors shall be subject to Section 14(f) of the 1934 Act and Rule 14f-1
promulgated thereunder. The Company shall promptly take all actions necessary
to effect the appointment of Parent\'s designees, including mailing to
its stockholders information with respect to the Company and its officers
and directors, as Section 14(f) and Rule 14f-1 require in order to fulfill
its obligations under this Section 1.3(b), which, unless Parent otherwise
elects, shall be mailed together with the Schedule 14D-9. Parent shall supply
to the Company in writing and be solely responsible for any information with
respect to itself and its nominees, officers, directors and affiliates
required by Section 14(f) and Rule 14f-1 and the Company\'s obligations under
Section 1.3(a) hereof shall be subject to the receipt of such information.

 

 

(c) Following the election or appointment of Parent\'s designees pursuant to
Section 1.3(a) and until the Effective Time (as defined in Section 2.2(b)
hereof), the approval of a majority of the directors of the Company then in
office who were not designated by Parent (the "Independent Directors") shall
be required to authorize (and such authorization shall constitute the
authorization of the Board of Directors and no other action on the part of
the Company, including any action by any other director of the Company, shall
be required to authorize) any 

 

 

 

 

 

 

 

 

 

6  

 

 

 

 

 

 

 

termination of this Agreement by the Company, any amendment of this Agreement
requiring action by the Board of Directors, any extension of time for
performance of any obligation or action hereunder by Parent or Merger
Sub and any waiver of compliance with any of the agreements or conditions
contained herein for the benefit of the Company.

 

 

Section 1.4 Top-Up Option.

 

 

(a) The Company grants to Merger Sub an irrevocable option, for so long as
this Agreement has not been terminated pursuant to the provisions hereof (the
"Top-Up Option"), to purchase from the Company up to the number of
authorized and unissued shares of Company Common Stock (including as
authorized and unissued shares, for purposes of this Section 1.4, any shares
of Company Common Stock held in the treasury of the Company) equal to
the number of shares that, when added to the number of shares owned by
Merger Sub at the time of exercise of the Top-Up Option, constitutes one
share more than the number of shares (the "Requisite Short-Form Merger
Shares") entitled to cast 90% of all the votes entitled to be cast by
the holders of the Company Common Stock on the Merger after the issuance of
all shares to be issued upon exercise of the Top-Up Option, calculated on
a fully-diluted basis or, as may be elected by Parent, on a primary basis as
of immediately prior to the issuance of such shares (such shares to be issued
upon exercise of the Top-Up Option, the "Top-Up Shares").

 

 

(b) The Top-Up Option may be exercised by Merger Sub, in whole or in part at
any time following the Offer Closing and prior to the earlier to occur of (i)
the Effective Time and (ii) the termination of this Agreement in accordance
with its terms, provided that Merger Sub shall own as of such time less than
the Requisite Short-Form Merger Shares. Notwithstanding anything in
this Agreement to the contrary, the Top-Up Option shall not be exercisable to
the extent (i) the issuance of the Top-Up Shares would require approval of
the Company\'s stockholders under Nasdaq Rule 4350, (ii) the number of shares
of Company Common Stock issuable upon exercise of the Top-Up Option would
exceed the number of authorized but unissued shares of Company Common Stock
that are not already reserved for issuance or (iii) any other provision of
applicable laws or judgment, injunction, order or decree shall prohibit the
exercise of the Top-Up Option or the delivery of the Top-Up Shares. The
aggregate purchase price payable for the Top-Up Shares being purchased by
Merger Sub pursuant to the Top-Up Option shall be determined by multiplying
the number of such shares by the Offer Price, without interest. Such
aggregate purchase price may be paid by Merger Sub, at its election, either
in the same form of consideration as the Offer Price or by executing and
delivering to the Company a promissory note having a principal amount equal
to such purchase price.

 

 

(c) The parties shall cooperate to ensure that the issuance and delivery of
the Top-Up Shares comply with all applicable laws, including compliance with
an applicable exemption from registration of the Top-Up Shares under the
Securities Act of 1933 (the "Securities Act"). In the event Merger Sub wishes
to exercise the Top-Up Option, Merger Sub shall give the Company at least
three business days prior written notice, specifying (i) the number of Top-
Up Shares that Merger Sub intends to purchase pursuant to the Top-Up Option;
(ii) the manner in which Merger Sub intends to pay the applicable purchase
price; and (iii) the place and time for the closing of such purchase. At the
closing of the purchase of the Top-Up Shares, Parent and Merger Sub shall
cause to be delivered to the Company the consideration required to be
delivered in exchange for the Top-Up Shares, and the Company shall cause to
be issued to Merger Sub a certificate representing the Top-Up Shares.

 

 

 

 

 

 

 

 

 

7  

 

 

 

 

 

 

 

(d) Parent and Merger Sub acknowledge that the Top-Up Shares that Merger Sub
may acquire upon exercise of the Top-Up Option will not be registered under
the Securities Act, and will be issued in reliance upon an exemption
thereunder for transactions not involving a public offering. Merger Sub
agrees that the Top-Up Option and the Top-Up Shares to be acquired upon
exercise of the Top-Up Option are being and will be acquired by Merger Sub
for the purpose of investment and not with a view to, or for resale in
connection with, any distribution thereof in violation of the Securities Act.
Any certificates evidencing the Top-Up Shares shall include any legends
required by applicable securities laws.

 

 

 

ARTICLE II

 

 

THE MERGER

 

 

Section 2.1 The Merger. Upon the terms and subject to the conditions of
this Agreement, and in accordance with the DGCL, at the Effective Time,
Merger Sub shall be merged with and into the Company. As a result of the
Merger, the separate corporate existence of Merger Sub shall cease and the
Company shall continue as the surviving entity following the Merger
(sometimes referred to herein as the "Surviving Corporation"). The existence
of the Company shall continue unaffected and unimpaired by the Merger and, as
the Surviving Corporation, it shall be governed by the DGCL.

 

 

Section 2.2 Closing; Effective Time.

 

 

(a) The closing of the Merger (the "Closing") shall take place at 10:00 a.m.,
New York City time, on a date to be specified by the parties, which shall be
no later than the third business day after the satisfaction or waiver of all
of the conditions set forth in Article VII hereof (other than those
conditions that by their nature are to be satisfied at the Closing, it
being understood that the occurrence of the Closing shall remain subject to
the satisfaction or waiver of such conditions at the Closing), at the offices
of Skadden, Arps, Slate, Meagher and Flom LLP, Four Times Square, New York, New
York 10036, unless another time, date or place is agreed to in writing by the
parties hereto. The date on which the Closing occurs is referred to herein as
the "Closing Date."

 

 

(b) Upon the terms and subject to the conditions of this Agreement, as soon as
practicable on the Closing Date, the parties shall cause the Merger to be
consummated by filing a certificate of merger (the "Certificate of Merger")
with the Secretary of State of the State of Delaware and by making all other
filings or recordings required under the DGCL. The Merger shall
become effective at such time as the Certificate of Merger is duly filed with
the Secretary of State of the State of Delaware, or at such subsequent date
or time as Parent and the Company shall agree and specify in the Certificate
of Merger. The time at which the Merger becomes effective is referred to
herein as the "Effective Time."

 

 

Section 2.3 Effect of the Merger. At the Effective Time, the effect of the
Merger shall be as provided in the applicable provisions of the DGCL. Without
limiting the

 

 

 

 

 

 

 

 

 

 

8  

 

 

 

 

 

 

generality of the foregoing, and subject thereto, at the Effective Time,
except as otherwise provided herein, all the property, rights, privileges,
powers and franchises of the Company and Merger Sub shall vest in the
Surviving Corporation, and all debts, liabilities, obligations,
restrictions, disabilities and duties of the Company and Merger Sub shall
become the debts, liabilities, obligations, restrictions, disabilities and
duties of the Surviving Corporation.

 

 

Section 2.4 Organizational Documents of the Surviving Corporation.
The Company Certificate of Incorporation, as in effect immediately prior to
the Effective Time, shall be the Certificate of Incorporation of the
Surviving Corporation until thereafter changed or amended as provided therein
or by applicable Law. The Bylaws of the Company, as in effect
immediately prior to the Effective Time, shall be the Bylaws of the Surviving
Corporation until thereafter changed or amended as provided therein or by
applicable Law.

 

 

Section 2.5 Directors and Officers of the Surviving Corporation.
The directors of Merger Sub immediately prior to the Effective Time shall be
the directors of the Surviving Corporation until the earlier of their
resignation or removal or until their respective successors are duly
designated, as the case may be. The officers of the Company immediately prior
to the Effective Time shall be the initial officers of the Surviving
Corporation until the earlier of their resignation or removal or until their
respective successors are duly designated, as the case may be.

 

 

 

ARTICLE III

 

 

EFFECTS OF THE MERGER; EXCHANGE OF CERTIFICATES

 

 

Section 3.1 Effect on Capital Stock. Upon the terms and subject to the
conditions of this Agreement, at the Effective Time, by virtue of the Merger
and without any action on the part of Parent, Merger Sub, the Company or the
holders of any shares of Company Common Stock:

 

 

(a) Conversion of Company Common Stock. Each share of Company Common Stock
issued and outstanding immediately prior to the Effective Time (including
without limitation all vested and unvested shares of restricted stock issued
in connection with restricted stock awards granted to the executive officers
of the Company (the transfer restrictions on which shares shall terminate
immediately prior to the Effective Time) but not including shares to be
canceled pursuant to Section 3.1(c) hereof and Dissenting Shares) shall be
converted into the right to receive cash and Contingent
Cash Consideration Payments equal in form and amount to the Offer Price
paid in the Offer (the "Merger Consideration"). As of the Effective Time,
all such shares of Company Common Stock shall no longer be outstanding and
shall automatically be canceled and shall cease to exist, and each holder
of any Company Common Stock shall cease to have any rights with respect
thereto, except the right to receive the Merger Consideration, to be issued or
paid in consideration therefor in accordance with Section 3.2, without
interest.

 

 

(b) Conversion of Merger Sub Common Stock. Each share of common stock, par
value $0.01 per share, of Merger Sub (the "Merger Sub Common Stock") that is
issued and outstanding immediately prior to the Effective Time shall be
converted into one validly issued, fully paid and nonassessable share of
common stock, $0.001 par value per share, of the Surviving Corporation, and
the shares of the Surviving Corporation into which the shares of Merger Sub
Common Stock are so converted shall be the only shares of the

 

 

 

 

 

 

 

 

 

9  

 

 

 

 

 

 

 

Surviving Corporation that are issued and outstanding immediately after the
Effective Time. Following the Effective Time, each certificate evidencing
ownership of shares of Merger Sub Common Stock shall evidence ownership of
such shares of the Surviving Corporation.

 

 

(c) Cancellation of Certain Shares. Each share, if any, of Company Common
Stock that is held by the Company as treasury shares and each share of
Company Common Stock which is owned by the Company or Parent or by any direct
or indirect wholly-owned subsidiary of the Company or Parent shall be
canceled without any conversion, and no consideration shall be delivered in
respect thereof.

 

 

(d) Company Options. Effective not later than the Closing, the Company shall
take all actions required to provide that, effective as of the Closing, the
Company Stock Plans (as defined in Section 4.2(a) hereof) and all Company
Options (as defined in Section 4.2(a) hereof) outstanding immediately before
the Closing shall be cancelled and of no further force or effect, and in
consideration for such cancellation of Company Options outstanding under
the Company Stock Plans immediately before the Closing, the holders
thereof (whether or not such Company Options shall otherwise be exercisable
at the Effective Time) shall automatically (and without any further action
being required on the part of the holders thereof) receive, at the earliest
Valuation Point (as defined in Section 9.14(ff)), if any, at which then
applicable Per Share Paid Value (as defined in Section 9.14(y)) exceeds the
per-share exercise price under such Company Option:

 

 

(i) an amount in cash equal to (A) the number of shares of Company Common
Stock subject to each such Company Option held by such holder multiplied by
the excess, of (I) then applicable Per Share Paid Value over (II) the per-
share exercise price under such Company Option (with such payments to be
subject to any applicable Tax withholding in accordance with Section 3.1(h));
and

 

 

(ii) the right to receive, in respect of each share of Company Common Stock
subject to each such Company Option held by such holder, each Contingent Cash
Consideration Payment that, as of such Valuation Point, has not yet become
payable pursuant to the terms of the Contingent Cash Consideration
Agreements.

 

 

(e) Other Equity Awards. Each other award outstanding immediately before the
Effective Time under the Company Stock Plans other than the Company Options
(including, without limitation, any performance share awards (each, a
"Performace Share Award", deferred stock units, and rights under the 2008
Employee Stock Purchase Plan of the Company (the "2008 ESPP") shall be
cancelled and of no further force or effect as of the Effective Time. In
exchange for the cancellation of each such award, to the extent vested as of
immediately before the Effective Time in accordance with the terms of the
such award (including any vesting that occurs under the terms of the
applicable award as a result of the consummation of this Agreement) and
except as set forth in Section 3.1(f) below with respect to
certain Performance Share Awards or in Section 3.1(g) below with repsect to
the 2008 ESPP, the holder of such awards shall receive the per share Merger
Consideration for each share of Company Common

 

 

 

 

 

 

 

 

 

10  

 

 

 

 

 

 

 

Stock underlying such award (with such payment to be subject to any
applicable Tax withholding in accordance with Section 3.1(h)). Prior to the
Effective Time, the Company shall take all actions necessary such that no
Person has any rights to acquire Company Common Stock or common stock of the
Parent or any of its subsidiaries (including the Surviving Corporation)
pursuant to any Company Benefit Plan or Company Benefit Agreement following
the Effective Time.

 

 

(f) 2008 Employee Stock Purchase Plan. Each participant in the 2008 ESPP, in
exchange for the cancellation of their rights under the 2008 ESPP as set
forth in Section 3.1(e) above, shall receive the per share Merger
Consideration (with such payment to be subject to any applicable Tax
withholding in accordance with Section 3.1(h) for a number of shares equal to
the shares of Company Common Stock that would have been issued under the
terms of the 2008 ESPP with respect to such participant\'s payroll
deductions accumulated as of the Effective Time assuming the 2008 ESPP had
been approved by the stockholders of the Company prior to the Effective Time
and assuming that the purchase date under the 2008 ESPP was the Closing Date.
The Company shall not commence any new purchase periods under the 2008 ESPP
after the date hereof.

 

 

(g) Withholding. Parent, the Surviving Corporation of the Exchange Agent
shall be entitled to deduct and withhold from the consideration otherwise
payable pursuant to this Agreement to any holder of Company Common Stock
or Company Options such amounts as Parent, the Surviving Corporation or
the Exchange Agent is or may be reasonably required to deduct and withhold
with respect to the making of such payment under applicable Law. To the
extent that amounts are so withheld and paid over to the appropriate taxing
authority by Parent, the Surviving Corporation or the Exchange Agent, such
withheld amounts shall be treated for all purposes of this Agreement as
having been paid to the holder of the Company Common Stock or Company Options
in respect of which such deduction and withholding was made by Parent, the
Surviving Corporation or the Paying Agent.

 

 

Section 3.2 Exchange of Shares and Certificates.

 

 

(a) Exchange Agent. At or prior to the Effective Time, Parent shall engage a
nationally-recognized financial institution reasonably satisfactory to the
Company to act as 

 

 

 

 

 

 

 

 

 

11  

 

 

 

 

 

 

 

exchange agent in connection with the Merger (the "Exchange Agent"). At the
Effective Time, Parent shall deposit with the Exchange Agent, in trust for
the benefit of the holders of shares of Company Common Stock immediately
prior to the Effective Time, the cash portion of the Merger Consideration to
be paid in respect of the Company Common Stock. All cash deposited with the
Exchange Agent shall hereinafter be referred to as the "Exchange Fund."

 

 

(b) Exchange Procedures. Promptly after the Effective Time, Parent shall
cause the Exchange Agent to mail to each holder of record of (i) a
certificate or certificates which immediately prior to the Effective Time
represented outstanding shares of Company Common Stock (the "Certificates") or
(ii) uncertificated shares of Company Common Stock (the
"Uncertificated Shares"), in each case, which at the Effective Time
were converted into the right to receive the Merger Consideration pursuant
to Section 3.1 hereof, (i) a letter of transmittal (which, in the case
of Certificates, shall specify that delivery shall be effected, and risk of
loss and title to the Certificates shall pass, only upon delivery of the
Certificates to the Exchange Agent and shall be in such form and have such
other provisions as Parent may reasonably specify) and (ii) instructions for
use in effecting the surrender of the Certificates or Uncertificated Shares
in exchange for the Merger Consideration. Upon (i) surrender of Certificates
for cancellation to the Exchange Agent or to such other agent or agents as
may be appointed by Parent, together with such letter of transmittal, duly
completed and validly executed in accordance with the instructions thereto or
(ii) or receipt of an "agent\'s message" by the Exchange Agent (or such
other evidence, if any, of transfer as the Exchange Agent may reasonably
request) in the case of a book-entry transfer of Uncertificated Shares, and
such other documents as may reasonably be required by the Exchange Agent, the
holder of such Certificates or Uncertificated Shares shall be entitled to
receive in exchange the portion of the Merger Consideration to which such
holder is entitled pursuant to Section 3.1, and any Certificates so
surrendered shall forthwith be cancelled. If any portion of the Merger
Consideration is to be paid to a Person (as defined in Section 9.14(dd))
other than the Person in whose name the surrendered Certificate or the
transferred Uncertificated Share is registered, it shall be a condition to
such payment that (i) either such Certificate shall be properly endorsed or
shall otherwise be in proper form for transfer or such Uncertificated Share
shall be properly transferred and (ii) the Person requesting such payment
shall pay to the Exchange Agent any transfer or other Taxes required as a
result of such payment to a Person other than the registered holder of such
Certificate or Uncertificated Share or establish to the satisfaction of
Parent that such Tax has been paid or is not payable. Until surrendered
as contemplated by this Section 3.2(b), each Certificate or Uncertificated
Share shall be deemed at any time after the Effective Time to represent only
the right to receive the Merger Consideration upon such surrender.

 

 

(c) No Further Ownership Rights in Company Common Stock. All Merger
Consideration issued and paid upon the surrender for exchange of Certificates
or Uncertificated Shares in accordance with the terms of this Article III
shall be deemed to have been issued and paid in full satisfaction of all
rights pertaining to the shares of Company Common Stock previously represented
by such Certificates or Uncertificated Shares. At the Effective Time,
the stock transfer books of the Company shall be closed and there shall be no
further registration of transfers on the stock transfer books of the
Surviving Corporation of the shares of Company Common Stock which were
outstanding immediately prior to the Effective Time. If, after the Effective
Time, Certificates or Uncertificated Shares are presented to
the Surviving Corporation 

 

 

 

 

 

 

 

 

 

12  

 

 

 

 

 

 

 

or the Exchange Agent for any reason, they shall be cancelled and exchanged
as provided in this Article III.

 

 

(d) Termination of Exchange Fund. Any portion of the Exchange Fund which
remains undistributed to the holders of Company Common Stock six months after
the Effective Time shall be delivered to Parent, upon demand, and any holders
of Company Common Stock who have not theretofore complied with this Article
III shall thereafter look only to Parent for payment of their claim for the
Merger Consideration.

 

 

(e) No Liability. None of Parent, Merger Sub, the Company or the Exchange
Agent or any of their respective directors, officers, employees and agents
shall be liable to any Person in respect of Merger Consideration delivered
to a public official pursuant to any applicable abandoned property, escheat
or similar law. If any Certificate or Uncertificated Share shall not have
been surrendered prior to three years after the Effective Time,
or immediately prior to such earlier date on which any cash or Contingent
Cash Consideration Payments would otherwise escheat to or become the property
of any Governmental Entity (as defined in Section 4.5), any such cash or
Contingent Consideration Cash Payments shall, to the extent permitted by
applicable Law, become the property of the Surviving Corporation, free and
clear of all claims or interests of any Person previously entitled thereto.

 

 

(f) Investment of Exchange Fund. The Exchange Agent shall invest any cash
included in the Exchange Fund as directed by Parent on a daily basis provided
that no such investment or loss thereon shall affect the amounts payable to
former stockholders of the Company after the Effective Time pursuant to this
Article III. Any interest and other income resulting from such investment
shall become a part of the Exchange Fund, and any amounts in excess of the
amounts payable pursuant to this Article III shall promptly be paid
to Parent.

 

 

(g) Withholding Rights. Parent and the Exchange Agent shall be entitled to
deduct and withhold from any consideration payable pursuant to this Agreement
to any Person who was a holder of Company Common Stock immediately prior to
the Effective Time such amounts as Parent or the Exchange Agent may be
required to deduct and withhold with respect to the making of such payment
under the Code or any other provision of federal, state, local or foreign
tax law. To the extent that amounts are so withheld by Parent or the Exchange
Agent, such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the Person to whom such consideration would
otherwise have been paid.

 

 

(h) Lost, Stolen or Destroyed Certificates. In the event any Certificates
shall have been lost, stolen or destroyed, the Exchange Agent shall issue in
exchange for such lost, stolen or destroyed Certificates, upon the making of
an affidavit of that fact by the holder thereof, such portion of the
Merger Consideration as may be required pursuant to Section 3.1(a);
provided, however, that Parent may, in its discretion and as a condition
precedent to the issuance thereof, require the owner of such lost, stolen or
destroyed Certificates to deliver an agreement of indemnification in form
reasonably satisfactory to Parent, or a bond in such sum as Parent
may reasonably direct as indemnity, against any claim that may be
made against Parent or the Exchange Agent in respect of the Certificates
alleged to have been lost, stolen or destroyed.

 

 

 

 

 

 

 

 

 

13  

 

 

 

 

 

 

 

 

Section 3.3 Dissenting Shares. Notwithstanding any provision of this
Agreement to the contrary, shares of Company Common Stock that are issued and
outstanding immediately prior to the Effective Time and which are held by
holders of such shares of Company Common Stock who properly exercise
appraisal rights with respect thereto in accordance with Section 262 of DGCL
(the "Dissenting Shares") shall not be exchangeable for the right to receive
the Merger Consideration, and holders of such Dissenting Shares will be
entitled only to receive payment of the appraised value of such shares of
Company Common Stock in accordance with the provisions of such Section 262
unless and until such holders fail to perfect or effectively withdraw or lose
their rights to appraisal and payment under the DGCL. If, after the Effective
Time, any such holder fails to perfect or effectively withdraws or loses such
right, such shares of Company Common Stock will thereupon be treated as if
they had been converted into and to have become exchangeable for, at the
Effective Time, the right to receive the Merger Consideration without any
interest thereon. The Company shall give Parent (i) prompt notice of any
demands received by the Company for appraisals of shares of Company Common
Stock and (ii) the opportunity to direct all negotiations and proceedings
with respect to demands for appraisal under the DGCL. The Company shall not,
except with the prior written consent of Parent, make any payment with
respect to any demands for appraisal or offer to settle or settle any such
demands.

 

 

Section 3.4 Nebido CCCP Escrow. At the Offer Closing, Parent will deposit
$175,000,000] million in cash with the Paying Agent under the Nebido
Contingent Cash Consideration Agreement, which amount is equal to the
aggregate Approval With Label Payment Amount (as defined in the Nebido
Contingent Cash Consideration Agreement) payable upon the occurrence of the
Approval With Label Milestone Date (as defined in the Nebido Contingent Cash
Consideration Agreement) by such Paying Agent in accordance with the Nebido
Contingent Cash Consideration Agreement.

 

 

 

ARTICLE IV

 

 

REPRESENTATIONS AND WARRANTIES OF COMPANY

 

 

The Company represents and warrants to Parent and Merger Sub as of the date
hereof and as of the Closing Date (except for those representations and
warranties made as of a specific date or time) as follows (except (i) as set
forth in the written disclosure letter (which letter shall in each case
specifically identify by reference to Sections of this Agreement any
exceptions to each of the representations, warranties and covenants contained
in this Agreement; provided, however, that any information set forth in one
section of such disclosure letter shall be deemed to apply to each other
section or subsection thereof or hereof to which its relevance is readily
apparent on its face) delivered by the Company to Parent and Merger Sub in
connection with the execution and delivery of this Agreement (the
"Company Disclosure Letter") or (ii) as disclosed in the Company SEC Reports
(as defined in Section 4.7(a)) on or prior to the date hereof (and without
regard to any amendment thereto filed after the date of this Agreement)):

 

 

Section 4.1 Organization, Standing and Corporate Power

 

 

(a) The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite
corporate power and

 

 

 

 

 

 

 

 

 

14  

 

 

 

 

 

 

authority and all necessary governmental approvals to own, lease and operate
its properties and to carry on its business as now being conducted, except
where the failure to have such governmental approvals would not, individually
or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect (as defined in Section 9.14(hh)). The Company is
duly qualified or licensed to do business and is in good standing in each
jurisdiction in which the nature or conduct of its business or the ownership,
leasing or operation of its properties requires it to be so qualified,
licensed or in good standing, except for such jurisdictions where the failure
to be so qualified, licensed or to be in good standing would not,
individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect.

 

 

(b) Each Company Subsidiary (as defined in Section 4.2(d)) is a corporation
or other legal entity duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization and
has all requisite corporate (or similar) power and authority and all
necessary governmental approvals to own, lease and operate its properties and
to carry on its business as now being conducted, except where the failure to
have such governmental approvals would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. Each
Company Subsidiary is duly qualified or licensed to do business and is in
good standing in each jurisdiction in which the nature or conduct of its
business or the ownership, leasing or operation of its properties requires it
to be so qualified, licensed or in good standing, except for such
jurisdictions where the failure to be so qualified, licensed or to be in good
standing would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect.

 

 

(c) The Company has furnished or made available to Parent true and complete
copies of the Restated Certificate of Incorporation of the Company, as
amended through the date of this Agreement (as so amended, the
"Company Certificate of Incorporation"); the Bylaws of the Company, as
amended through the date of this Agreement (as so amended, the
"Company Bylaws" and together with the Company Certificate of Incorporation,
"Company Organizational Documents"); and the comparable charter and
organizational documents of each Company Subsidiary, in each case as amended
through the date of this Agreement. The Company Organizational Documents
are in full force and effect and have not been amended or
otherwise modified. The Company is not in violation of any provision of
the Company Organizational Documents, and no Company Subsidiary is in
material violation of any provision of its certificate of incorporation,
bylaws or equivalent organizational documents. The Company has made available
to Parent complete and correct copies of the minutes (or, in the case of
minutes that have not yet been finalized, drafts thereof) of all meetings of
the stockholders of the Company and each of the Company Subsidiaries (to the
extent available), the boards of directors of the Company and each of
the Company Subsidiaries (to the extent available) and the committees of
each such board of directors, in each case held since January 1, 2006 and
prior to the date hereof.

 

 

Section 4.2 Capitalization

 

 

(a) The authorized capital stock of the Company consists of (i) 200,000,000
shares of Company Common Stock, par value $0.001 per share, and (ii)
5,000,000 shares of preferred stock, par value $0.001 per
share ("Company Preferred Stock"). At the close of business on December
31, 2008, (i) 78,187,842 shares of Company Common Stock were issued 

 

 

 

 

 

 

 

 

15  

 

 

 

 

 

 

 

 

and outstanding, (including 540,230 shares of Company Common Stock that were
outstanding as of the relevant time but were subject to vesting or other
forfeiture restrictions or a right of repurchase by Company as of such time),
(ii) zero shares of Company Common Stock were held by Company in its treasury,
(iii) an aggregate 17,450,020 shares of Company Common Stock were reserved
for issuance pursuant to outstanding awards and rights under the Company\'s
1994 Long-Term Incentive Plan, 1995 Employee Stock Purchase Plan, 1998
Employee Stock Option Plan, 2000 Stock Option Plan, 2004 Equity Incentive
Plan and 2008 Employee Stock Purchase Plan (collectively,
the "Company Stock Plans"), of which (A) 13,063,089 shares of Company Common
Stock were subject to outstanding and unexercised options entitling the
holder thereof to purchase a share of Company Common Stock (each, a
"Company Option"), (B) up to 1,083,828 shares of Company Common Stock were
issuable pursuant to outstanding performance share awards with service and
market-based vesting criteria, (C) 100,000 shares of Company Common Stock were
issuable pursuant to deferred stock units, (D) 1,500,000 shares were reserved
under the Company\'s 2008 Employee Stock Purchase Plan and (E) 1,703,103
shares of Company Common Stock that are reserved but are not allocated to any
specific outstanding rights or awards, (iv) 355,442 shares were reserved for
issuance relating to outstanding obligations regarding CPEC LLC, and (v)
10,806,040 shares of Company Common Stock are reserved for issuance upon
conversion of the 6.25% Convertible Senior Notes due 2009. At the close of
business on January 2, 2009, no shares of Company Preferred Stock were issued
and outstanding.

 

 

(b) Except as set forth in Section 4.2(a) above, at the close of business on
January 2, 2009, no shares of capital stock or other voting securities of
the Company were issued, reserved for issuance or outstanding. From January
1, 2009, until the date of this Agreement, there have been no issuances by
the Company of shares of capital stock of, or other equity or voting
interests in, the Company, other than the issuance of shares of Company
Common Stock pursuant to the exercise of Company Options outstanding as of
January 1, 2009, in accordance with their terms. Except as set forth in
Section 4.2(a) above, as of the date hereof, there are no options, warrants,
convertible or exchangeable securities, subscriptions, stock appreciation
rights, phantom stock rights or stock equivalents or other
rights, agreements, arrangements or commitments (contingent or otherwise) of
any character issued or authorized by the Company or any Company Subsidiary
(i) relating to any issued or unissued capital stock or equity interest of
the Company or any Company Subsidiary, (ii) obligating the Company or any
Company Subsidiary to issue, deliver or sell, or cause to be issued,
delivered or sold, any shares of capital stock of, or options,
warrants, convertible or exchangeable securities, subscriptions or
other equity interests in the Company or any Company Subsidiary or (iii)
that give any Person the right to receive any economic benefit or right
similar to or derived from the economic benefits and rights accruing to
holders of capital stock of the Company or any Company Subsidiary (each of
(i), (ii) and (iii), collectively, the "Company Stock Rights"). All
outstanding shares of Company Common Stock are, and all shares of Company
Common Stock that may be issued prior to the Effective Time will be when
issued, duly authorized, validly issued, fully paid and nonassessable. There
are no outstanding contractual obligations of the Company or any Company
Subsidiary to repurchase, redeem or otherwise acquire any capital stock
or equity interest of the Company (including any shares of Company Common
Stock) or any Company Subsidiary or any Company Stock Rights or to pay any
dividend or make any other distribution in respect thereof or to
provide funds to, or make any investment (in the form of a loan, capital
contribution or otherwise) in, any Person, other than pursuant to the Company
Stock Plans.

 

 

 

 

 

 

 

 

16  

 

 

 

 

 

 

 

(c) Section 4.2(c) of the Company Disclosure Letter sets forth a true,
complete and correct list, as of January 2, 2009, of (i) all
Company Options, the number of shares of Company Common Stock subject
thereto, the grant dates, expiration dates, the exercise or base prices and
the names of the holders thereof, and (ii) all other outstanding
awards under the Company Stock Plans, the number of shares of Company Common
Stock subject thereto, the holders thereof and the vesting schedules thereof.
Each outstanding Company Option, restricted stock award, deferred stock unit,
performance stock award and employee stock purchase plan right, may, be
treated at the Effective Time as set forth in Section 3.1.

 

 

(d) Exhibit 21 to the Company\'s Annual Report on Form 10-K for the fiscal
year ended September 30, 2008 includes all the Subsidiaries of the Company
(each a "Company Subsidiary" and together, the "Company Subsidiaries") in
existence as of the date hereof. All the outstanding shares of capital stock
of, or other equity interests in, each such Company Subsidiary have been duly
authorized and validly issued and are fully paid and nonassessable and are,
except as set forth in such Exhibit 21, owned directly or indirectly by
the Company, free and clear of all pledges, claims, liens, charges,
encumbrances and security interests of any kind or nature whatsoever
(collectively, "Liens") and free of any other restriction (including any
restriction on the right to vote, sell or otherwise dispose of such capital
stock or other ownership interests), except for restrictions imposed
by applicable securities laws. Neither the Company nor any of the Company
Subsidiaries directly or indirectly owns or has any right or obligation to
subscribe for or otherwise acquire any equity or similar interest in, or any
interest convertible into or exchangeable or exercisable for,
any corporation, partnership, joint venture or other business association or
entity (other than the Company Subsidiaries).

 

 

Section 4.3 Authority.

 

 

(a) The Company has all necessary corporate power and authority to execute
and deliver this Agreement, to perform its obligations hereunder and, subject
to obtaining the Company Stockholder Approval (as defined below) if required
in connection with this Agreement, the Offer and the Merger, to consummate the
Merger and the other transactions contemplated hereby. The execution,
delivery and performance by the Company of this Agreement and the
consummation by the Company of the Offer and the Merger and the other
transactions contemplated hereby, have been duly authorized by all necessary
corporate action on the part of the Company and no other corporate
proceedings on the part of the Company are necessary to authorize this
Agreement or to consummate the Offer and the Merger or the other
transactions contemplated hereby (other than obtaining the Company
Stockholder Approval and the filing and recordation of appropriate merger
documents as required by the DGCL). This Agreement has been duly executed
and delivered by the Company and, assuming the due authorization, execution
and delivery by the other parties hereto, constitutes a legal, valid and
binding obligation of the Company enforceable against the Company
in accordance with its terms subject, as to enforcement of remedies, to
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
the rights and remedies of creditors generally and to the effect of general
principles of equity. If approval of the Company Stockholders is required
pursuant to the DGCL, the affirmative vote of a majority of outstanding
shares of Company Common Stock entitled to vote

 

 

 

 

 

 

 

 

17  

 

 

 

 

 

 

 

accordance with the DGCL, the Company Certificate of Incorporation and the
Company Bylaws (the "Company Stockholder Approval") is the only vote of the
holders of capital stock of the Company necessary to approve this Agreement,
the Merger and the other transactions contemplated hereby.

 

 

(b) The Company Board, at a meeting duly called and held, duly
and unanimously adopted resolutions (i) approving this Agreement, the
Offer, the Merger and the other transactions contemplated by this Agreement,
(ii) determining that this Agreement is advisable and that the terms of the
Offer, the Merger and the other transactions contemplated by this Agreement
are fair to and in the best interests of the Company and its stockholders,
and (iii) recommending that the Company\'s stockholders adopt
this Agreement. Such resolutions are sufficient to render the provisions of
Section 203 of the DGCL inapplicable to this Agreement and the other
Contingent Cash Consideration Agreements, the Offer, the Merger and the other
transactions contemplated by this Agreement. To the knowledge of the Company,
no other state takeover statute or similar statute or regulation applies or
purports to apply to the Company with respect to this Agreement, the Offer,
the Merger or any other transaction contemplated by this Agreement or the
Contingent Cash Consideration Agreements and the transactions contemplated
thereby.

 

 

(c) UBS Securities LLC has delivered to the Company Board its opinion to the
effect that, as of the date of such opinion and based on the assumptions,
qualifications and limitations contained therein, the consideration to be
received by the holders of Company Common Stock (other than as set forth in
such opinion) pursuant to the Offer and the Merger, taken together, is fair,
from a financial point of view, to such holders. The Company will make
available to Parent a correct and complete copy of the form of such opinion
solely for informational purposes after receipt thereof by the Company.

 

 

Section 4.4 No Conflict. The execution and delivery of this Agreement by
the Company do not, and the performance of this Agreement by the Company and
the Offer and the consummation of the Merger and the other transactions
contemplated hereby will not, (a) assuming the Company Stockholder Approval
is obtained, if required for consummation of the Merger, conflict with or
violate (i) the Company Certificate of Incorporation or the Company Bylaws or
(ii) the equivalent organizational documents of any of the Company
Subsidiaries, (b) assuming compliance with Section 4.5 hereof and assuming
the Company Stockholder Approval is obtained, if required for consummation of
the Merger, conflict with or violate any United States federal, state or
local or any foreign statute, law, rule, regulation, ordinance, code or any
other requirement or rule of law (a "Law") or any charge, order, writ,
injunction, judgment, guideline, guidance, decree, ruling, determination,
directive, award or settlement, whether civil, criminal or administrative (an
"Order"), or any rule or regulation of any securities exchange on which the
Company\'s Common Stock is listed for trading, in each case applicable to the
Company or any of the Company Subsidiaries or by which any property or asset
of the Company or any of the Company Subsidiaries is bound or affected, (c)
result in a breach of or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, give to others any
right of termination, amendment, acceleration or cancellation of, result in
the triggering of any payment or other obligation or any right of consent, or
result in the creation of a Lien on any property or asset of the Company or
any of the Company Subsidiaries pursuant to any note, bond, mortgage,
indenture, contract, agreement, lease, license, permit, franchise or other
instrument or obligation to which the Company or any of the Company
Subsidiaries is a

 

 

 

 

 

 

 

 

 

18  

 

 

 

 

 

 

 

 

party or by which the Company or any of the Company Subsidiaries or any
property or asset of any of them is bound or affected (including any Company
Material Contract (as defined in Section 4.13) and any Company Permit (as
defined in Section 4.6(b)), or (d) result in the loss of or otherwise impair
the right, title or interest of the Company or any Company Subsidiaries in
and to any of the material Company IP, except, in the case of clauses
(a)(ii), (b) and (c) above, for any such conflicts, violations, breaches,
defaults or other occurrences which have not had and are not reasonably
expected to have, individually or in the aggregate, a Company Material
Adverse Effect.

 

 

Section 4.5 Required Filings and Consents. The execution and delivery by
the Company of this Agreement does not, and the performance by the Company of
this Agreement will not, require any consent, approval, order, authorization
or permit of, or declaration, registration, filing with, or notification to,
any United States federal, state or local or any foreign government or any
court, administrative or regulatory authority or commission or other
governmental or government-authorized authority or agency, domestic or
foreign (a "Governmental Entity"), except for (i) applicable requirements, if
any, of (A) the Exchange Act, including, without limitation, the filing with
the SEC of the Schedule 14D-9 and the Proxy Statement (as defined in Section
6.9(a)), (B) state securities or "blue sky" laws, (C) the DGCL to file the
Certificate of Merger or other appropriate documentation and (D) Nasdaq, (ii)
those required by the HSR Act, (iii) such filings and approvals as are
required to be made or obtained under any foreign antitrust, competition or
similar Laws in connection with the consummation of the Merger and the other
transactions contemplated by this Agreement, and (iv) the filing of customary
applications and notices, as applicable with the U.S. Food and Drug
Administration ((the "FDA") or any other federal, state, local or foreign
Governmental Entity (such as the European Medicines Agency ("EMEA") and
Health Canada) that is concerned with or regulates the marketing, sale,
use, handling and control, safety, efficacy, reliability or manufacturing of
drug or biological products or medical devices or is concerned with or
regulates public health care programs (each, a "Regulatory Authority")).

 

 

Section 4.6 Compliance; Regulatory Compliance. Other than tax matters,
employee benefits matters, labor and employment matters, environmental
matters or intellectual property matters, which are the subjects of Sections
4.10, 4.14, 4.15, 4.16, and 4.17 respectively:

 

 

(a) Each of the Company and the Company Subsidiaries (i) has been operated at
all times in compliance with all Laws and Orders applicable to the
Company or any of the Company Subsidiaries or by which any
property, business or asset of the Company or any of the Company Subsidiaries
is bound or affected and (ii) is not in default or violation of any
governmental licenses, permits or franchises to which the Company or any of
the Company Subsidiaries is a party or by which the Company or any of the
Company Subsidiaries or any property or asset of the Company or any of the
Company Subsidiaries is bound or affected other than, in the case of clauses
(i) and (ii) above, failures to comply, defaults or violations which do not
have and are not reasonably expected to have, individually or in the
aggregate, a Company Material Adverse Effect. Neither the Company nor
any Company Subsidiary has received any written communication during the
past two years from a Governmental Entity that alleges that Company or a
Company Subsidiary is not in compliance in any material respect with any
applicable Law and Order.

 

 

 

 

 

 

 

 

19  

 

 

 

 

 

 

 

(b) Each of the Company, the Company Subsidiaries and their respective
employees and, to the knowledge of the Company, business partners,
as applicable, has in effect all required filings, licenses, permits,
certificates, exemptions, orders, consents, clearances,
registrations, approvals and authorizations of all Governmental Entities
(including all authorizations under the regulations of the Federal Food, Drug
and Cosmetic Act of 1938, as amended (the "FDCA"), and the regulations of the
FDA promulgated thereunder and any of the foregoing required by any other
Regulatory Authority, including the EMEA and Health Canada) and third Persons
necessary for the conduct of the Company\'s and the Company Subsidiaries\'
business and the use of their properties and assets (including the marketing
and sale of the Products), as presently conducted and used (the
"Company Permits"), and all Company Permits are valid and in full force and
effect, except where such failure has not had, or is not reasonably expected
to have, individually or in the aggregate, a Company Material Adverse Effect;
and neither the Company nor any Company Subsidiary has received
written notice from any Governmental Entity or third Person that any such
Company Permit is subject to any adverse action which has had, or is
reasonably expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

 

 

Section 4.7 SEC Filings; Financial Statements.

 

 

(a) The Company has filed all forms, reports, statements and
documents required to be filed with the SEC since October 1, 2006 (the
"Company SEC Reports"), each of which has complied in all material respects
with the applicable requirements of the Securities Act and the rules and
regulations promulgated thereunder, the Exchange Act and the rules and
regulations promulgated thereunder, and the Sarbanes-Oxley Act of 2002
(the "Sarbanes-Oxley Act") and the rules and regulations promulgated
thereunder, each as in effect on the date so filed, except to the extent
updated, amended, restated or corrected by a subsequent Company SEC Report
filed or furnished to the SEC by the Company, and in either case, publicly
available prior to the date hereof (each, a "Company Filed SEC Report").
None of the Company SEC Reports (including any financial statements or
schedules included or incorporated by reference therein) contained when filed
or currently contains, and any Company SEC Reports filed with the SEC
subsequent to the date hereof will not contain, any untrue statement of a
material fact or omission to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, except to the
extent updated, amended, restated or corrected by a subsequent Company
Filed SEC Report.

 

 

(b) Except to the extent updated, amended, restated or corrected by a
subsequent Company Filed SEC Report, all of the financial
statements included in the Company SEC Reports, in each case, including any
related notes thereto, as filed with the SEC (those filed with the SEC are
collectively referred to as the "Company Financial Statements"), comply as
to form in all material respects with applicable accounting requirements and
the published rules of the SEC with respect thereto and have been prepared in
accordance with U.S. generally accepted accounting principles ("GAAP")
applied on a consistent basis throughout the periods involved (except as may
be indicated in the notes thereto or, in the case of the unaudited
statements, as may be permitted by Form 10-Q of the SEC and subject, in the
case of the unaudited statements, to normal, recurring year-end
audit adjustments). The consolidated balance sheets (including the related
notes) included in such Company Financial Statements (if applicable, as
updated, amended, restated or corrected in a subsequent Company Filed SEC
Report) fairly present, in all material respects, the consolidated financial
position of the Company and the Company Subsidiaries at the respective dates
thereof, and the consolidated statements of operations, stockholders\' equity
and cash flows (in each case, including the related notes) included in such
Company Financial Statements (if applicable, as updated, amended, restated or
corrected in a subsequent Company Filed SEC 

 

 

 

 

 

 

 

 

 

20  

 

 

 

 

 

 

 

Report) fairly present, in all material respects, the consolidated statements
of operations, stockholders\' equity and cash flows of the Company and the
Company Subsidiaries for the periods indicated, subject, in the case of the
unaudited statements, to normal, recurring year-end audit adjustments.

 

 

(c) Neither the Company nor any Company Subsidiary has any
material Liabilities (as defined below) except for (i) Liabilities that are
reflected, or for which reserves were established, on the audited
consolidated balance sheet of the Company and the Company Subsidiaries as
of September 30, 2008, (ii) Liabilities incurred in the ordinary course
of business and consistent with past practice since September 30, 2008, (iii)
Liabilities that are disclosed in the Company SEC Reports and (iv)
Liabilities incurred in connection with this Agreement and the transactions
contemplated hereby. As used in this Agreement, the term "Liability" means
any and all debts, liabilities and obligations, whether accrued or fixed,
absolute or contingent, known or unknown or matured or unmatured,
including those arising under any Law and those arising under any Contract.

 

 

(d) Each of the principal executive officer of the Company and the principal
financial officer of the Company (or each former principal executive officer
of Company and each former principal financial officer of the Company, as
applicable) has made all applicable certifications required by Rule 13a-14
or 15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes-
Oxley Act with respect to the Company SEC Reports, and the statements
contained in such certifications are true and accurate. For purposes of this
Agreement, "principal executive officer" and "principal financial officer"
shall have the meanings given to such terms in the Sarbanes-Oxley Act.
Neither the Company nor any of the Company Subsidiaries has any outstanding,
or has arranged any outstanding, "extensions of credit" to directors or
executive officers within the meaning of Section 402 of the Sarbanes-
Oxley Act.

 

 

(i) The Company maintains a system of "internal control over financial
reporting" (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act) sufficient to provide reasonable assurance (A) that transactions
are recorded as necessary to permit preparation of financial statements
in conformity with GAAP, consistently applied, (B) that transactions are
executed only in accordance with the authorization of management and (C)
regarding prevention or timely detection of the unauthorized acquisition, use
or disposition of the Company\'s assets.

 

 

(ii) The Company\'s "disclosure controls and procedures" (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) are reasonably designed to
ensure that all information (both financial and non-financial) required to be
disclosed by the Company in the reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC, and that all such
information is accumulated and communicated to the Company\'s management as
appropriate to allow timely decisions regarding required disclosure and to
make the

 

 

 

 

 

 

 

 

 

21  

 

 

 

 

 

 

 

certifications of the chief executive officer and chief financial officer of
the Company required under the Exchange Act with respect to such reports.

 

 

(iii)  Neither the Company nor any of the Company Subsidiaries is a party
to, or has any commitment to become a party to, any joint venture, off-
balance sheet partnership or any similar contract (including any contract or
arrangement relating to any transaction or relationship between or among the
Company or any of the Company Subsidiaries, on the one hand, and any
unconsolidated Affiliate, including any structured finance, special purpose
or limited purpose entity or Person, on the other hand, or any "off-balance
sheet arrangements" (as defined in Item 303(a) of Regulation S-K of the
SEC), where the result, purpose or intended effect of such contract is to
avoid disclosure of any material transaction involving, or material
liabilities of, the Company or any of the Company Subsidiaries in
the Company\'s or such Company Subsidiary\'s published financial statements
or other Company SEC Reports.

 

 

(iv) Since October 1, 2006, the Company has not received any oral or written
notification of any (x) "significant deficiency" or (y) "material weakness" in
the Company\'s internal control over financial reporting. For purposes of
this Agreement, the terms "significant deficiency" and "material weakness"
shall have the meanings assigned to them by the Public Company Accounting
Oversight Board in Auditing Standard No. 2, as in effect on the date hereof.

 

 

(e) None of the Company Subsidiaries is, or has at any time since October 1,
2006 been, subject to the reporting requirements of Sections 13(a) and 15(d)
of the Exchange Act.

 

 

Section 4.8 Absence of Certain Changes or Events. Except as contemplated by
this Agreement, since the date of the most recent audited financial
statements included in the Company SEC Reports and through the date hereof,
each of the Company and the Company Subsidiaries has conducted its respective
businesses only in the ordinary course in all material respects and in a
manner consistent with prior practice in all material respects and there has
not been any event or occurrence of any condition that has had or
is reasonably expected to have, individually or in the aggregate, a
Company Material Adverse Effect. Except as contemplated by this
Agreement, since the date of the most recent audited financial statements
included in the Company SEC Reports and through the date hereof, there has
not been (i) any material change in accounting methods, principles or
practices employed by the Company, other than as required by Law or GAAP or
(ii) any action of the types described in Section 6.1(b) which, had such
action been taken after the date of this Agreement, would be in violation of
such Section.

 

 

Section 4.9 FDA and Related Matters.

 

 

(a) Section 4.9 of the Company Disclosure Letter sets forth a true and
complete list of all Regulatory Authorizations from the FDA, EMEA and all
other Regulatory Authorities owned by the Company or the Company Subsidiaries
or held by Company Partners (as defined in Section 4.9(b) hereof) and
relating to the Core Products (as defined in Section 9.14(g)) and used in the
conduct of the Company\'s business, and there are no other Regulatory 

 

 

 

 

 

 

 

 

 

22  

 

 

 

 

 

 

 

Authorizations required for the Company, the Company Subsidiaries or the
Core Products in connection with the conduct of the Company\'s business as
currently conducted. All such Regulatory Authorizations owned by the Company
or a Company Subsidiary are, and to the knowledge of the Company all other
Regulatory Authorizations are, in all material respects, (i) in full force and
effect, (ii) validly registered and on file with applicable Regulatory
Authorities, (iii) in compliance with all formal filing and
maintenance requirements, and (iv) in good standing, valid and enforceable.
The Company and the Company Subsidiaries have filed all required notices and
responses to notices, supplemental applications, reports (including
adverse experience reports) and other information with the FDA, EMEA and all
other applicable Regulatory Authorities.

 

 

(b) Without limiting the generality of any other representations and
warranties made by the Company under this Agreement, to the knowledge of the
Company, the conduct of the business of the Company and the Company
Subsidiaries as currently conducted is in compliance in all material respects
with (1) all written communications, requirements and applicable Laws and
Orders of the FDA, EMEA and other Regulatory Authorities and (2) all
Regulatory Authorizations, including all requirements of the FDA, the EMEA
and all other Regulatory Authorities in warning letters, notices of adverse
findings and Section 305 notices and similar letters or notices, and in
connection with all product recalls, notifications and safety alerts, and any
request from the FDA, the EMEA or any Regulatory Authority requesting the
Company or any Company Subsidiary to cease to investigate, test or market any
product, and all consent decrees (including plea agreements) issued with
respect to the Company or any Company Subsidiary. There are no, and have
not been, any inspection reports, warning letters, notices of adverse
findings, Section 305 notices or similar written documents received by the
Company or, to the knowledge of the Company, by any Company Partner, that
assert a lack of compliance with any applicable Laws, Orders, or regulatory
requirements that have not been fully resolved to the satisfaction of the
FDA, the EMEA or any other Regulatory Authorities, as applicable. None of the
Company or any of the Company Subsidiaries has knowledge (or has been
notified by a third party) of any pending regulatory action, investigation or
inquiry of any sort by the FDA, EMEA or any other Regulatory Authority (other
than non-material routine or periodic inspections or reviews) against any of
the Company, a Company Subsidiary, the Core Products or any Person that
manufactures, develops or distributes the Core Products pursuant to a
development, commercialization, manufacturing, supply or other collaboration
arrangement with the Company or any Company Subsidiary (each, a
"Company Partner"), and, to the knowledge of the Company, there is no
basis for any adverse regulatory action. Without limiting the foregoing, (i)
to the knowledge of the Company, there have been no product recalls,
warnings, notifications or safety alerts conducted or issued by the Company
or Company Subsidiaries, the FDA, the EMEA or any other Regulatory
Authorities with respect to the Company\'s and the Company Subsidiaries\'
Products, none of the foregoing has been requested or demanded by the FDA,
the EMEA or any other Regulatory Authorities, and to the Company\'s knowledge,
and there is no reasonable basis for any of the foregoing; (ii) none of the
Company, the Company Subsidiaries or, to the knowledge of the Company, any of
their respective agents or subcontractors, has been convicted of any crime
or engaged in any conduct which would reasonably be expected to result in
criminal liability, debarment or disqualification by the FDA, the EMEA or
any other Regulatory Authority, and (iii) no criminal, injunctive, seizure
or civil

 

 

 

 

 

 

 

 

 

23  

 

 

 

 

 

 

 

penalty actions have at any time been commenced or threatened by any
Regulatory Authority against the Company or any Company Subsidiary or, to
the knowledge of the Company, any of their respective agents or
subcontractors, and there are no consent decrees (including plea agreements)
or similar actions to which the Company or any Company Subsidiary is bound
or which relate to the Core Products. Neither the Company nor any Company
Subsidiary is, to the knowledge of the Company, employing or utilizing the
services of any individual who has been debarred, temporarily denied approval
or suspended under any applicable Law or Order. To the knowledge of the
Company, neither the Company nor any Company Subsidiary has made any untrue
statement of fact or fraudulent statement to the FDA, the EMEA or any other
Regulatory Authority nor have they failed to disclose any fact required to
be disclosed to the FDA, the EMEA or any other Regulatory Authority, and to
the knowledge of the Company, no Company Partner (as defined below) has made
any untrue statement of fact or fraudulent statement to the FDA, the EMEA or
any other Regulatory Authority relating to the Products, nor to the knowledge
of the Company, has any Company Partner failed to disclose any facts
required to be disclosed to the FDA, the EMEA or any other Regulatory
Authority relating to the Products.

 

 

(c) The Company and the Company Subsidiaries have made available to Parent
complete and accurate copies of all Regulatory Authorizations and regulatory
dossiers relating thereto, all serious adverse event reports, periodic
adverse event reports and other pharmacoviligence reports and data, and all
other material Regulatory Authority communications, documents and
other information submitted by the Company to or received by the Company
from the FDA, the EMEA or any equivalent Regulatory Authority,
including inspection reports, warning letters and similar documents, relating
to the Company or any Company Subsidiary, the conduct of their business, or
the Core Products.

 

 

(d) All preclinical studies and clinical trials conducted or being conducted
with respect to the Company\'s and the Company Subsidiaries\' Products by or
at the direction of the Company or any Company Subsidiary have been and are
being conducted in material compliance with the applicable requirements of
Good Laboratory Practices and Good Clinical Practices and applicable
regulations and guidances that relate to the conduct of clinical studies,
and, the Company (1) is not aware of any failure by any Company Partner to
conduct clinical studies in compliance with such applicable requirements,
regulations and guidances and (2) has not received any notifications from any
institutional review board (IRB) raising any issues. All results of
studies, tests and trials related to the Core Products and conducted by or at
the direction of the Company, and all other material information related to
such studies, tests and trials, have been made available to Parent.

 

 

(e) The manufacture of products by the Company and any Company Subsidiary is,
or, in the case of any products manufactured by a Company Partner, to the
knowledge of the Company is, being conducted in material compliance with the
applicable requirements of Current Good Manufacturing Practices. In addition,
the Company and each Company Subsidiary and, to the knowledge of the Company,
their respective Company Partners, are in material compliance with
all applicable registration and listing requirements, including, for
example, those set forth in 21 U.S.C. Section 360 and 21 C.F.R. Parts 207 and
807 and all similar applicable Laws and Orders. To the knowledge of the
Company, no Product sold by the Company or held in inventory by the Company
has been adulterated or misbranded. All labeling is in compliance with FDA,
EMEA and other Regulatory Authority requirements, and all advertising and
promotional materials of the Company and each Company Subsidiary are in
material compliance with FDA, EMEA and other applicable Regulatory Authority
requirements.

 

 

 

 

 

 

 

 

24  

 

 

 

 

 

 

Section 4.10 Taxes.

 

 

(a) Each of the Company and each Company Subsidiary has duly filed all Tax
Returns required to be filed by it, and all such Tax Returns are true,
complete and accurate, except to the extent that all such failures to file,
taken together, have not had and are not reasonably expected to have a
Company Material Adverse Effect. The Company and each of the Company
Subsidiaries have paid (or the Company has paid on its behalf) (i) all taxes
shown as due on such Tax Returns and (ii) all material Taxes otherwise due
and payable, except for those Taxes (x) being contested in good faith
by appropriate proceedings and for which adequate reserves have been
established in the financial statements included in the Company Filed
SEC Reports in accordance with GAAP. There are no Liens for any Taxes upon
the assets of the Company or the Company Subsidiaries, other than (A)
statutory Liens for Taxes not yet due and payable and (B) Liens for Taxes
contested in good faith by appropriate proceedings.

 

 

(b) There is no audit, examination, deficiency, refund litigation, proposed
adjustment or matter in controversy currently in existence with respect to any
Taxes or Tax Return of the Company or any of the Company Subsidiaries.
Neither the Company nor any of the Company Subsidiaries has received
notice of any claim made by a Governmental Entity in a jurisdiction where the
Company or any of the Company Subsidiaries, as applicable, does not file a
Tax Return, that the Company or such Company Subsidiary is or may
be subject to taxation by that jurisdiction. There are no outstanding
requests, agreements, consents or waivers to extend the statutory period of
limitations applicable to the assessment of any Taxes or deficiencies against
the Company or the Company Subsidiaries, and no power of attorney granted
by either the Company or any of the Company Subsidiaries with respect to any
Taxes is currently in force.

 

 

(c) Neither the Company nor any of the Company Subsidiaries has constituted
either a "distributing corporation" or a "controlled corporation" (within the
meaning of Section 355(a)(1)(A) of the Code) in a distribution of stock
qualifying for tax-free treatment under Section 355 of the Code (i) in
the two years prior to the date of this Agreement or (ii) in a distribution
which could otherwise constitute part of a "plan" or "series of
related transactions" (within the meaning of Section 355(e) of the Code) in
conjunction with the Merger.

 

 

(d) Neither the Company nor any of the Company Subsidiaries has participated,
within the meaning of Treasury Regulation Sections 1.6011-4(c), or has been a
"material advisor" or "promoter" (as those terms are defined in Section 6111
and 6112 of the Code) in (A) any "reportable transaction" within the meaning
of Sections 6011, 6662A and 6707A of the Code, (B) any "confidential
corporate tax shelter" within the meaning of Section 6111 of the Code or (C)
any "potentially abusive tax shelter" within the meaning of Section 6112
of the Code.

 

 

(e) The Company and the Company Subsidiaries have complied in all material
respects with all applicable Laws relating to the payment and withholding of
Taxes.

 

 

 

(f) Neither the Company nor any of the Company Subsidiaries has any liability
for any material amount of Taxes of any Person (other than the Company and
the Company Subsidiaries) under Treasury Regulation  1.1502-6 (or any
similar provision of any state, local

 

 

 

 

 

 

 

 

 

25  

 

 

 

 

 

 

 

or foreign law), as a transferee or successor, by contract or otherwise,
that, individually or in the aggregate, has had or would reasonably be
expected to have a Company Material Adverse Effect.

 

 

(g) Neither the Company nor any of the Company Subsidiaries has since
October 1, 2006 (A) changed an annual accounting period or changed any
accounting method, (B) settled any material Tax claim or assessment, or (C)
received a Tax ruling or entered into a closing agreement with any
taxing authority.

 

 

(h) As used in this Agreement (A) "Taxes" means any and all federal,
state, local, foreign or other taxes of any kind (together with any and all
interest, penalties, additions to tax and additional amounts imposed with
respect thereto) imposed by any Governmental Entity, including, without
limitation, taxes or other similar charges on or with respect to
income, franchises, windfall or other profits, gross receipts, property,
capital, sales, use, transfer, inventory, license, capital stock, payroll,
employment, unemployment, social security, workers\' compensation, severance,
stamp, occupation, premium or net worth, and taxes or other similar charges
in the nature of excise, withholding, ad valorem, value added, estimated
taxes, or custom duties and (B) "Tax Return" means any report, return,
document, declaration or other information or filing required to be filed
with respect to taxes (whether or not a payment is required to be made with
respect to such filing), including information returns, any documents with
respect to or accompanying payments of estimated taxes, or with respect to
or accompanying requests for the extension of time in which to file any such
report, return, document, declaration or other information.

 

 

Section 4.11 Change of Control Arrangements; No Excess Parachute Payment.

 

 

(a) Neither the execution and delivery of this Agreement, the Offer, the
consummation of the Merger or the other transactions contemplated by this
Agreement nor compliance with the terms hereof will (either alone or in
conjunction with any other event), except as otherwise set forth in Section
4.11(a) of the Company Disclosure Letter, (i) entitle any current or
former employee, officer, director or consultant of the Company or any
Company Subsidiary (each, a "Company Participant") to enhanced severance
or termination pay, change in control or similar payments or benefits, (ii)
result in, cause the accelerated vesting or delivery of, or increase the
amount or value of, any payment or benefit to any Company Participant, (iii)
trigger any payment or funding (through a grantor trust or otherwise) of any
compensation or benefits under, increase the amount payable or trigger any
other material obligation pursuant to, or increase the cost of, any
Company Benefit Plan (as defined in Section 4.14(a)) or Company Benefit
Agreement (as defined in Section 4.14(a)) or (iv) result in any breach
or violation of, or a default under, any Company Benefit Plan or Company
Benefit Agreement. The total amount of all payments and the fair market value
of all non-cash benefits (other than benefits pursuant to the Company
Stock Options or any Company Common Stock held by any Company Participant
that does not constitute restricted shares as of the date hereof) that may
become payable or be provided to any Company Participant under the Company
Benefit Plans and Company Benefit Agreements (assuming for such purpose that
such individual\'s employment were terminated immediately following the
Effective Time as if the Effective Time were the date hereof) will not
exceed the amount set forth in Section 4.11(a) of the Company
Disclosure Letter.

 

 

 

 

 

 

 

 

 

26  

 

 

 

 

 

 

 

 

(b) Other than payments that shall be made to Persons set forth on Section
4.11(b) of the Company Disclosure Letter (the "Primary Company Executives"),
no amount or other entitlement that could be received (whether in cash or
property or the vesting of property) as a result of the Offer, the Merger or
any other transaction contemplated by this Agreement (alone or
in combination with any other event) by any other Company Participant who
is a "disqualified individual" (as such term is defined in
Treasury Regulation Section 1.280G-1) under any Company Benefit Plan, Company
Benefit Agreement or other compensation arrangement would be characterized as
an "excess parachute payment" (as such term is defined in Section 280G(b)(1)
of the Code), and no such other disqualified individual is entitled to
receive any additional payment (e.g., any Tax gross up or other
payment) from the Company, Parent or any other Person in the event that the
excise Tax required by Section 4999(a) of the Code is imposed on such
disqualified individual. Section 4.11(b) of the Company Disclosure Letter
sets forth (i) a complete and accurate list of the Company\'s reasonable, good
faith estimate of the maximum amount that could be received (whether in cash
or property or the vesting of property, and including the amount of any Tax
gross up) by each Primary Company Executive as a result of the Offer, the
Merger or any other transaction contemplated by this Agreement (alone or in
combination with any other event) under all Company Benefit Agreements and
Company Benefit Plans and (ii) the "base amount" (as defined in Section
280G(b)(3) of the Code) for each Primary Company Executive, estimated as of
the date of Closing.

 

 

Section 4.12 Litigation. Other than tax matters, employee benefits matters,
labor and employment matters, environmental matters or intellectual property
matters, which are the subjects of Sections 4.10, 4.14, 4.15, 4.16 and 4.17,
respectively:

 

 

(a) There is no claim, suit, action, investigation, indictment or
information, or administrative, arbitration or other proceeding
("Litigation") pending or, to the knowledge of the Company, threatened
against or affecting the Company or any of the Company Subsidiaries or any of
their respective assets which, individually or in the aggregate, has had or,
if adversely determined, would reasonably be expected to have, a Company
Material Adverse Effect.

 

 

(b) There is no Order of any Governmental Entity or arbitrator outstanding
against, or, to the knowledge of the Company, investigation by, any
Governmental Entity involving the Company or any of the Company Subsidiaries
or any of their respective assets that, individually or in the aggregate, has
had or is reasonably expected to have a Company Material Adverse Effect.

 

 

Section 4.13 Material Contracts.

 

 

(a) Except for (1) Contracts filed or listed as an exhibit to the Company\'s
annual report on Form 10-K for the fiscal year ended September 30, 2008 and
(2) those Contracts set forth on Section 4.13(a) of the Company Disclosure
Letter, neither the Company nor any Company Subsidiary is party to any
Company Material Contract. For the purposes of this Agreement,
"Company Material Contract" shall mean the following (including any series of
one or more related Contracts):

 

 

(i) Any severance agreement and any employment or other Contract (as
defined in Section 9.14(g)) with an employee or former employee, officer or

 

 

 

 

 

 

 

 

 

27  

 

 

 

 

 

 

 

 

director of the Company or any Company Subsidiary providing for aggregate
compensation in excess of $50,000 in any twelve month period (other than any
unwritten Contract for the employment of any such employee or former employee
implied at law);

 

 

(ii) Except as contemplated by the budget attached as Schedule 4.13(a)(ii),
any Contract for capital expenditures or the acquisition or construction of
fixed assets which requires aggregate future payments in excess of $50,000;

 

 

(iii) Any Contract (A) entered into other than in the ordinary course of
business containing covenants of the Company or any Company Subsidiary (A) to
indemnify or hold harmless another Person, unless such indemnification or
hold harmless obligation to such Person, or group of Persons, as the case may
be, is less than $50,000 or (B) containing covenants of the Company or any
Company Subsidiary not to (or otherwise restricting or limiting the
ability of the Company or any Company Subsidiary to) compete in any line
of business or geographic or therapeutic area, including any covenant not
to compete with respect to the manufacture, marketing, distribution or sale
of any product or product line;

 

 

(iv) Any Contract requiring aggregate future payments or expenditures and
relating to Cleanup, abatement, remediation or similar actions in connection
with environmental liabilities;

 

 

(v) Any license, royalty Contract or other Contract with respect to
(i) material Company IP relating to Core Products to which the Company or
any Company Subsidiary is a party that grants, assigns or otherwise
transfers to any Person, or restricts the use or registration of,
any material rights (including any licenses, assignments, consents to use or
register, options or rights of negotiation), title or interest in or to such
Intellectual Property (as defined in Section 9.14(r)) or (ii) Intellectual
Property which, pursuant to the terms thereof, requires, or may require upon
the occurrence of certain events, future material payments by the Company or
any Company Subsidiary;

 

 

(vi) Any Contract pursuant to which the Company or any Company Subsidiary is
required to (with or without the satisfaction of any conditions), or obtains
or grants any material rights (including any options or rights of
negotiation) to, undertake the development or commercialization of
any pharmaceutical product or technology, or any material interest therein;

 

 

(vii) Any Contract pursuant to which the Company or any Company Subsidiary
has entered into a partnership or joint venture with any other Person (other
than the Company or any Company Subsidiary);

 

 

(viii) Any indenture, mortgage, loan or credit Contract under which the
Company or any Company Subsidiary has outstanding indebtedness in a
principal amount in excess of $50,000 or any outstanding note, bond,
indenture or other evidence of Indebtedness in a principal amount in excess
of $50,000 for borrowed 

 

 

 

 

 

 

 

 

 

28  

 

 

 

 

 

 

money or otherwise, or guaranteed outstanding indebtedness for money borrowed
by others;

 

 

(ix) Any Contract under which the Company or any Company Subsidiary is (A) a
lessee of real property, (B) a lessee of, or holds or uses, any machinery,
equipment, vehicle or other tangible personal property owned by a third person
or entity, (C) a lessor of real property, or (D) a lessor of any tangible
personal property owned by the Company or Company Subsidiary, in any case
referred to in clauses (B) or (D) only which requires future annual payments
in excess of $50,000;

 

 

(x) Any Contract under which the Company or any Company Subsidiary is a
purchaser or supplier of goods and services which, pursuant to the terms
thereof, requires future payments by the Company or any Company Subsidiary in
excess of $50,000 per annum;

 

 

(xi) Any material Contract (including guarantees) between the Company and any
Company Subsidiary, other than any Contract relating to the operation of the
Company and the Company Subsidiaries in the ordinary course;

 

 

(xii) Any Contract which requires future payments by the Company or any
Company Subsidiary in excess of $50,000 per annum containing "change of
control" or similar provisions;

 

 

(xiii) Any Contract relating to the acquisition or disposition of
any business or any material assets other than in the ordinary course
of business (whether by merger, sale of stock or assets or otherwise);

 

 

(xiv) Any Contract entered into other than in the ordinary course of business
that (A) involves aggregate payments by or to the Company or any Company
Subsidiary in excess of $50,000 per annum, other than a purchase or sales
order or other Contract entered into in the ordinary course of
business consistent with past practice or (B) by its terms does
not terminate within one year after the date of such Contract and is not
cancelable during such period without penalty or without payment;

 

 

(xv) Any Contract the termination or breach of which, or in respect of which
the failure to obtain any consent required in connection with the
transactions contemplated by this Agreement, is reasonably likely to have a
Company Material Adverse Effect; and

 

 

(xvi) Any material Contracts relating in any material respect to any Core
Product (any such contract, a "Products Contract").

 

 

To the knowledge of the Company, all Company Material Contracts are valid
and in full force and effect and, to the knowledge of the Company,
enforceable in accordance with their respective terms, subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other laws relating to
or affecting the rights and remedies of creditors generally and to general

 

 

 

 

 

 

 

 

29  

 

 

 

 

 

 

 

principles of equity (regardless of whether considered in a proceeding in
equity or at law), except to the extent that (x) they have
previously expired or terminated in accordance with their terms, (y) in
the case of Company Material Contracts that are not Products Contracts, any
failures to be in full force and effect which, individually or in the
aggregate, are not reasonably likely to have a Company Material Adverse
Effect, and (z) in the case of Company Material Contracts that are Products
Contracts, any failures to be in full force and effect which, individually or
in the aggregate, are not reasonably likely to materially and adversely
affect the related Product. Neither the Company nor any Company Subsidiary,
nor, to the knowledge of the Company, any counterparty to any Company
Material Contract, has violated any provision of, or committed or failed to
perform any act which, with or without notice, lapse of time or both, would
constitute a default under the provisions of, any Company Material Contract,
except in each case for those violations or defaults which, individually or in
the aggregate, are not reasonably likely to have a Company Material Adverse
Effect. Neither the Company nor any Company Subsidiary, nor, to the knowledge
of the Company, any counterparty to any Products Contract has (A) violated
any provision of, or committed or failed to perform any act which, with or
without notice, lapse of time or both, would constitute a default under the
provisions of any Products Contract or (B) notified the Company, either
orally or in writing, of any intent to breach, fail to perform, terminate, or
not renew any Products Contract, other than, in the case of (A) and (B)
above, any such violations, commissions, failures or notifications that,
individually or in the aggregate, are not reasonably likely to materially
and adversely affect the related Product. The Company has no knowledge of
any pending or threatened bankruptcy, insolvency or similar proceeding with
respect to any party to any Company Material Contract which has had or is
reasonably expected to have a Company Material Adverse Effect. Neither the
Company nor any Company Subsidiary (i) is a party to any voting agreement
with respect to the voting of any securities of the Company or (ii) has any
contractual obligation to file a registration statement under the Securities
Act, in respect of any securities of the Company or any Company Subsidiary.

 

 

Section 4.14 Employee Benefit Plans.

 

 

(a) Section 4.14(a)(i) of the Company Disclosure Letter sets forth a list, as
of the date hereof, of all "employee pension benefit plans" (as defined in
Section 3(2) of the Employee Retirement Income Security Act of 1974, as
amended ("ERISA")) (sometimes referred to individually as a
"Company Pension Plan" and collectively as the "Company Pension Plans"), all
"employee welfare benefit plans" (as defined in Section 3(1) of
ERISA) (sometimes referred to individually as a "Company Welfare Plan" and
collectively as the "Company Welfare Plans"), and each vacation or paid time
off, severance, termination, retention, change in control, employment,
incentive compensation, performance, profit sharing, stock-based, stock-
related, stock option, fringe benefit, perquisite, stock purchase, stock
ownership, phantom stock and deferred compensation plan, arrangement,
agreement and understanding and other compensation, benefit and fringe
benefit plans, arrangements, agreements and understandings (whether or not
legally binding), sponsored, maintained, contributed to or required to be
sponsored, maintained or contributed to, by the Company, any Company
Subsidiary or any other Person that, together with the Company, is treated as
a single employer under Section 414(b), (c), (m) or (o) of the Code or any
other applicable Law (each, a "Commonly Controlled Entity"), in each case,
providing benefits to any Company Participant, but not including the
Company Benefit Agreements (all such plans, arrangements, agreements and
understandings, including any such plan, arrangement, agreement or
understanding entered 

 

 

 

 

 

 

 

 

 

30  

 

 

 

 

 

 

into or adopted on or after the date of this Agreement, collectively,
"Company Benefit Plans"). Section 4.14(a)(ii) of the Company Disclosure
Letter sets forth a list, as of the date hereof, of (i) each employment,
deferred compensation, change in control, severance, termination,
employee benefit, loan or indemnification agreement between the Company or
any Company Subsidiary, on the one hand, and any Company Participant, on the
other hand, and (ii) each contract between the Company or any Company
Subsidiary, on the one hand, and any Company Participant, on the other hand
(all such contracts under the foregoing clauses (i) and (ii), including any
contract which is entered into on or after the date of this Agreement,
collectively, "Company Benefit Agreements").

 

 

(b) The Company has made available to Parent true and complete copies of (i)
each Company Benefit Plan and each Company Benefit Agreement (or, in the case
of any unwritten Company Benefit Plan or Company Benefit Agreement, a written
summary of the material provisions of such plan or agreement) in effect on
the date hereof, (ii) the most recent report on Form 5500 filed with the
Internal Revenue Service with respect to each Company Benefit Plan in effect
on the date hereof, to the extent any such report was required by applicable
Law, (iii) the most recent summary plan description for each Company Benefit
Plan for which such a summary plan description is required by applicable Law
and (iv) each currently effective trust agreement or other funding vehicle
relating to any Company Benefit Plan. Neither the Company nor any Commonly
Controlled Entity has sponsored, maintained, contributed to or been obligated
to sponsor, maintain or contribute to, or has any actual or contingent
liability under, any benefit plan that is subject to Title IV of ERISA or
Section 412 of the Code or is otherwise a defined benefit pension plan or is a
plan described in Section 3(40) of ERISA or Section 413 of the Code. With
respect to any Company Welfare Plan or any Company Benefit Agreement that is
an employee welfare benefit plan, (A) no such Company Welfare Plan or Company
Benefit Agreement is funded through a "welfare benefits fund" (as such term is
defined in Section 419(e) of the Code), (B) each such Company Welfare Plan
and Company Benefit Agreement that is a "group health plan" (as such term is
defined in Section 5000(b)(1) of the Code) materially complies with the
applicable requirements of Section 4980B(f) of the Code and any applicable
similar state or local Law and (C) to the knowledge of the Company, each
such Company Welfare Plan and Company Benefit Agreement (including any such
plan or agreement covering retirees or other former employees) may be
amended or terminated without material liability to the Company or any
Company Subsidiary on or at any time after the Effective Time. No Company
Welfare Plan or Company Benefit Agreement that is an employee welfare benefit
plan as defined under ERISA Section 3(1) provides benefits to, or on behalf
of, any former employee after the termination of employment except (1) where
the full cost of such benefit is borne entirely by the former employee
(or his eligible dependents or beneficiaries) or (2) where the benefit is
required by Section 4980B of the Code.

 

 

(c) To the knowledge of the Company (i) each Company Benefit Plan and
Company Benefit Agreement has been administered in all material respects in
accordance with its terms and with all applicable Laws, including ERISA and
the Code; (ii) all material contributions, including participant
contributions, and benefit payments required under each Company Benefit Plan
and Company Benefit Agreement have been made in full on a timely and proper
basis pursuant to the terms of such plan or agreement and applicable Law;
(iii) no Company Participant has received or is reasonably expected to
receive any payment or benefit from the Company or any Company Subsidiary
that would be nondeductible pursuant to Section

 

 

 

 

 

 

 

 

 

31  

 

 

 

 

 

 

 

162(m) of the Code or any other applicable Law, except as otherwise set
forth in Section 4.14(c) of the Company Disclosure Letter; (iv) each
Company Pension Plan that is intended to comply with the provisions
of Section 401(a) of the Code has been the subject of a determination letter
from the Internal Revenue Service or an application therefor with respect
to all material and applicable Tax law changes to the effect that such
Company Pension Plan currently is qualified and exempt from income
Taxes under Section 401(a) of the Code and the trust relating to such plan is
exempt from income Taxes under Section 501(a) of the Code, and, to the
knowledge of the Company, no such determination letter has been revoked and,
to the knowledge of the Company, revocation has not been threatened, and,
to the knowledge of the Company, no event has occurred since the date of the
most recent determination letter or application therefor relating to any
such Company Pension Plan that is reasonably expected to affect the
qualification of such Company Pension Plan adversely or materially increase
the costs relating thereto or require security under Section 307 of
ERISA; (v) the Company has made available to Parent a copy of the most
recent determination letter received with respect to each Company Pension
Plan for which such a letter has been issued, as well as a copy of any
pending application for a determination letter and a complete and accurate
list of all amendments to any Company Pension Plan in effect as of the date
hereof as to which a favorable determination letter has not yet been
received; (vi) there are no understandings, agreements or undertakings,
written or oral, with any Person (other than pursuant to the express terms
of the applicable Company Benefit Plan or Company Benefit Agreement) that are
(pursuant to any such understandings, agreements or undertakings) reasonably
expected to result in any material liabilities if such Company Benefit Plan
or Company Benefit Agreement were amended or terminated upon or at any time
after the Effective Time or that would prevent any unilateral action by the
Company (or, after the Effective Time, Parent) to effect such amendment or
termination; (vii) only officers, directors and employees of the Company or
any Company Subsidiaries are eligible for compensation or benefits under the
terms of each Company Benefit Plan and Company Benefit Agreements, and, to
the knowledge of the Company, each individual who is classified by the
Company or any Company Subsidiary as an "employee" or as an "independent
contractor" is properly so classified; and (viii) except as set forth in
Section 4.14(b) of the Company Disclosure Letter or Section 4.14(c) of the
Company Disclosure Letter, notwithstanding any oral or written representation
to the contrary, no Company Participant is entitled to any gross-up, make-
whole or other additional payment from the Company or any Company Subsidiary
in respect of any Tax (including Federal, state, local or foreign income,
excise or other Taxes (including Taxes imposed under Section 409A of the
Code)) or interest or penalty related thereto.

 

 

(d) To the knowledge of the Company, each Company Benefit Plan and each
Company Benefit Agreement for the benefit of any employee, officer or
director of the Company that is a "nonqualified deferred compensation plan"
within the meaning of Section 409A(d)(1) of the Code (a
"Nonqualified Deferred Compensation Plan") subject to Section 409A of the
Code has been operated in material compliance with Section 409A of the
Code since January 1, 2005, based upon a good faith,
reasonable interpretation of (i) Section 409A of the Code and (ii)(A) the
Final Regulations issued thereunder or (B) Internal Revenue Service Notice
2005-1 (clauses (i) and (ii), together, the "409A Authorities"), and the
Company has used its reasonable best efforts to amend each
Nonqualified Deferred Compensation Plan to the extent required to comply
with Section 409A and the Final Regulations issued thereunder.

 

 

 

 

 

 

 

 

 

32  

 

 

 

 

 

 

 

Section 4.15 Labor and Employment Matters.

 

 

(a) The Company and the Company Subsidiaries are neither party to, nor bound
by, any labor agreement, collective bargaining agreement, work rules
or practices, or any other labor-related agreements or arrangements with any
labor union, labor organization or works council; there are no labor
agreements, collective bargaining agreements or any other labor-related
agreements that pertain to any of the employees of the Company or the
Company Subsidiaries; and no employees of the Company or the Company
Subsidiaries are represented by any labor organization with respect to their
employment with the Company or the Company Subsidiaries.

 

 

(b) No labor union, labor organization, works council, or group of employees
of the Company or the Company Subsidiaries has made a pending demand for
recognition or certification, and there are no representation or
certification proceedings or petitions seeking a representation proceeding
presently pending or threatened in writing to be brought or filed with the
National Labor Relations Board or any other labor relations tribunal
or authority. The Company and the Company Subsidiaries have no knowledge of
any labor union organizing activities with respect to any employees of the
Company or the Company Subsidiaries.

 

 

(c) From January 1, 2004 to the date of this Agreement, there has been no
actual or, to the knowledge of the Company or the Company Subsidiaries,
threatened material labor arbitrations, material grievances, labor disputes,
strikes, lockouts, slowdowns or work stoppages against or affecting the
Company or the Company Subsidiaries.

 

 

(d) The Company and the Company Subsidiaries are in compliance in all
material respects with all applicable laws respecting employment and
employment practices, including, without limitation, all laws respecting
terms and conditions of employment, health and safety, wages and hours, child
labor, immigration, employment discrimination, disability rights or benefits,
equal opportunity, plant closures and layoffs, affirmative action, workers\'
compensation, labor relations, employee leave issues and unemployment
insurance, except where such non-compliance would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect.

 

 

(e) The Company and the Company Subsidiaries are not delinquent in any
material respect in payments to any employees or former employees for any
services or amounts required to be reimbursed or otherwise paid, except where
such delinquency would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect.

 

 

(f) To the knowledge of the Company, no employee of the Company or any Company
Subsidiary is in any respect in violation of any term of any employment
agreement, nondisclosure agreement, common law nondisclosure obligation,
fiduciary duty, non-competition agreement, restrictive covenant or other
obligation to a former employer of any such employee relating (i) to the
right of any such employee to be employed by the Company or the Company
Subsidiaries or (ii) to the knowledge or use of trade secrets or proprietary
information, except for such violations as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect.

 

 

 

 

 

 

 

 

 

33  

 

 

 

 

 

 

 

 

(g) The Company and the Company Subsidiaries have no knowledge that any of
the individuals at or above the level of Vice-President intends to terminate
his or her employment.

 

 

Section 4.16 Environmental Matters.

 

 

(a) Each of the Company and the Company Subsidiaries has been at all times
and is in compliance with all applicable Environmental Laws, including, but
not limited to, possessing all Environmental Permits (as defined in Section
9.14(i)) required for its operations under applicable Environmental Laws,
except for such noncompliance as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. To the
extent that any applicable Environmental Law requires the Company or any
Company Subsidiary to have filed applications to renew any such Environmental
Permits, the Company and each such Company Subsidiary has filed such
applications in accordance with the time periods set forth in such
Environmental Law in order to allow continued operation in accordance with
the terms of such Environmental Permits, except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material Adverse
Effect.

 

 

(b) There is no pending or, to the knowledge of the Company, threatened claim,
lawsuit or administrative proceeding against the Company or any Company
Subsidiary under or pursuant to any Environmental Law that, individually or
in the aggregate, would reasonably be expected to have a Company Material
Adverse Effect.

 

 

(c) Neither the Company nor any Company Subsidiary has received written
notice from any Person, including but not limited to any Governmental Entity,
alleging that the Company or such Company Subsidiary has been or is in
violation or potentially in violation of any applicable Environmental Law or
otherwise may be liable under any applicable Environmental Law, except with
respect to matters that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. Neither the
Company nor any Company Subsidiary has received any written requests for
information from any Person, including, but not limited to any Governmental
Entity, with respect to any matter that could result in liability pursuant to
any Environmental Law, including, but not limited to, written requests
for information pursuant to the federal Comprehensive Environmental
Response, Compensation and Liability Act ("CERCLA"), except with respect to
such matters that, individually or in the aggregate, would reasonably be
expected to have a Company Material Adverse Effect.

 

 

(d) Neither the Company nor any Company Subsidiary is a party or subject to
any administrative or judicial order or decree pursuant to the Environmental
Laws that, individually or in the aggregate, would reasonably be expected to
have a Company Material Adverse Effect.

 

 

(e) With respect to real property currently or formerly owned, leased or
operated by the Company or any Company Subsidiary, to the knowledge of the
Company, there have been no Releases of Hazardous Substances (as defined in
Section 9.14(n)) on or underneath any of such real property that,
individually or in the aggregate, would reasonably be expected to have a
Company Material Adverse Effect.

 

 

 

 

 

 

 

 

 

34  

 

 

 

 

 

 

 

 

(f) The transactions contemplated by this Agreement will not require any
filing or other action under any so-called "transaction-triggered"
Environmental Laws, including, but not limited to, the New Jersey Industrial
Site Recovery Act and the Connecticut Transfer Act.

 

 

(g) To the knowledge of the Company, there are presently no conditions or
circumstances, including, but not limited to, pending or proposed
Environmental Laws or any changes or amendments to existing Environmental
Laws or Environmental Permits that would be reasonably likely to require the
Company or any Company Subsidiary to incur expenditures or conduct any
Cleanup under any current Environmental Laws that, individually or in the
aggregate, would reasonably be expected to have a Company Material Adverse
Effect.

 

 

Section 4.17 Intellectual Property.

 

 

(a) Set forth in Section 4.17(a) to the Company Disclosure Letter is a true
and complete list of all (A) patents and patent applications, trademarks and
service marks and all applications and registrations therefor, all Internet
domain names and copyrights included in the Company Owned IP and (B) patents,
patent applications, trademarks and service marks included in the Company
Licensed IP that are related to any Products.

 

 

(b) The Company has or the Company Subsidiaries have an unrestricted and
exclusive ownership interest in all Company Owned IP (in each case, free and
clear of any Liens) and is listed in the records of the appropriate United
States, foreign or other registry as the sole and exclusive current owner of
record for each application and registration included in the Company Owned
IP. The Company IP includes all Intellectual Property, and the Company\'s and
the Company Subsidiaries\' rights in and to the Company IP include all
Intellectual Property rights, used or otherwise exploited in or necessary for
the conduct of the business of the Company and the Company Subsidiaries as
currently conducted and planned to be conducted. No academic institution or
Governmental Entity has any right, title or interest in or to any Company
Owned IP (including any "march in" rights) or any Intellectual
Property included in Section 4.17(a) of the Company Disclosure Letter. The
Company or a Company Subsidiary has taken commercially reasonable efforts, or
contractually requires the Company Partners in those jurisdictions where the
Products are marketed or sold solely through Company Partners to
take commercially reasonable efforts, to make appropriate submissions of the
Company IP to the FDA\'s "Orange Book" and all equivalent documents
maintained by the EMEA or any other Regulatory Authority for jurisdictions in
which the Company or any of the Company Subsidiaries sells, markets or
authorizes the sale or marketing of the Products.

 

 

(c) To the knowledge of the Company, the Contracts under which the Company
has been granted rights in any Intellectual Property owned or controlled by a
third Person are valid and legally enforceable, and free and clear of
all Liens. The Company has provided Parent with access to true and complete
copies of all Contracts under which the Company or any Company Subsidiary has
obtained or granted any rights, title or interests in or to, or which by
their terms expressly restrict the Company or any Company Subsidiaries with
respect to any Intellectual Property (each, an "IP Contract") related to any
or all of the Products, other than standard license agreements for
commercially-available, off-the-shelf software. The Company or a Company
Subsidiary has the exclusive right to develop, commercialize, manufacture,
market, sell, import and otherwise exploit each of the Products and neither
the

 

 

 

 

 

 

 

 

 

35  

 

 

 

 

 

 

 

Company nor any Company Subsidiary has granted, assigned or otherwise
transferred to any Person any right, title or interest in or to any Product
or Product IP.

 

 

(d) To the knowledge of the Company, no Person, during the past six years,
has misappropriated, infringed, diluted, or otherwise violated, either
directly or indirectly, any Company IP, nor is any Person currently
doing so. To the knowledge of the Company, no Litigation has been brought or
threatened against any Person during the past six years, with respect to any
Company IP by the Company, any Company Subsidiaries or, with respect to any
or all of the Product IP and to the knowledge of the Company, by any of
their licensors during the past six years and, to the knowledge of the
Company, there is no basis for any Litigation regarding any of the foregoing.

 

 

(e) (A) There has not been any Litigation during the past six years
with respect to any Company IP, there is no pending Litigation and, to the
knowledge of the Company, there is no threatened Litigation (1) alleging
misappropriation, infringement, dilution or other violation by the Company or
any Company Subsidiary of any Intellectual Property of any Person, (2)
challenging the Company\'s or any Company Subsidiary\'s ownership or use of,
or the registrability or maintenance of, any Company Owned IP, (3)
challenging the validity or enforceability of any Company Owned IP,
(4) alleging that the use by the Company or any Company Subsidiary of
Company Licensed IP is in breach of any applicable grant, license, agreement,
instrument or other arrangement pursuant to which the Company or any
Affiliate acquired the right to use such Intellectual Property, or (5)
alleging misuse or antitrust violations arising from the use or other
exploitation of any Intellectual Property, and (B) with respect to (1) any
or all of the Products and (2) any other material Company IP, to the
knowledge of the Company, there is no basis for any Litigation regarding any
of the foregoing in (A)(1), (A)(2), (A)(3), (A)(4) or (A)(5); no Company IP
has been or is being used or enforced by the Company or the Company
Subsidiaries or, with respect to any or all of the Product IP, by any of
their licensors, in a manner that, individually or in the aggregate, is
reasonably likely to result in the cancellation, invalidity or
unenforceability of such Intellectual Property.

 

 

(f) All patents and patent applications, trademark registrations and
applications and all other applications, registrations and filings under the
Company IP (A) meet all material applicable requirements for obtaining a
patent, trademark registration or other Intellectual Property
registration, including any applicable disclosure requirements, (B) are
subsisting, in full force and effect, (C) to the knowledge of the Company,
are valid and enforceable, (D) have not expired, been cancelled or abandoned,
and (E) have had paid in a timely manner all registration, maintenance and
renewal fees necessary to preserve the rights of the Company and the Company
Subsidiaries in connection with such Intellectual Property.

 

 

(g) The Company and the Company Subsidiaries have taken all commercially
reasonable measures to obtain patent rights worldwide, to the extent
commercially reasonable to do so, under Company Owned IP and Company Licensed
IP as to which they have the necessary prosecution rights, and, to
the knowledge of the Company, have not forfeited or otherwise lost any right
to file any material patent applications or obtain any material patents in
any country in North America or those countries in Europe or Asia in which the
Company has the necessary prosecution rights and where the Company,
Company Subsidiaries or Company Partners market, sell, manufacture, develop
or distribute the Products, such as by failing to meet any filing 

 

 

 

 

 

 

 

 

 

36  

 

 

 

 

 

 

 

deadline or otherwise; the Company and the Company Subsidiaries have no
reason to believe that the scope of any issued claims under any patents under
the Company IP should be less than the scope reflected as of the date hereof
in such patents or that the scope of any issued claims under any patent
applications under the Company IP will or should be materially less than the
scope reflected as of the date hereof in such patent applications.

 

 

(h) Neither the Company nor any Company Subsidiary has granted any Person any
right to control the prosecution or registration of any Product IP or to
bring, defend or otherwise control any Litigations with respect to Product
IP, except as expressly permitted under an IP Contract.

 

 

(i) Neither the Company nor any Company Subsidiary has entered into nor is
subject to any consents, judgments, orders, indemnifications, forbearances to
sue, settlement agreements, licenses or other arrangements in connection with
the resolution of any disputes or Litigation that (A) restricts the Company
or any Company Subsidiaries with respect to any material Intellectual
Property, (B) restricts the Company\'s or any Company Subsidiary\'s businesses
in any material manner in order to accommodate any Person\'s Intellectual
Property, or (C) permits any Person to use any material Company IP except as
expressly permitted under an IP Contract.

 

 

(j) The Company and each Company Subsidiary has implemented commercially
reasonable measures to maintain the confidentiality of the trade secrets and
other proprietary information under the Company IP. No current or former
employee or contractor of the Company or any Company Subsidiary owns any
right, title or interest in or to any of the Company Owned IP. To the
knowledge of the Company, there has not been any disclosure of any material
confidential information of the Company or any Company Subsidiary (including
any such information of any other Person disclosed in confidence to the
Company or any Company Subsidiary) to any Person in a manner that
has resulted or is likely to result in the loss of trade secret or other
rights in and to such information. Except as set forth in Section 4.17(j) of
the Company Disclosure Letter, the Company and the Company Subsidiaries have
complied in all material respects with all applicable Laws, as well as its
own rules, policies, and procedures, relating to privacy, data protection,
and the collection and use of personally identifiable information.

 

 

Section 4.18 Stockholders\' Rights Agreement. Neither the Company nor any
Company Subsidiary has adopted, or intends to adopt, a stockholders\' rights
agreement or any similar plan or agreement which limits or impairs the
ability to purchase, or become the direct or indirect beneficial owner of,
shares or any other equity or debt securities of the Company or any of the
Company Subsidiaries.

 

 

Section 4.19 Brokers; Schedule of Fees and Expenses. No broker, investment
banker, financial advisor or other Person, other than UBS Securities LLC, the
fees and expenses of which will be paid by the Company, is entitled to any
broker\'s, finder\'s, financial advisor\'s or other similar fee or commission
in connection with the Offer, the Merger and the other
transactions contemplated by this Agreement based upon arrangements made by
or on behalf of the Company. The estimated aggregate fees and expenses
incurred and to be incurred by the Company in connection with the Offer, the
Merger and the other transactions contemplated by

 

 

 

 

 

 

 

 

 

37  

 

 

 

 

 

 

 

this Agreement (including the fees of UBS Securities LLC and the fees of
the Company\'s legal counsel) are set forth in Section 4.19 of the Company
Disclosure Letter. The Company has furnished to Parent a true and complete
copy of all agreements between the Company and UBS Securities LLC relating to
the Offer, the Merger and the other transactions contemplated by
this Agreement.

 

 

Section 4.20 Insurance. The Company has delivered to Parent prior to the
date hereof a list that is true and complete in all material respects of all
material insurance policies in force naming the Company, any of the Company
Subsidiaries or employees thereof as an insured or beneficiary or as a loss
payable payee or for which the Company or any Company Subsidiary has paid or
is obligated to pay all or part of the premiums. Except as has not had, or is
not reasonably expected to have, individually or in the aggregate, a Company
Material Adverse Effect, all such insurance policies are in full force and
effect, all premiums due and payable thereon have been paid, and neither the
Company nor any Company Subsidiary has received, as of the date hereof,
written notice of any pending or threatened cancellation or premium increase
(retroactive or otherwise) with respect thereto. Each of the Company and each
Company Subsidiary is in compliance with all conditions contained in such
insurance policies, except where the failure to so comply has not had, or is
not reasonably expected to have, individually or in the aggregate, a Company
Material Adverse Effect.

 

 

 

ARTICLE V

 

 

REPRESENTATIONS AND WARRANTIES

 

OF PARENT AND MERGER SUB

 

 

Each of Parent and Merger Sub represents and warrants to the Company as of
the date hereof and as of the Closing Date (except for those representations
and warranties made as of a specific date or time) as follows (except as
disclosed in the Parent SEC Reports (as defined in Section 5.6(a))) on or
prior to the date hereof (and without regard to any amendment thereto filed
after the date of this Agreement)).

 

 

Section 5.1 Organization and Good Standing. Each of Parent and Merger Sub
is a corporation duly organized, validly existing and in good standing under
the laws of its jurisdiction of incorporation. Parent is the legal and
beneficial owner of all of the issued and outstanding capital stock of Merger
Sub. Merger Sub was formed at the direction of Parent solely for the purposes
of effecting the Merger and the other transactions contemplated hereby.

 

 

Section 5.2 Authority.

 

 

(a) Each of Parent and Merger Sub has all necessary corporate power and
authority to execute and deliver this Agreement and the other Transaction
Agreements to which it is a party, to perform its obligations hereunder and
thereunder and to consummate the Offer, the Merger and the other
transactions contemplated hereby and thereby. The execution, delivery and
performance by each of Parent and Merger Sub of this Agreement and the
other Transaction Agreements to which it is a party and the consummation by
each of Parent and Merger Sub of the Merger and the other transactions
contemplated hereby and thereby, have been duly authorized by all necessary
corporate action on the part of each of Parent and Merger Sub and

 

 

 

 

 

 

 

 

 

38  

 

 

 

 

 

 

 

 

no other corporate proceedings on the part of each of Parent or Merger Sub,
respectively, are necessary to authorize this Agreement and the Transaction
Agreements to which it is a party or to consummate the Offer or the Merger or
the other transactions contemplated hereby and thereby (other than the filing
and recordation of appropriate merger documents as required by the DGCL).
Each of this Agreement and the other Transaction Agreements to which it is
a party has been, or prior to the Effective Time will be, duly executed and
delivered by each of Parent and Merger Sub, as applicable, and,
assuming the due authorization, execution and delivery by the other parties
hereto and thereto, constitutes, or prior to the Effective Time will
constitute, a legal, valid and binding obligation of each of Parent and
Merger Sub enforceable against each of Parent and Merger Sub in
accordance with its terms subject, as to enforcement of remedies,
to bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting the rights and remedies of creditors generally and to the effect of
general principles of equity. The affirmative vote of a majority of the
total votes cast by holders of common stock, par value $0.01 per share, of
Merger Sub entitled to vote is the only vote of the holders of capital stock
of Merger Sub necessary to approve this Agreement, the
Transaction Agreements to which it is a party, the Merger and the other
transactions contemplated hereby and thereby.

 

 

(b) The Parent Board, at a meeting duly called and held duly and unanimously
adopted resolutions approving this Agreement and the other Transaction
Agreements, the Offer, the Merger, and the other transactions contemplated by
this Agreement.

 

 

(c) The Board of Directors of Merger Sub, at a meeting duly called and held
(or acting by written consent) duly and unanimously adopted resolutions (i)
approving this Agreement, the Offer, the Merger and the other transactions
contemplated by this Agreement, (ii) determining that the terms of the Offer,
the Merger and the other transactions contemplated by this Agreement
are fair to and in the best interests of Merger Sub and its stockholders and
(iii) recommending that Parent, as the sole stockholder of Merger Sub,
approve and adopt this Agreement and the Merger.

 

 

(d) Parent, in its capacity as sole stockholder of Merger Sub, has
unanimously approved and adopted this Agreement and the Merger.

 

 

Section 5.3 No Conflict. The execution and delivery of this Agreement by
each of Parent and Merger Sub do not, and the performance of this Agreement
and the Transaction Agreements to which it is a party by each of Parent and
Merger Sub and the consummation of the Merger and the other transactions
contemplated hereby and thereby will not (a) conflict with or violate (i) the
Certificate of Incorporation of Parent or the Bylaws of Parent or (ii) the
Certificate of Incorporation of Merger Sub or the Bylaws of Merger Sub, (b)
subject to Section 5.4, conflict with or violate any Law or any Order or any
rule or regulation of any securities exchange on which Parent\'s common stock
is listed for trading, or (c) result in a breach of or constitute a default
(or an event which with notice or lapse of time or both would become a
default) under, give to others any right of termination, amendment,
acceleration or cancellation of, result in the triggering of any payment or
other obligation or any right of consent, or result in the creation of a Lien
on any property or asset of Parent or any of its Subsidiaries pursuant to any
note, bond, mortgage, indenture, contract, agreement, lease, license, permit,
franchise or other instrument or obligation to which Parent or any of its
Subsidiaries is a party or by which Parent or any of its Subsidiaries or any
property or asset of any of them is bound or

 

 

 

 

 

 

 

 

 

39  

 

 

 

 

 

 

 

affected except, in the case of clauses (b) and (c) above, for any such
conflicts, violations, breaches, defaults or other occurrences which have not
had and are not reasonably expected to have, individually or in the
aggregate, a Parent Material Adverse Effect.

 

 

Section 5.4 Required Filings and Consents. The execution and delivery by
each of Parent and Merger Sub of this Agreement and the Transaction
Agreements to which it is a party do not, and the performance by each of
Parent and Merger Sub of this Agreement and the Transaction Agreements to
which it is a party will not, require any consent, approval,
order, authorization or permit of, or declaration, registration, filing with,
or notification to, any Governmental Entity, except for (i)
applicable requirements, if any, of (A) the Exchange Act, including, without
limitation, the filing with the SEC of the Schedule TO and the Proxy
Statement, (B) state securities or "blue sky" laws, (C) the DGCL to file the
Certificate of Merger or other appropriate documentation and (D) Nasdaq, (ii)
those required by the HSR Act, (iii) such filings and approvals as are
required to be made or obtained under any foreign antitrust, competition or
similar Laws in connection with the consummation of the Merger and the other
transactions contemplated by this Agreement, and (iv) the filing of customary
applications and notices, as applicable, with the FDA, the EMEA or any other
Regulatory Authority.

 

 

Section 5.5 Compliance; Regulatory Compliance. Parent (i) has been operated
at all times in compliance with all Laws and Orders applicable to Parent or
by which any property, business or asset of Parent is bound or affected and
(ii) is not in default or violation of any governmental licenses, permits or
franchises to which Parent is a party or by which Parent or any property or
asset of Parent is bound or affected other than, in the case of clauses (i)
and (ii) above, failures to comply, defaults or violations which do not have
and are not reasonably expected to have, individually or in the aggregate, a
Parent Material Adverse Effect. Parent has not received any
written communication during the past two years from a Governmental Entity
that alleges that Parent is not in compliance in any material respect with
any applicable Law or Order other than any noncompliance that has not had and
is not reasonably expected to have, individually or in the aggregate, a
Parent Material Adverse Effect.

 

 

Section 5.6 SEC Filings; Financial Statements.

 

 

(a) Parent has filed all forms, reports, statements and documents required to
be filed with the SEC since December 31, 2005 (the "Parent SEC Reports"),
each of which has complied in all material respects with the applicable
requirements of the Securities Act and the rules and regulations promulgated
thereunder, the Exchange Act and the rules and regulations promulgated
thereunder, and the Sarbanes-Oxley Act and the rules and
regulations thereunder, each as in effect on the date so filed, except to the
extent updated, amended, restated or corrected by a subsequent Parent SEC
Report filed or furnished to the SEC by Parent, and in either case,
publicly available prior to the date hereof (each, a "Parent Filed SEC
Report"). None of the Parent SEC Reports (including any financial statements
or schedules included or incorporated by reference therein) contained when
filed or currently contains, and any Parent SEC Reports filed with the SEC
subsequent to the date hereof will not contain, any untrue statement of a
material fact or omission to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, except to the
extent updated, amended, restated or corrected by a subsequent Parent Filed
SEC Report.

 

 

 

 

 

 

 

 

40  

 

 

 

 

 

 

(b) Except to the extent updated, amended, restated or corrected by a
subsequent Parent Filed SEC Report, all of the financial statements included
in the Parent SEC Reports, in each case, including any related notes thereto,
as filed with the SEC (those filed with the SEC are collectively referred to
as the "Parent Financial Statements"), comply as to form in all
material respects with applicable accounting requirements and the published
rules of the SEC with respect thereto and have been prepared in accordance
with GAAP applied on a consistent basis throughout the periods involved
(except as may be indicated in the notes thereto or, in the case of the
unaudited statements, as may be permitted by Form 10-Q of the SEC and
subject, in the case of the unaudited statements, to normal, year-end audit
adjustments which are not reasonably expected to have, individually or in the
aggregate, a Parent Material Adverse Effect). The consolidated balance sheets
(including the related notes) included in such Parent Financial Statements
(if applicable, as updated, amended, restated or corrected in a subsequent
Parent Filed SEC Report) fairly present, in all material respects, the
consolidated financial position of Parent and the Parent Subsidiaries at
the respective dates thereof, and the consolidated statements of operations,
stockholders\' equity and cash flows (in each case, including the related
notes) included in such Parent Financial Statements (if applicable, as
updated, amended, restated or corrected in a subsequent Parent Filed SEC
Report) fairly present, in all material respects, the consolidated statements
of operations, stockholders\' equity and cash flows of Parent and the Parent
Subsidiaries for the periods indicated, subject, in the case of the unaudited
statements, to normal, year-end audit adjustments which are not reasonably
expected to have, individually or in the aggregate, a Parent Material
Adverse Effect.

 

 

Section 5.7 Absence of Certain Changes or Events. Except as contemplated by
this Agreement, since the date of the most recent audited financial
statements included in the Parent SEC Reports and through the date hereof,
Parent and its Subsidiaries have conducted their respective businesses only
in the ordinary course in all material respects and in a manner
consistent with prior practice in all material respects and there has not
been any event or occurrence of any condition that has had or is reasonably
expected to have, individually or in the aggregate, a Parent Material Adverse
Effect.

 

 

Section 5.8 Litigation. There is no Litigation pending or, to the knowledge
of Parent, threatened against or affecting Parent or any Subsidiary of Parent
or any of their respective assets which, if adversely determined,
individually or in the aggregate, has had or is reasonably expected to have a
Parent Material Adverse Effect.

 

 

Section 5.9 Financing. Parent has cash available or has existing borrowing
facilities or firm financing commitments that, together with the cash of the
Company, are sufficient to enable it to pay the cash portion of the Merger
Consideration payable as required by this Agreement and to otherwise
consummate the transactions contemplated by this Agreement.

 

 

Section 5.10 Brokers. No broker, investment banker, financial advisor or
other Person, other than Morgan Stanley and Co., Inc., the fees and expenses of
which will be paid by Parent, is entitled to any broker\'s, finder\'s,
financial advisor\'s or other similar fee or commissionin connection with
the Merger and the other transactions contemplated by this Agreement based
upon arrangements made by or on behalf of Parent.

 

 

 

 

 

 

 

 

 

41  

 

 

 

 

 

 

 

ARTICLE VI

 

 

COVENANTS

 

 

Section 6.1 Conduct of Company\'s Business Pending the Merger.

 

 

(a) From the date of this Agreement until the earlier of (i) such time as
designees of Parent first constitute at least a majority of the Company Board
pursuant to Section 1.3(a) and (ii) the Effective Time, except as otherwise
consented to by Parent in writing (including by electronic mail) (such
consent not to be unreasonably delayed), and except as disclosed in Section
6.1(a) of the Company Disclosure Letter or as otherwise explicitly required
by this Agreement, (i) the Company shall, and shall cause the
Company Subsidiaries to, conduct their respective businesses only in, and the
Company and the Company Subsidiaries shall not take any action except
in, the ordinary course of business consistent with past practice and (ii)
the Company and the Company Subsidiaries shall use their reasonable best
efforts to preserve intact their business organizations, to preserve their
assets and properties in good repair and condition, to keep available the
services of their current officers and employees and to preserve, in all
material respects, the current relationships of the Company and the Company
Subsidiaries with customers, suppliers, licensors, licensees, distributors
and other Persons with which the Company or the Company Subsidiaries have
business dealings.

 

 

(b) Without limiting the generality of the foregoing, except as set forth in
Section 6.1(b) of the Company Disclosure Letter or as otherwise explicitly
required by this Agreement, from the date of this Agreement until the earlier
of (i) such time as designees of Parent first constitute at least a majority
of the Company Board pursuant to Section 1.3(a) and (ii), except as otherwise
consented to by Parent in writing (including by electronic mail)(such consent
not to be unreasonably withheld or delayed), the Company shall not, nor
shall the Company permit any of the Company Subsidiaries to:

 

 

(i) amend the Company Organizational Documents or the equivalent
organizational documents of any Company Subsidiary;

 

 

(ii) declare or pay any dividends on or make other distributions (whether in
cash, stock or property) in respect of any of its capital stock, except for
dividends and distributions by a direct or indirect wholly owned Company
Subsidiary to its parent;

 

 

(iii) subdivide, reclassify, recapitalize, split, combine or exchange or
enter into any similar transaction with respect to any of its capital stock
or issue or authorize or propose the issuance of any other securities
in respect of, in lieu of or in substitution for shares of its capital
stock, except for any split, combination or reclassification of capital stock
of a wholly-owned Company Subsidiary, or any issuance or authorization or
proposal to issue or authorize any securities of a wholly-owned Company
Subsidiary to the Company or another wholly-owned Company Subsidiary;

 

 

 

 

 

 

 

 

 

42  

 

 

 

 

 

 

 

(iv) repurchase, redeem or otherwise acquire any shares of its capital stock
or any Company Stock Rights, other than in connection with (A) the forfeiture
or expiration of outstanding Company Options and (B) the withholding of
shares of Company Common Stock to satisfy Tax obligations with respect to the
exercise of Company Options pursuant to any obligations contained in the
Company Stock Plans;

 

 

(v) issue, deliver or sell, or authorize, propose or reserve for issuance,
delivery or sale, or otherwise encumber, any shares of its capital stock or
any Company Stock Rights, other than (A) the issuance of shares upon
the exercise of Company Options, in each case outstanding on the date of
this Agreement in accordance with their present terms and (B) the issuance of
stock options and shares of capital stock to newly hired employees (the
hiring of whom is otherwise permissible pursuant to the terms of this
Agreement) in the ordinary course of business under the Company Stock Plans
in existence as of the date hereof;

 

 

(vi) create, assume or incur any indebtedness for borrowed money or guaranty
any such indebtedness of another Person, or repay, redeem or repurchase
any such indebtedness;

 

 

(vii) make any loans, advances or capital contributions to, or any
investments in, any other Person (other than loans or advances between any
wholly owned Company Subsidiaries or between the Company and any wholly owned
Company Subsidiaries);

 

 

(viii) (x) sell, assign, lease, license, sell and leaseback, mortgage,
pledge or otherwise encumber or dispose of any assets or properties that are
material, individually or in the aggregate, to the Company and the Company
Subsidiaries, taken as a whole, or (y) enter into, modify or amend any lease
of property, except for modifications or amendments that are not adverse to
the Surviving Corporation;

 

 

(ix) directly or indirectly acquire (x) by merging or consolidating with, or
by purchasing assets of, or by any other manner, any division, business or
equity interest of any Person (including in a transaction involving a tender
or exchange offer, business combination, recapitalization,
liquidation, dissolution, joint venture or similar transaction) or (y) any
material assets;

 

 

(x) implement or adopt any material change in its accounting policies other
than as may be required by applicable Law or GAAP and as concurred with by
the Company\'s independent auditors;

 

 

(xi) except to the minimum extent required in order to comply with applicable
Law: (A) amend any of the terms or conditions of employment for any of
its directors or officers, (B) adopt, enter into, terminate or amend any
Company 

 

 

 

 

 

 

 

 

 

43  

 

 

 

 

 

 

 

Benefit Plan, Company Benefit Agreement or collective bargaining agreement,
other than amendments that are immaterial or administrative in nature, (C)
increase in any manner the compensation or benefits of, or pay any bonus to,
any Company Participant, other than annual salary increases and target
bonuses to be paid to Company employees below the vice president level in
the ordinary course of business consistent with past practice, (D) grant any
awards under any Company Benefit Plan (including the grant of stock options,
stock appreciation rights, performance units, restricted stock, deferred
stock awards, stock purchase rights or other stock-based or stock-
related awards) except grants to employees who are not officers or directors
of the Company in the ordinary course of business consistent with past
practices, including with respect to amounts, not to exceed 1,000 shares in
the aggregate or remove or modify existing restrictions in any Company
Benefit Plan or Company Benefit Agreement on any awards made thereunder, (E)
take any action to accelerate the vesting or payment of any compensation or
benefits under any contract, Company Benefit Plan or Company Benefit
Agreement (except to the extent provided for under any Company Benefit Plans
or Company Benefit Agreements in existence as of the date hereof) or (F)
make any material determination under any Company Benefit Plan or Company
Benefit Agreement that is inconsistent with the ordinary course of business
or past practice;

 

 

(xii) modify or amend in any material respect or terminate or cancel
or waive, release or assign any material rights or claims with respect to,
any Company Material Contract or enter into any agreement or contract that
would qualify as a Company Material Contract;

 

 

(xiii) enter into any material Contract relating to the development
or commercialization of any Product or pharmaceutical product, including
but not limited to licensing, development, manufacturing, co-development,
marketing or co-marketing agreements;

 

 

(xiv)  pay, loan or advance (other than the payment of compensation,
directors\' fees or reimbursement of expenses in the ordinary course of
business, including pursuant to existing indemnification agreements with
officers and directors) any amount to, or sell, transfer or lease any
properties or assets (real, personal or mixed, tangible or intangible)
to, or enter into any agreement with, any of its officers or directors or
any Affiliate or Associate of any of its officers or directors;

 

 

(xv)  form or commence the operations of any business or any corporation,
partnership, joint venture, business association or other business
organization or division thereof or enter into any new line of business that
is material to Company and the Company Subsidiaries, taken as a whole;

 

 

(xvi) make any material tax election or settle or compromise any material tax
liability or refund;

 

 

(xvii) (A) pay, discharge, settle or satisfy any claims, Litigation,
Liabilities or obligations (whether absolute, accrued, asserted or
unasserted,

 

 

 

 

 

 

 

 

 

44  

 

 

 

 

 

 

contingent or otherwise), other than the payment, discharge, settlement or
satisfaction, in the ordinary course of business consistent with past
practice or in accordance with their terms, of Liabilities: (1) reflected or
reserved against in, or contemplated by, the most recent consolidated
financial statements (or the notes thereto) included in the Company SEC
Reports or (2) incurred in the ordinary course of business consistent with
past practice or, (B) cancel any material indebtedness (individually or in
the aggregate) or waive any claims or rights of substantial value;

 

 

(xviii) Except as contemplated by the budget attached as Schedule
4.13(a)(ii), make or agree to make any new capital expenditure or
expenditures which, individually, are in excess of $150,000 or, in the
aggregate, are in excess of $500,000;

 

 

(xix) fail to take any action necessary or advisable to protect or maintain
the Company Owned IP (to the extent that necessary prosecution rights are
held by the Company) that is material to the conduct of the business of the
Company as currently conducted and planned by the Company to be conducted,
including the prosecution of all pending applications for patents and
trademarks, the filing of any documents or other information or the payment
of any maintenance or other fees related thereto; or

 

 

(xx) authorize, or commit or agree to take, any of the foregoing actions.

 

 

Section 6.2 Access to Information; Confidentiality.

 

 

(a) Subject to the confidentiality agreement between Parent and the Company,
dated September 30, 2008 (the "Confidentiality Agreement") and applicable
Law, the Company shall, and shall cause each of its Subsidiaries to, afford
to Parent and its officers, employees, accountants, counsel, financial
advisors and other Representatives, full access at all reasonable times on
reasonable notice during the period between the date of this Agreement and the
earlier of the Effective Time and the termination of this Agreement in
accordance with Section 8.1 to all their properties, books, contracts,
commitments, personnel and records, including for the purpose of conducting
Phase I environmental site assessments (provided, that such access shall
not unreasonably interfere with the business or operations of the Company)
and, during such period, the Company shall, and shall cause each of its
Subsidiaries to, furnish promptly to Parent (i) a copy of each
report, schedule, registration statement and other document filed by it
during such period pursuant to the requirements of federal or state
securities laws, and (ii) all other information concerning its business,
properties, litigation matters, personnel and environmental compliance
and property condition as Parent may reasonably request, including bi-weekly
sales reports, bi-weekly headcount reports, bi-weekly cash reports, bi-
weekly accounts receivable reports and bi-weekly reports on the average
selling price of all marketed products of the Company and its Subsidiaries;
provided, that nothing in this Section 6.2 shall require the Company to
provide any access, or to disclose any information, if permitting such access
or disclosing such information would (x) violate applicable Law, (y) violate
any of its obligations with respect to confidentiality (provided, that the
Company shall, upon the request of Parent, use its reasonable best efforts to
obtain the required consent of any third party to such access or

 

 

 

 

 

 

 

 

 

45  

 

 

 

 

 

 

 

disclosure), or (z) result in the loss of attorney-client privilege
(provided, that the Company shall use its reasonable best efforts to
allow for such access or disclosure in a manner that does not result in a
loss of attorney-client privilege). In addition, the Company and its
officers and employees shall reasonably cooperate with Parent in Parent\'s
efforts to comply with the rules and regulations affecting public companies,
including the Sarbanes-Oxley Act. No review pursuant to this Section 6.2
shall affect or be deemed to modify any representation or warranty contained
herein, the covenants or agreements of the parties hereto or the conditions
to the obligations of the parties hereto under this Agreement. All
information provided pursuant to this Section 6.2 shall be subject to the
terms of the Confidentiality Agreement.

 

 

(b) As soon as practicable after the date hereof, the parties shall create a
joint transition management committee (the "Transition Committee") consisting
of two Representatives from each of the parties hereto designated from time
to time as agreed by the Chief Executive Officers of each of Parent and the
Company. The Transition Committee shall be responsible for organizing,
developing, managing and implementing a transition plan for the prompt and
efficient integration of the business organizations of Parent and the Company
and their respective Subsidiaries (the "Transition Plan") subject to the
requirement that control of the management, properties and assets of Parent
and the Company, as set forth in this Agreement, shall at all times prior to
the Effective Time remain under the control of their respective Boards of
Directors.

 

 

Section 6.3 Notification of Certain Matters; Regulatory Communications.

 

 

(a) Parent shall give prompt notice to the Company and the Company shall give
prompt notice to Parent, as the case may be, of the occurrence, or failure
to occur, of any event, which occurrence or failure to occur is reasonably
likely to cause (a)(i) any representation or warranty of such party contained
in this Agreement that is qualified as to "materiality", "Company Material
Adverse Effect" or "Parent Material Adverse Effect" to be untrue or
inaccurate in any respect or (ii) any other representation or warranty of
such party contained in this Agreement to be untrue or inaccurate in any
material respect, in each case at any time from and after the date of this
Agreement until the Offer Closing or (b) any material failure of Parent and
Merger Sub or the Company, as the case may be, to comply with or satisfy
any covenant, condition or agreement to be complied with or satisfied by it
under this Agreement. In addition, Parent shall give prompt notice to
the Company and the Company shall give prompt notice to Parent, as the case
may be, of any change or event having, or which is reasonably likely to have,
a Company Material Adverse Effect or Parent Material Adverse Effect, as the
case may be, or which would be reasonably likely to result in the failure of
any of the conditions set forth in Annex A to be satisfied. Notwithstanding
the above, the delivery of any notice pursuant to this Section 6.3 will not
limit or otherwise affect the representations, warranties, covenants or
agreements of the parties, the remedies available hereunder to the party
receiving such notice or the conditions to such party\'s obligation to
consummate the Offer or the Merger.

 

 

(b) The Company: (i) shall keep Parent promptly informed of (A) any
communication (written or oral) with or from the FDA, EMEA and any other
Regulatory Authority and (B) any material communications (written or
oral) received from any Person relating to the Company IP and (ii) shall not
make any submissions to, or have discussions with, the FDA, EMEA and any
other Regulatory Authority without prior disclosure to Parent of the

 

 

 

 

 

 

 

 

 

46  

 

 

 

 

 

 

 

details of such communications or submissions. Parent shall keep the Company
informed on a periodic basis of any material communications from the FDA,
EMEA, the National Institutes of Health, the Medical Research Council (UK)
and any other Regulatory Authority relating to any of the Products.

 

 

Section 6.4 Antitrust Filings; Reasonable Best Efforts.

 

 

(a) Each party shall make or cause to be made, in cooperation with the other
parties and to the extent applicable and as promptly as practicable, (i) an
appropriate filing of a Notification and Report Form pursuant to the HSR Act
with respect to the transactions contemplated hereby and (ii) all other
necessary filings, forms, declarations, notifications, registrations and
notices with other Governmental Entities under Competition Laws relating to
the transactions contemplated hereby. "Competition Laws" mean the HSR Act,
the Sherman Antitrust Act of 1890, as amended, the Clayton Act of 1914, as
amended, the Federal Trade Commission Act, as amended, and any other United
States federal or state or foreign statutes, rules, regulations, orders,
decrees, administrative or judicial doctrines or other laws that are designed
to prohibit, restrict or regulate actions having the purpose or effect of
monopolization or restraint of trade. Each party shall use its reasonable
best efforts to respond at the earliest practicable date to any requests for
additional information made by the United States Department of Justice or any
other Governmental Entities, and act in good faith and reasonably cooperate
with the other party in connection with any investigation of any Governmental
Entity. Each party shall use its reasonable best efforts to furnish to each
other all information required for any filing, form, declaration,
notification, registration and notice. Each party shall give the other party
reasonable prior notice of any communication with, and any proposed
understanding or agreement with, any Governmental Entity regarding any
filings, forms, declarations, notifications, registrations or notices, and
permit the other to review and discuss in advance, and consider in good
faith the views of the other in connection with, any proposed communication,
understanding or agreement with any Governmental Entity with respect to the
transactions contemplated by the Agreement. None of the parties shall
independently participate in any meeting, or engage in any substantive
conversation, with any Governmental Entity in respect of any filings or
inquiry without giving the other party prior notice of the meeting and,
unless prohibited by such Governmental Entity, the opportunity to attend
and/or participate. The parties will consult and cooperate with one
another in connection with any information or proposals submitted in
connection with proceedings under or relating to any Competition Law. Without
limiting the foregoing, the Company and Parent shall each use its reasonable
best efforts: (i) to avoid the entry of any judgment that would restrain,
prevent or delay the Closing; (ii) to eliminate every impediment under
any Competition Law that may be asserted by any Governmental Entity so as to
enable the Closing to occur as soon as reasonably possible (and in any event
no later than the Outside Date (as defined herein)); and (iii) vigorously to
contest and resist any such action or proceeding, including any
administrative or judicial action.

 

 

(b) Subject to Section 6.4(c), each of the parties to this Agreement agrees
to use its reasonable best efforts to take, or cause to be taken,
all actions, and to do, or cause to be done, and to assist and cooperate
with the other parties to this Agreement in doing, all things necessary,
proper or advisable to consummate and make effective, in the most expeditious
manner practicable, the Offer, the Merger and the other transactions
contemplated by this Agreement, including (i) the obtaining of all other
necessary actions or nonactions, waivers, consents, licenses, permits,
authorizations, orders and approvals from Governmental Entities and

 

 

 

 

 

 

 

 

 

47  

 

 

 

 

 

 

 

the making of all other necessary registrations and filings (including
filings with Governmental Entities, if any), (ii) the obtaining of all
consents, approvals or waivers from third parties related to or required in
connection with the Offer or the Merger that are necessary to consummate
the Offer, the Merger and the transactions contemplated by this Agreement,
(iii) the preparation of the Proxy Statement and any other documents that may
be required to be filed with the SEC, (iv) the execution and delivery of
any additional instruments reasonably necessary to consummate
the transactions contemplated by, and to fully carry out the purposes of,
this Agreement, and (v) the providing of all such information concerning such
party, its subsidiaries, its Affiliates and its subsidiaries\' and
Affiliates\' officers, directors, employees and partners as may be reasonably
requested in connection with any of the matters set forth in Section 6.4(a)
or this Section 6.4(b). Each of Parent and the Company agrees that it
will use its reasonable best efforts to obtain prior to the Offer Closing
each of the consents that are listed in Section 6.4(b) of the Company
Disclosure Letter.

 

 

(c) Notwithstanding anything to the contrary in this Section 6.4, neither
Parent nor the Company shall be required in order to resolve any objections
asserted under Competition Laws by any Governmental Entity with respect to
the transactions contemplated by this Agreement to divest any of its
businesses, product lines or assets, or take or agree to take any
other action or agree to any limitation or restriction.

 

 

Section 6.5 No Solicitation; Company Board Recommendation.

 

 

(a) The Company shall not, nor shall it authorize or permit any of
the Company Subsidiaries or its or their Representatives to, directly or
indirectly, (i) solicit, initiate or encourage, or take any other action
designed to, or which is reasonably expected to, facilitate, any Company
Takeover Proposal, (ii) enter into any agreement with respect to any Company
Takeover Proposal or (iii) enter into, continue or otherwise participate in
any discussions or negotiations regarding, or furnish to any Person any
information with respect to, or otherwise cooperate with, any proposal that
constitutes, or is reasonably expected to lead to, any Company Takeover
Proposal. The Company shall, and shall cause the Company Subsidiaries and its
Representatives to, immediately cease and cause to be terminated all existing
discussions or negotiations with any Person conducted heretofore with respect
to any proposal that constitutes, or is reasonably expected to lead to,
any Company Takeover Proposal and request the prompt return or
destruction of all confidential information previously furnished.
Notwithstanding the foregoing, at any time prior to the Offer Closing, in
response to a bona fide written Company Takeover Proposal that the Company
Board determines (after consultation with outside counsel and a financial
advisor of nationally recognized reputation) constitutes, or is reasonably
expected to lead to, a Superior Proposal, and which Company Takeover Proposal
was not solicited after the date hereof, was made after the date hereof and
did not otherwise result from a breach of this Section 6.5(a), the Company
may, if a majority of the Company Board determines (after consultation with
outside counsel) that it is necessary to take such actions in order to comply
with its fiduciary duties to the stockholders of the Company under applicable
Law, and subject to compliance with this Section 6.5(a) and Section 6.5(c)
and after giving Parent written notice of such determination, (x) furnish
information with respect to the Company and the Company Subsidiaries to the
Person making such Company Takeover Proposal (and its Representatives)
pursuant to a customary confidentiality agreement (which agreement shall
include a customary "standstill" or similar covenant) not less restrictive of
such Person than the Confidentiality

 

 

 

 

 

 

 

 

 

48  

 

 

 

 

 

 

Agreement and containing provisions allowing necessary disclosures to Parent
pursuant to Section 6.5(c) hereof; provided that (1) all such information
has previously been provided to Parent or is provided to Parent prior to the
time it is provided to such Person and (2) such customary
confidentiality agreement expressly provides the right for the Company to
comply with the terms of this Agreement, including Section 6.5(b) and Section
6.5(c), and (y) participate in discussions or negotiations with the Person
making such Company Takeover Proposal (and its Representatives)
regarding such Company Takeover Proposal. Without limiting the foregoing, it
is agreed that any violation of the restrictions set forth in this Section
6.5(a) by any Representative or Affiliate of the Company or any
Company Subsidiary shall be deemed to be a breach of this Section 6.5(a) by
the Company.

 

 

The term "Company Takeover Proposal" means any inquiry, proposal or offer
from any Person relating to, or that is reasonably expected to lead to, any
direct or indirect acquisition or purchase, in one transaction or a series of
transactions, of any Product or of assets or businesses that constitute 15%
or more of the revenues, net income, EBITDA (earnings before interest
expense, taxes, depreciation and amortization) or the assets of the Company
and the Company Subsidiaries, taken as a whole, or 15% or more of any class
of equity securities of the Company or any Company Subsidiary, any tender
offer or exchange offer that if consummated would result in any Person
beneficially owning 15% or more of any class of equity securities of the
Company or any Company Subsidiary, or any merger, consolidation, business
combination, recapitalization, liquidation, dissolution, joint venture,
binding share exchange or similar transaction involving the Company or any
Company Subsidiary pursuant to which any Person or the stockholders of any
Person would own 15% or more of any class of equity securities of the Company
or any Company Subsidiary or of any resulting parent company of the Company,
other than the transactions contemplated by this Agreement.

 

 

The term "Superior Proposal" means a bona fide Company Takeover Proposal
(provided, that for purposes of this definition references to 15% in the
definition of "Company Takeover Proposal" shall be deemed to be references to
50%) which the Company Board determines in good faith (after consultation
with outside counsel and a financial advisor of nationally recognized
reputation) to be (i) more favorable to the stockholders of the Company from
a financial point of view than the Offer and the Merger, taking into account
all relevant factors (including all the terms and conditions of such proposal
and the Offer and this Agreement (including any changes to the terms of the
Offer and this Agreement proposed by Parent in response to such offer or
otherwise)) and (ii) reasonably capable of being completed, taking into
account all financial, legal, regulatory and other aspects of such proposal.

 

 

(b) Neither the Company Board nor any committee thereof shall, (i) (A)
withdraw (or qualify or modify in a manner adverse to Parent or Merger Sub),
or publicly propose to withdraw (or qualify or modify in a manner adverse to
Parent or Merger Sub), the adoption, approval, recommendation or declaration
of advisability by the Company Board or any such committee thereof of
this Agreement, the Offer, the Merger or the other transactions
contemplated by this Agreement or (B) recommend, adopt, approve or declare
advisable, or propose publicly to recommend, adopt, approve or declare
advisable, any Company Takeover Proposal (any action described in this
clause (i) being referred to as a "Company Adverse Recommendation Change")
or (ii) adopt, approve, recommend or declare advisable, or propose to adopt,
approve, recommend or declare advisable, or allow the Company or any of the

 

 

 

 

 

 

 

 

 

49  

 

 

 

 

 

 

Company Subsidiaries to execute or enter into, any letter of intent,
memorandum of understanding, agreement in principle, merger agreement,
acquisition agreement, option agreement, joint venture agreement, partnership
agreement or other similar agreement constituting or related to, or that is
intended to or is reasonably expected to lead to, any Company
Takeover Proposal (other than a confidentiality agreement referred to in
Section 6.5(a) pursuant to and in accordance with the limitations set
forth therein). Notwithstanding the foregoing, at any time prior to Offer
Closing Date, the Company Board may make a Company Adverse
Recommendation Change if a majority of the Company Board determines (after
consultation with outside counsel) that it is necessary to take such actions
in order to comply with its fiduciary duties to the stockholders of the
Company under applicable Law; provided, however, that no such Company
Adverse Recommendation Change may be made until after the fifth calendar day
following Parent\'s receipt of written notice (a "Company Notice of Adverse
Recommendation") from the Company advising Parent that the Company Board
intends to take such action and specifying the reasons therefor, including
the terms and conditions of any Superior Proposal that is the basis of the
proposed action by the Company Board (it being understood and agreed that (x)
any amendment to any material term of such Superior Proposal or (y) with
respect to any previous Company Adverse Recommendation Change, any material
change in the principal stated rationale by the Company Board for
such previous Company Adverse Recommendation Change, shall, in the case
of either (x) or (y), require a new Company Notice of Adverse Recommendation
and a new five (5) calendar day-period). In determining whether to make
a Company Adverse Recommendation Change, the Company Board shall take
into account any changes to the terms of this Agreement proposed by Parent in
response to a Company Notice of Adverse Recommendation or otherwise.

 

 

(c) In addition to the obligations of the Company set forth in Section 6.5(a)
and Section 6.5(b), (i) the Company shall promptly advise Parent orally and
in writing (and in any case within 24 hours) of any Company
Takeover Proposal or any inquiry that is reasonably expected to lead to any
Company Takeover Proposal, the material terms and conditions of any such
Company Takeover Proposal or inquiry (including any changes thereto) and the
identity of the Person making any such Company Takeover Proposal or inquiry
and (ii) the Company shall (A) keep Parent fully and promptly informed of the
status and material details (including any change to any material term
thereof) of any such Company Takeover Proposal or inquiry and (B) provide to
Parent promptly after receipt or delivery thereof copies of all
correspondence and other written material sent or provided to the Company or
any of the Company Subsidiaries from any Person that describes any of the
terms or conditions of any Company Takeover Proposal or inquiry.
In addition, during the period from the date of this Agreement through the
Offer Closing, the Company shall not terminate, amend, modify or waive
any provision of any confidentiality agreement to which it or any of its
Subsidiaries is a party. During such period, the Company shall enforce, to
the fullest extent permitted under applicable law, the provisions of any such
agreement, including by obtaining injunctions to prevent any breaches of such
agreements and to enforce specifically the terms and provisions thereof in
any court of the United States of America or of any state having
jurisdiction.

 

 

(d) Nothing contained in this Agreement shall prohibit the Company from taking
and disclosing to its stockholders a position contemplated by Rule 14(e)-2(a)
or Rule 14(d)-9 promulgated under the Exchange Act or from making any
disclosure to the Company\'s stockholders (including, without limitation,
any amendments to its Schedule 14D-9 relating to a

 

 

 

 

 

 

 

 

 

50  

 

 

 

 

 

 

 

Company Adverse Change Recommendation) if, in the good faith judgment of the
Company Board, after consultation with outside counsel, failure to so
disclose would be inconsistent with applicable Law; provided, however, that
all actions taken or agreed to be taken by the Company or the Company Board
or any committee thereof shall comply with the provisions of Section 6.5(a).

 

 

Section 6.6 Stockholder Litigation. The Company shall give Parent the
opportunity to participate (at Parent\'s expense) in the defense or
settlement of any stockholder Litigation against the Company and its
directors relating to the Offer, the Merger or the other
transactions contemplated by this Agreement; provided, however, that no
such settlement shall be agreed to without Parent\'s prior written consent,
which consent shall not be unreasonably withheld or delayed, except that
Parent shall not be obligated to consent to any settlement which does not
include full release of Parent and its Affiliates or which imposes an
injunction or other equitable relief upon Parent or any of its Affiliates
(including, after the Effective Time, the Surviving Corporation).

 

 

Section 6.7 Indemnification; Director and Officer Insurance. For not less
than six years from and after the Effective Time, Parent agrees to, and to
cause the Surviving Corporation to, indemnify and hold harmless all past
and present directors, officers and employees of the Company to the same
extent such Persons are indemnified as of the date of this Agreement by the
Company pursuant to the Company Certificate of Incorporation and Company By-
Laws and indemnification agreements, if any, in existence on the date of this
Agreement with any directors, officers or employees of the Company for acts
or omissions occurring at or prior to the Effective Time; provided, however,
that Parent agrees to, and to cause the Surviving Corporation to, indemnify
and hold harmless such Persons to the fullest extent permitted by law for
acts or omissions occurring in connection with the approval of this Agreement
and the consummation of the transactions contemplated hereby. Parent shall
cause the Surviving Corporation to provide, for an aggregate period of not
less than six years from the Effective Time, the Company\'s current directors
and officers an insurance and indemnification policy that provides coverage
for events occurring prior to the Effective Time (the "DandO Insurance") that
is no less favorable than the Company\'s existing policy or, if substantially
equivalent insurance coverage is unavailable, the best available coverage;
provided, however, that the Surviving Corporation shall not be required to
pay an annual premium for the DandO Insurance in excess of 250 percent of the
last annual premium paid prior to the date of this Agreement; provided that
Parent may substitute therefor a single premium tail coverage with respect to
DandO Insurance at a level at least as favorable as in the DandO Insurance.

 

 

Section 6.8 Public Announcements. The initial press release shall be a
joint press release and thereafter, during the period between the date of
this Agreement and the earlier of the Offer Closing and the termination of
this Agreement in accordance with Section 8.1, the Company and Parent each
shall obtain the prior consent of the other prior to issuing any press
releases or making other public statements and communications with respect to
the Merger, the other transactions contemplated by this Agreement or
Products, except as may be required by Law or by obligations pursuant to any
listing agreement with or rules of Nasdaq. In addition, the Company and
Parent shall develop a joint communications strategy and each party shall
ensure that, during the period between the date of this Agreement and the
earlier of the Offer Closing 

 

 

 

 

 

 

 

 

 

51  

 

 

 

 

 

 

 

and the termination of this Agreement in accordance with Section 8.1, all
press releases and other public statements and communications (including any
communications that would require a filing under Rules 14d-2 or 14d-9 of the
Exchange Act), with analysts, members of the financial community or
otherwise, with respect to the Offer, the Merger, the other transactions
contemplated by this Agreement or Products shall be consistent in all
material respects with such joint communications strategy.

 

 

Section 6.9 Preparation of SEC Documents; Stockholders\' Meeting.

 

 

(a) If the adoption of this Agreement by the stockholders of the Company is
required by the DGCL, as soon as practicable following the Offer Closing,
the Company shall prepare and file with the SEC, subject to the prior review,
comment and approval of Parent (which approval shall not be unreasonably
withheld or delayed), a proxy statement relating to the Company Stockholder
Approval (such proxy statement, as amended or supplemented from time to time,
the "Proxy Statement"). The Company will use its reasonable best efforts
to cause the Proxy Statement to be mailed to the Company\'s stockholders as
promptly as practicable after clearing comments received from the SEC.
No filing of, or amendment or supplement to, the Proxy Statement will be
made by the Company without Parent\'s prior consent (which shall not
be unreasonably withheld or delayed) and without providing Parent the
reasonable opportunity to review and comment thereon. The Company will
advise Parent promptly of any request by the SEC for amendment of the
Proxy Statement or comments thereon and responses thereto or requests by the
SEC for additional information. If at any time prior to the Effective
Time any information relating to Parent or the Company, or any of their
respective Affiliates, officers or directors, should become known to Parent
or the Company which should be set forth in an amendment or supplement to the
Proxy Statement, so that any of such documents would not include any
misstatement of a material fact or omit to state any material fact
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading, the party which discovers such
information shall promptly notify the other parties hereto and an appropriate
amendment or supplement describing such information shall be promptly filed
with the SEC and, to the extent required by law, disseminated to the
stockholders of the Company.

 

 

(b) Each of the Company and Parent shall supply such information specifically
for inclusion or incorporation by reference in the Proxy Statement necessary
so that, at the date it is first mailed to the Company\'s stockholders or at
the time of the Company Stockholders\' Meeting, the Proxy Statement shall
not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made,
not misleading. Each of the parties hereto shall use their reasonable best
efforts so that the Proxy Statement will comply as to form in all material
respects with the requirements of the Exchange Act and the rules and
regulations thereunder.

 

 

(c) If the adoption of this Agreement by the stockholders of the Company is
required by the DGCL, the Company shall take all action necessary to duly
call, give notice of, convene and hold a meeting of its stockholders as
promptly as practicable for the purpose of obtaining the approval by
the Company\'s stockholders in accordance with the DGCL (the
"Company Stockholders\' Meeting"). The Company shall ensure that the
Company Stockholders\' Meeting is called, noticed, convened, held and
conducted, and that all proxies

 

 

 

 

 

 

 

 

 

52  

 

 

 

 

 

 

 

solicited in connection with the Company Stockholders\' Meeting are solicited
in compliance with applicable Law, the rules of Nasdaq and the Company
Organizational Documents.

 

 

(d) Notwithstanding the foregoing, if following the Offer and any subsequent
offering period and the exercise, if any, of the Top-Up Option, Parent and
its Subsidiaries shall own at least 90% of the outstanding shares of the
Company Common Stock, the parties hereto shall take all necessary and
appropriate action, including with respect to the transfer to Merger Sub of
any shares of Company Common Stock held by Parent or any Subsidiary of
Parent, to cause the Merger to become effective as soon as practicable after
the Offer Closing without the Company Stockholder\'s Meeting in accordance
with Section 253 of the DGCL.

 

 

Section 6.10 Employees.

 

 

(a) Parent shall or shall cause the Surviving Corporation to employ those
individuals set forth on Section 6.10(a) of the Company Disclosure
Letter (collectively, the "Nebido Transition Team") from the Offer Closing
until at least the earliest of (i) the Approval With Label Milestone Date
(as defined in the Nebido Contingent Cash Consideration Agreement), the
(ii) Approval Without Label Milestone Date (as defined in the
Nebido Contingent Cash Consideration Agreement, (iii) December 31, 2009 (the
"Nebido Transition Team Employment Period") and (iv) with respect to any
member of the Nebido Transition Team, such member\'s death, disability or
voluntary termination of employment. During the Nebido Transition Team
Employment Period, the management structure and reporting lines of the Nebido
Transition Team shall be as set forth on Section 6.10(a) of the Company
Disclosure Letter. Upon the Approval with Label Milestone Date or Approval
Without Label Milestone Date, provided that such date occurs on or prior to
December 31, 2009, each member of the Nebido Transition Team who is then
employed by Parent or the Surviving Corporation shall be provided with a cash
bonus in the amount set forth beside his or her name on Section 6.10(a) of
the Company Disclosure Letter.

 

 

(b) For a period of one year following the Offer Closing, Parent shall or
shall cause the Surviving Corporation to either (i) provide the employees
of the Company and the Company Subsidiaries who are employed immediately
prior to the Effective Time (the "Covered Employees") who remain employed
during such period by Parent, the Surviving Corporation or any of
their respective Subsidiaries with compensation and benefits (excluding
equity based compensation) which, taken as a whole, have a
value substantially comparable, in the aggregate, to the compensation and
benefits provided by the Company and the Company Subsidiaries as of the date
hereof or (ii) provide or cause the Surviving Corporation (or, in
such case, its successors or assigns) to provide Covered Employees
who remain employed during such period by Parent, the Surviving Corporation
or their

 

 

 

 

 

 

 

 

 

53  

 

 

 

 

 

 

 

respective Subsidiaries with compensation and benefits that, taken as
a whole, have a value substantially comparable, in the aggregate, to the
Covered Employees than those provided to similarly situated employees of
Parent and its Subsidiaries. In addition, except as set forth in Section
6.10(a), for a period of one year following the Offer Closing, Parent shall
or shall cause the Surviving Corporation to provide Covered Employees whose
employment is terminated by Parent or the Surviving Corporation
with severance benefits in accordance with such employee\'s individual
employment agreement or, in the absence of any such agreement, in accordance
with the severance policy of Parent in effect from time to time. Effective
not later than the Closing Date, Parent will establish a retention program
for those Company employees Parent determines to seek to retain. Parent shall
have no obligation and the Company shall take no action that would have the
effect of requiring Parent or the Surviving Corporation to continue any
specific plans or to continue the employment of any specific Person.

 

 

(c) For purposes of determining eligibility to participate in, and non-
forfeitable rights under, but not for purposes of benefit accrual under, any
employee benefit plan or arrangement of Parent or the Surviving Corporation or
any of their respective Subsidiaries, Covered Employees shall
receive service credit for service with the Company (and with any predecessor
or acquired entities or any other entities for which the Company granted
service credit) as if such service had been completed with Parent; provided,
however, that such service need not be recognized to the extent that such
recognition would result in any duplication of benefits for the same period
of service.

 

 

(d) To the extent applicable, Parent shall or shall cause the
Surviving Corporation and any of their respective Subsidiaries to waive, or
use reasonable best efforts to cause its insurance carriers to waive, any
pre-existing condition limitation on participation and coverage applicable to
any Covered Employee or any of his or her covered dependents under any health
or welfare plan of Parent or the Surviving Corporation or any of their
respective Subsidiaries (a "New Plan") in which such Covered Employee or
covered dependent shall become eligible to participate after the
Effective Time to the extent such Covered Employee or covered dependent was
no longer subject to such pre-existing condition limitation under the
corresponding Company Benefit Plan in which such Covered Employee or such
covered dependent was participating immediately before he or she became
eligible to participate in the New Plan. Parent shall or shall cause the
Surviving Corporation or the relevant Subsidiary of either to provide each
Covered Employee with credit for any co-payments and deductibles paid prior
to the Effective Time and during the calendar year in which the Effective
Time occurs under any Company Benefit Plan in satisfying any applicable co-
payment and deductible requirements for such calendar year under any New Plan
in which such Covered Employee participates after the Effective Time.

 

 

(e) Nothing in this Section 6.10 shall confer any rights or remedies of any
kind or description upon any Covered Employee or any other Person other than
the Company and Parent and their respective successors and assigns or be
construed as an amendment, waiver or creation of any Company Benefit Plan or
Company Benefit Agreement.

 

 

(f) The Company and the Company Subsidiaries shall refrain from causing any
employees of the Company or the Company Subsidiaries to suffer an "employment
loss" as defined in the Worker Adjustment and Retraining Notification Act of
1988 or any similar state or local law (collectively, the "WARN Act"), in
the ninety-one (91) days prior to the Offer Closing, without the prior consent
of Parent. Notwithstanding Section 6.8 of this Agreement, the 

 

 

 

 

 

 

 

 

54  

 

 

 

 

 

 

 

Company and the Company Subsidiaries, as applicable, shall cooperate with
and provide reasonable assistance to Parent or its agents in preparing
and delivering any notices required or potentially required pursuant to the
WARN Act (as determined by Parent in its sole discretion) to effectuate the
termination of the employment of any employees of the Company or the Company
Subsidiaries as of the Effective Time in compliance with the WARN Act;
provided, however, that all such notices shall indicate that the terminations
of employment are contingent upon the consummation of the Merger.

 

 

Section 6.11 Rule 16b-3. Prior to the Offer Closing, the Company shall use
reasonable best efforts to cause any dispositions of Company Common Stock
(including derivative securities with respect to Company Common Stock)
resulting from the transactions contemplated by this Agreement by each
individual who is subject to the reporting requirements of Section 16(a) of
the Exchange Act with respect to the Company to be exempt under Rule 16b-3
promulgated under the Exchange Act, such efforts to include all steps
required be taken in accordance with the No-Action Letter dated January 12,
1999, issued by the SEC to Skadden, Arps, Slate, Meagher and Flom LLP.

 

 

Section 6.12 Development Drugs. From and after the Offer Closing, Parent
shall use commercially reasonable efforts to develop, in the ordinary course,
each of Nebido and Octreotide; provided, that, with respect to (i)
Nebido, Parent\'s obligations under this Section 6.12 shall terminate on the
third anniversary of the Offer Closing and (ii) with respect
Octreotide, Parent\'s obligations under this Section 6.12 shall terminate on
the fourth anniversary of the Offer Closing. For the purposes of this
Section 6.12, "commercially reasonable efforts" shall mean efforts and
resources normally used by Parent for a product owned by it or to which it
has exclusive rights, which is of similar market potential at a similar stage
in its development or product life, taking into account issues of safety and
efficacy, product profile, competitiveness of the marketplace, the
proprietary position of the compound or product, the regulatory and
reimbursement structure involved, the profitability of the applicable
products, and other relevant factors.

 

 

Section 6.13 State Takeover Laws. If any state takeover Law becomes
applicable to the Merger or the other transactions contemplated by this
Agreement, the Company and the Company Board shall grant such approvals and
take such actions as are necessary so that such transactions may be
consummated as promptly as practicable on the terms contemplated by this
Agreement and otherwise act to eliminate or minimize the effects of such
statute or regulation on such transactions.

 

 

Section 6.14 Contingent Stock Rights. Prior to the Effective Time, Parent
shall:

 

 

(a) pursuant to the Stent Contingent Stock Rights Agreement, dated as of
April 17, 2007, between the Company and American Stock Transfer and
Trust Company (the "Stent Contingent Stock Rights Agreement"), execute and
deliver to the Rights Agent thereunder a supplemental contingent stock rights
agreement, providing that Parent shall (i) provide such cash and Contingent
Cash Consideration Payments as any Holder (as defined in the Stent
Contingent Stock Rights Agreement) would be entitled in accordance with the
terms of the Stent Contingent Stock Rights Agreement upon the occurrence of
the Milestone Date (as defined in the Stent Contingent Stock
Rights Agreement), and (ii) perform and observe each and every

 

 

 

 

 

 

 

 

55  

 

 

 

 

 

 

 

 

covenant, condition, obligation and liability under the Stent Contingent
Rights Agreement to be performed and observed by the Company; and

 

 

(b) pursuant to the Octreotide Contingent Stock Rights Agreement, dated as of
April 17, 2007, between the Company and American Stock Transfer and
Trust Company (the "Octreotide Contingent Stock Rights Agreement"), execute
and deliver to the Rights Agent thereunder a supplemental contingent stock
rights agreement, providing that Parent shall (i) provide such cash
and Contingent Cash Consideration Payments as any Holder (as defined in
the Octreotide Contingent Stock Rights Agreement) would be entitled in
accordance with the terms of the Octreotide Contingent Stock Rights Agreement
upon the occurrence of the Milestone Date (as defined in the Octreotide
Contingent Stock Rights Agreement), and (ii) perform and observe each and
every covenant, condition, obligation and liability under the Octreotide
Contingent Rights Agreement to be performed and observed by the Company.

 

 

(c) Rule 14d-10 Matters. Notwithstanding anything in this Agreement to the
contrary, the Company will not, after the date hereof and prior to the Offer
Closing, enter into, establish, amend or modify any plan, program, agreement
or arrangement pursuant to which compensation is paid or payable, or pursuant
to which benefits are provided, in each case to any former, current or future
director, officer, employee, consultant, advisor or independent contractor of
the Company or any of its Subsidiaries (or any person who would have assumed
such role or performed such duties but for a requirement to refrain from
assuming such role or performing such duties in such plan, program, agreement
or arrangement) unless, prior to such entry into, establishment, amendment
or modification, the Compensation Committee (each member of which shall be
an "independent director" in accordance with the requirements of Rule
14d-10(d)(2) under the Exchange Act at the time of any such action)
shall have taken all such steps as may be necessary to (i) approve as an
Employment Compensation Arrangement each such plan, program, agreement or
arrangement and (ii) satisfy the requirements of the non-exclusive safe
harbor under Rule 14d-10(d)(2) under the Exchange Act with respect to such
plan, program, agreement or arrangement.

 

 

Section 6.15 Voting of Shares. Parent shall vote (or cause to be voted) all
shares of Company Common Stock beneficially owned by it or Merger Sub in
favor of approval of the Merger at the Company Stockholders\' Meeting, unless
the DGCL does not require a vote of the stockholders of the Company for
consummation of the Merger.

 

 

Section 6.16 Conduct of Business by Parent and Merger Sub Pending the
Merger. From the date of this Agreement until the Offer Closing Date, except
as otherwise contemplated by this Agreement, Parent and Merger Sub agree that
they shall not, directly or indirectly, knowingly take or cause to be taken
any action that reasonably would be expected to materially delay or impair
the consummation of the transactions contemplated hereby.

 

 

Section 6.17 No Control of Other Party\'s Business. Nothing contained in
this Agreement shall give Parent, directly or indirectly, the right to
control or direct the Company\'s or its Subsidiaries\' operations prior to
the Offer Closing Date, and nothing contained in this Agreement shall give
the Company, directly or indirectly, the right to control or direct Parent\'s
or its Subsidiaries\' operations prior to the Offer Closing Date. Prior to
the Offer Closing Date, each

 

 

 

 

 

 

 

 

 

56  

 

 

 

 

 

 

 

of the Company and Parent shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision over its and
its Subsidiaries\' respective operations. 

 

 

 

ARTICLE VII

 

 

CONDITIONS

 

 

Section 7.1 Conditions to the Obligation of Each Party. The respective
obligations of the Company, Parent and Merger Sub to effect the Merger are
subject to the satisfaction or waiver of the following conditions:

 

 

(a) Prior to the Effective Time the Company Stockholder Approval shall have
been obtained, if required by the DGCL;

 

 

(b) At or prior to the Offer Closing, no applicable Law and no temporary
restraining order, preliminary or permanent injunction or other judgment,
order or decree entered, enacted, promulgated, enforced or issued by any
court or other Governmental Entity of competent jurisdiction in the United
States or any material foreign jurisdiction (collectively, "Judgments") shall
be and remain in effect which has the effect of prohibiting the consummation
of the Merger or the other transactions contemplated by this Agreement;

 

 

(c) At or prior to the Offer Closing, there shall not be pending or
threatened any suit, action or proceeding by any Governmental Entity which
challenges or seeks to enjoin the Merger or the other transactions
contemplated by this Agreement;

 

 

(d) At or prior to the Offer Closing, Merger Sub shall have previously
accepted for payment all shares of Company Common Stock validly tendered and
not withdrawn pursuant to the Offer.

 

 

Section 7.2 Failure of Conditions. None of the Company, Parent or Merger
Sub may rely on the failure of any condition set forth in Section 7.1 to be
satisfied to excuse performance by such party of its obligations under this
Agreement if such failure was caused by such party\'s failure to act in good
faith and in a manner consistent with the terms of this Agreement.

 

 

 

ARTICLE VIII

 

 

TERMINATION, AMENDMENT AND WAIVER

 

 

Section 8.1 Termination. Subject to Section 1.3(c), this Agreement may be
terminated and the Offer and the Merger may be abandoned at any time prior to
the Effective Time:

 

 

(a) by mutual written consent of Parent and the Company;

 

 

(b) by either the Parent or the Company:

 

 

 

 

 

 

 

 

 

57  

 

 

 

 

 

 

 

 

 

(i) if the Offer Closing shall not have occurred by July 1, 2009 (the
"Outside Date"); provided, however, that the right to terminate
this Agreement pursuant to this Section 8.1(b)(i) shall not be available to
any party whose failure to fulfill any covenant or agreement contained in
this Agreement has been the cause of, or resulted in, the failure of the
Offer Closing to have occurred on or by such date; or

 

 

(ii) if any Judgment having any of the effects set forth in Section 7.1(b)
shall be in effect and shall have become final and nonappealable;

 

 

(c) prior to the Offer Closing, by Parent, if the Company shall have breached
or failed to perform any of its representations, warranties, covenants or
other agreements contained in this Agreement, which breach or failure to
perform (i) would give rise to the failure of a condition set forth in clauses
(v) or (vi) of Exhibit A and (ii) has not been waived by Parent and is
incapable of being cured, or is not cured, by the Company within 20 calendar
days following receipt of written notice of such breach or failure to perform
from Parent;

 

 

(d) by Parent:

 

 

(i) at any time prior to the Offer Closing, upon a Company Adverse
Recommendation Change; or

 

 

(ii) if the Company Board fails to reaffirm publicly its recommendation to
the Company\'s stockholders to tender their shares of Company Common Stock in
the Offer and to vote in favor of the Merger within seven days of Parent\'s
written request for such reaffirmation;

 

 

(e) prior to the Offer Closing by Parent, if the Company shall
have materially breached any of the provisions of Section 6.5;

 

 

(f) Prior to the Offer Closing by the Company, if (i) Parent or Merger Sub
shall have breached or failed to perform in any material respect any of its
representations, warranties, covenants or other agreements contained in this
Agreement, which breach or failure to perform (A) would result in the
representations and warranties of Parent and Merger Sub contained in this
Agreement and in any certificate or other writing delivered by Parent or
Merger Sub pursuant hereto that are qualified by materiality or Parent
Material Adverse Effect not being true and correct in all respects both as of
the date of this Agreement and as of the Offer Closing Date as though made on
and as of the Offer Closing Date (except to the extent such representations
and warranties expressly relate to an earlier date, in which case such
representations and warranties shall be true and correct in all respects on
and as of such earlier date) or (B) the representations and warranties of
Parent and Merger Sub in this Agreement and in any certificate or other
writing delivered by Parent or Merger Sub pursuant hereto that are not so
qualified not being true and correct in all material respects both as of the
date of this Agreement and as of the Offer Closing Date as though made on and
as of the Offer Closing Date (except to the extent such representations and
warranties expressly relate to an earlier date, in which case such
representations and warranties shall be true and correct in all material
respects on and as of such earlier date); or (ii) Parent and Merger Sub shall
not have performed in all 

 

 

 

 

 

 

 

 

58  

 

 

 

 

 

 

 

material respects all obligations required to be performed by them under this
Agreement at or prior to the Closing Date, and in the case of either (i) or
(ii) above, such breach or failure to perform is incapable of being cured, or
is not cured, by Parent within 20 calendar days following receipt of written
notice of such breach or failure to perform from the Company; 

 

 

(g) by the Company, at any time prior to Offer Closing, to accept and enter
into a binding agreement with respect to a Superior Proposal; provided that
for the termination of this Agreement pursuant to this subsection (g) to be
effected, the Company shall have complied with the provisions of
Section 6.5(a) and the Company shall have paid the Company Termination Fee
(as defined in Section 8.2(c)) and otherwise complied with its obligations
under Section 8.2(c));

 

 

(h) prior to the Offer Closing, by Parent, if a Hydron Impeding Event shall
have occurred; or

 

 

(i) by the Company, if (1) Merger Sub fails to commence the Offer
in violation of Section 1.1 hereof and such breach is not cured within 20
calendar days following receipt of written notice of such breach from the
Company, (2) the Offer shall have expired or been terminated without
Merger Sub having purchased any shares of Company Common Stock pursuant
thereto or (3) Merger Sub, in violation of the terms of this Agreement, fails
to accept for payment and to purchase validly tendered shares of Company
Common Stock pursuant to the Offer; provided, that the right to terminate
this Agreement pursuant to clause (2) of this Section 8.1(i) shall not be
available if the Company\'s failure to fulfill any covenant or agreement
contained in this Agreement has been the cause of, or resulted in,
the failure of the Offer having expired or terminated with Merger Sub
having purchased any shares of Company Common Stock pursuant thereto.

 

 

Section 8.2 Effect of Termination.

 

 

(a) In the event of the termination of this Agreement by either Parent or the
Company pursuant to Section 8.1 hereof, this Agreement shall forthwith be
terminated and have no further effect, the obligations of the
parties hereunder shall terminate, and there shall be no liability on the
part of any party hereto with respect thereto, except that (i) the provisions
of Section 4.19, Section 5.10, the last sentence of Section 6.3(a), this
Section 8.2, Section 8.3 and Article IX shall survive the termination of
this Agreement and (ii) nothing herein shall relieve any party from liability
or damages for fraud or for any willful breach or hereof or for any willful
misrepresentation.

 

 

(b) Except as provided in this Section 8.2, all fees and expenses incurred
in connection with the Offer, the Merger, this Agreement and the
transactions contemplated by this Agreement shall be paid by the
party incurring such fees or expenses, whether or not the Offer or the
Merger is consummated.

 

 

(c) (i) In the event that: (w) (A) prior to the Offer Closing, a Company
Takeover Proposal shall have been made to the Company and such Company
Takeover Proposal becomes publicly known prior to the Offer Closing or
shall have been made directly to the stockholders of the Company generally
prior to the Offer Closing and, in either case, such

 

 

 

 

 

 

 

 

 

59  

 

 

 

 

 

 

 

Company Takeover Proposal shall not have been publicly withdrawn at least two
business days prior to the Offer Closing or any Person shall have
publicly announced an intention (whether or not conditional) to make a
Company Takeover Proposal, (B) this Agreement is terminated by Parent
pursuant to Section 8.1(c) or Section 8.1(e) and (C) within 12 months after
such termination, the Company enters into a definitive agreement to
consummate a Company Takeover Proposal or consummates a Company Takeover
Proposal; or (x) (A) prior to the Offer Closing, a Company Takeover Proposal
shall have been made to the Company or shall have been made directly to the
stockholders of the Company generally or shall have otherwise become publicly
known or any Person shall have publicly announced an intention (whether or not
conditional) to make a Company Takeover Proposal, (B) this Agreement is
terminated by Parent or the Company pursuant to Section 8.1(b)(i) and (C)
within 12 months after such termination, the Company enters into a definitive
agreement to consummate a Company Takeover Proposal or consummates a
Company Takeover Proposal; or (y) this Agreement is terminated by Parent
pursuant to Section 8.1(d); or (z) this Agreement is terminated by Company
pursuant to Section 8.1(g), then the Company shall pay Parent a fee equal to
$20 million (the "Company Termination Fee") by wire transfer of same-day
funds on the date of termination of this Agreement (except that in the case
of termination pursuant to clause (w) or (x) above, the Company shall pay
Parent 50% of the Company Termination Fee upon such termination and 50% of
the Company Termination Fee on the date of execution of such definitive
agreement or, if earlier, consummation of such transactions).

 

 

(ii) In the event that this Agreement is terminated by Parent pursuant to (A)
Section 8.1(c) or (B) Section 8.1(h) and the cause of the Hydron Impeding
Event underlying such termination is not an act of God, natural disaster, war
(whether or not declared) or terrorism (and, in the case of either (A) or
(B), no amount is payable by Company pursuant to Section 8.2(c)), then, in
the case or either (A) or (B), Company shall pay Parent a fee equal to
Parent\'s out-of-pocket fees and expenses incurred in connection with
the Merger, this Agreement and the transactions contemplated hereby but not
in excess of $5 million, by wire transfer of same-day funds three (3)
business days after the date of such termination of this Agreement as
referred to in this sentence; provided that the foregoing shall not limit
or be deemed to limit any liability of the Company or damages or other remedy
to which Parent may be entitled as a result of any willful breach of this
Agreement by the Company. The Company will not be obligated to make a payment
pursuant to this Section 8.2(c)(ii) if Company has paid or is required to pay
the Company Termination Fee set forth in Section 8.2(c), and any fees paid by
the Company under this Section 8.2(c)(ii) will be credited against any such
Company Termination Fee to the extent that such fee subsequently becomes
payable by the Company.

 

 

(iii) The Company acknowledges that the agreements contained in this
Section 8.2(c) are an integral part of the transactions contemplated by this
Agreement, and that, without these agreements, Parent would not enter into
this Agreement; accordingly, if the Company fails promptly to pay
the amount(s) due pursuant to this Section 8.2(c), and, to obtain such
payment, Parent commences a suit which results in a judgment against the
Company for the amount(s) due pursuant to this Section 8.2(c), the Company
shall pay to Parent its out-of-pocket costs and expenses (including
attorneys\' fees and expenses) in connection with such suit, together
with interest on such amount(s) at the prime rate of Citibank, N.A. in effect
on the date such payment was required to be made.

 

 

 

 

 

 

 

 

 

60  

 

 

 

 

 

 

 

Section 8.3 Amendments. Subject to Section 1.3(c) and subject to compliance
with applicable Law, this Agreement may be amended by the parties, by action
taken or authorized by their respective boards of directors, at any time
before or after approval of the matters presented in connection with the
Merger by the stockholders the Company; provided, however, that after any
approval of the transactions contemplated by this Agreement by
the stockholders of the Company, there may not be, without further approval
of the stockholders of the Company, any amendment of this Agreement that
changes the amount or the form of the consideration to be delivered under
this Agreement to the holders of Company Common Stock, or which by applicable
Law otherwise expressly requires the further approval of such stockholders.
No amendment shall be made to this Agreement after the Effective Time. This
Agreement may not be amended except by an instrument in writing signed on
behalf of each of the parties.

 

 

Section 8.4 Waiver. Subject to Section 1.3(c), at any time prior to the
Effective Time, whether before or after the Company Stockholders\' Meeting,
any party hereto may (i) extend the time for the performance of any of the
covenants, obligations or other acts of any other party hereto or (ii) waive
any inaccuracy of any representations or warranties or compliance with any of
the agreements, covenants or conditions of any other party or with any
conditions to its own obligations. Any agreement on the part of a party
hereto to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such party by its duly authorized
officer. The failure of any party to this Agreement to assert any of its
rights under this Agreement or otherwise shall not constitute a waiver of
such rights. The waiver of any such right with respect to particular facts
and other circumstances shall not be deemed a waiver with respect to any
other facts and circumstances and each such right shall be deemed an ongoing
right that may be asserted at any time and from time to time.

 

 

 

ARTICLE IX

 

 

GENERAL PROVISIONS

 

 

Section 9.1 Nonsurvival of Representations and Warranties. None of the
representations and warranties in this Agreement or in any
instrument delivered pursuant to this Agreement shall survive the
Effective Time. This Section 9.1 shall not limit the survival of any
covenant or agreement of the parties in the Agreement which by its terms
contemplates performance after the Effective Time.

 

Section 9.2 Notices. All notices, requests, claims, demands and other
communications under this Agreement shall be in writing and shall be deemed
given if delivered personally, sent via electronic mail (receipt confirmed),
facsimile (receipt confirmed) or sent by a nationally recognized overnight
courier (providing proof of delivery) to the parties at the following
addresses (or at such other address for a party as shall be specified by like
notice):

 

 

 

 

 

 

 

 

61  

 

 

 

 

 

 

(a) if to the Company to:

 

 

 

Indevus Pharmaceuticals, Inc.

 

33 Hayden Avenue

 

Lexington, MA 02421

 

Fax No.: (781) 861-3830

 

Attention: Mark Butler, Esq.

 

 

 

with a copy to:

 

 

Burns and Levinson LLP

 

125 Summer Street

 

Boston, MA 02110

 

Fax No: 617) 345-3299

 

Attention: Josef B. Volman, Esq.

 

 

(b) if to Parent or Merger Sub, to it at: 


 

 

Endo Pharmaceuticals Holdings Inc.

 

100 Endo Boulevard

 

Chadds Ford, PA 19317

 

Fax No.: (610) 558-9864

 

Attention: Caroline B. Manogue, Esq.

 

 

 

with a copy to:

 

 

Skadden, Arps, Slate, Meagher and Flom LLP

 

Four Times Square

 

New York, NY 10036

 

Fax No: (212) 735-2000

 

Attention: Eileen T. Nugent, Esq.

 

 

Section 9.3 Interpretation. When a reference is made in this Agreement to an
Article, Section or Exhibit, such reference shall be to an Article or Section
of, or an Exhibit to, this Agreement unless otherwise indicated. Whenever the
words "include," "includes" or "including" are used in this Agreement, they
shall be deemed to be followed by the words "without limitation." The words
"hereof," "herein" and "hereunder" and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement. All terms defined in this Agreement
shall have the defined meanings when used in any certificate or other
document made or delivered pursuant hereto unless otherwise defined therein.
The definitions contained in this Agreement are applicable to the singular as
well as the plural forms of such terms and to the masculine as well as to the
feminine and neuter genders of such term. Any agreement, instrument or
statute defined or referred to herein or in any agreement or instrument that
is referred to herein means such agreement, instrument or statute as from
time to time amended, modified or supplemented, including (in the case of
agreements or instruments) by waiver or consent and (in the case of statutes)
by succession of comparable successor statutes and references to all
attachments thereto and instruments incorporated therein. References to a
Person are also to its permitted successors and assigns.

 

 

 

 

 

 

 

 

62  

 

 

 

 

 

 

Section 9.4 Counterparts. This Agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties.

 

 

Section 9.5 Entire Agreement; No Third-Party Beneficiaries. This Agreement
and the other Transaction Agreements (including the Confidentiality Agreement
and the documents and instruments referred to herein or therein)
(a) constitutes the entire agreement, and supersedes all prior agreements
and understandings, both written and oral, among the parties with respect to
the subject matter of this Agreement and (b) except for the provisions of
Section 6.7, is not intended to confer, nor shall it confer, upon any Person
other than the parties hereto any rights or remedies or benefits of any
nature whatsoever.

 

 

Section 9.6 Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of
conflict of laws thereof.

 

 

Section 9.7 Assignment. Neither this Agreement nor any of the rights,
interests or obligations under this Agreement shall be assigned, in whole or
in part, by operation of law or otherwise by either of the parties hereto
without the prior written consent of the other party. Any assignment in
violation of the preceding sentence shall be void. Subject to the preceding
two sentences, this Agreement will be binding upon, inure to the benefit of,
and be enforceable by, the parties and their respective successors and
assigns.

 

 

Section 9.8 Consent to Jurisdiction. Each of the parties hereto (a)
consents to submit itself to the personal jurisdiction of any federal court
located in the State of Delaware or any Delaware state court for the purpose
of any action or proceeding arising out of this Agreement or any of the
transactions contemplated by this Agreement, (b) agrees that it will not
attempt to deny or defeat such personal jurisdiction by motion or
other request for leave from any such court, and (c) agrees that it will not
bring any action relating to this Agreement or any of the transactions
contemplated by this Agreement in any court other than a federal court
located in the State of Delaware or a Delaware state court.

 

 

Section 9.9 Headings, etc. The headings and table of contents contained in
this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. The disclosure of any
matter in the Company Disclosure Letter shall expressly not be deemed to
constitute an admission by the Company or Parent, respectively, or to
otherwise imply, that any such matter is material for the purpose of this
Agreement.

 

 

Section 9.10 Severability. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of law or
public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect, insofar as the foregoing can be
accomplished without materially affecting the economic benefits anticipated
by the parties to this Agreement. Upon such determination that any term or
other provision is invalid, illegal or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as
to effect the original intent of the parties as closely as

 

 

 

 

 

 

 

 

 

63  

 

 

 

 

 

 

possible to the fullest extent permitted by applicable Law in an acceptable
manner to the end that the transactions contemplated hereby are fulfilled to
the extent possible.

 

 

 

Section 9.11 Failure or Indulgence Not Waiver; Remedies Cumulative.
No failure or delay on the part of any party hereto in the exercise of any
right hereunder shall impair such right or be construed to be a waiver of,
or acquiescence in, any breach of any representation, warranty or agreement
herein, nor shall any single or partial exercise of any such right preclude
any other or further exercise thereof or of any other right. All rights
and remedies existing under this Agreement are cumulative to, and not
exclusive of, any rights or remedies otherwise available.

 

 

Section 9.12 Waiver of Jury Trial. EACH OF PARENT, MERGER SUB AND THE
COMPANY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE)
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR THE ACTIONS OF PARENT, MERGER SUB OR THE COMPANY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.

 

 

Section 9.13 Specific Performance. The parties agree that irreparable
damage would occur and that the parties would not have any adequate remedy at
law in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the parties shall be entitled to an injunction
or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement in any federal court
located in the State of Delaware or in Delaware state court, this being in
addition to any other remedy to which they are entitled at law or in equity.

 

 

Section 9.14 Certain Definitions.

 

 

(a) "Cleanup" means all actions required to: (1) cleanup, remove, treat or
remediate Hazardous Substances in the indoor or outdoor environment; (2)
prevent the Release of Hazardous Substances so that they do not migrate,
endanger or threaten to endanger public health or welfare or the indoor or
outdoor environment; (3) perform pre-remedial studies and investigations
and post-remedial monitoring and care; or (4) respond to any government
requests for information or documents in any way relating to cleanup,
removal, treatment or remediation or potential cleanup, removal, treatment or
remediation of Hazardous Substances in the indoor or outdoor environment.

 

 

(b) "Company Licensed IP" shall mean all Intellectual Property owned or
controlled by a third Person and licensed to the Company or any
Company Subsidiary.

 

 

(c) "Company Owned IP" shall mean any Intellectual Property in which the
Company or any Company Subsidiary has any ownership interest, whether singly,
jointly or otherwise.

 

 

(d) "Company IP" shall mean the Company Licensed IP and the Company
Owned IP.

 

 

 

 

 

 

 

 

 

64  

 

 

 

 

 

 

 

(e)  "Contingent Cash Consideration Agreements " shall mean, collectively,
the Nebido Contingent Cash Consideration Agreement and the Octreotide
Contingent Cash Consideration Agreement.

 

 

(f) "Contingent Cash Consideration Payments " shall mean, collectively, the
Nebido Contingent Cash Consideration Payments and the Octreotide Contingent
Cash Consideration Payments.

 

 

(g) "Contract" shall mean any written or oral agreement, contract,
subcontract, settlement agreement, lease, sublease, binding understanding,
instrument, note, option, bond, mortgage, indenture, trust document, loan or
credit agreement, purchase order, license, sublicense, insurance
policy, benefit plan or legally binding commitment or undertaking of any
nature, as in effect as of the date hereof or as may hereinafter be
in effect.

 

 

(h) "Core Product" shall mean (1) the Products listed under the heading "OUR
CORE PRODUCTS AND PRODUCT CANDIDATES" in the Company\'s Annual Report on Form
10-K for the fiscal year ended September 30, 2008 and (2) the
Hydron Technology.

 

 

(i) "Environmental Laws" shall mean all federal, state, local or foreign
laws, statutes, regulations, ordinances, decrees, directives, judgments,
common law, or other enforceable requirements of Governmental Entities,
relating to pollution or protection of human health and safety (including
workplace health and safety) or the environment, including, without
limitation, laws relating to Releases or threatened Release of
Hazardous Substances, the protection of human health as a result of exposure
to Hazardous Substances, the storage, transport or disposal of solid and
hazardous waste, discharges of substances to surface water or groundwater,
air emissions, recordkeeping, notification, disclosure and reporting
requirements respecting Hazardous Substances, and all laws relating to
endangered or threatened species of fish, wildlife and plants and
the management or use of natural resources.

 

 

(j) "Environmental Permits" means permits, licenses, approvals, exemptions,
registrations, certificates, identification numbers or other authorizations
issued pursuant to Environmental Law.

 

 

(k) "FIRPTA Certificate" means a certificate executed on behalf of
the Company certifying that the Company is not a United States real property
holding corporation (as defined in section 897(c)(2) of the Code) in the form
and manner that complies with section 1445 of the Code and the Treasury
Regulations promulgated thereunder.

 

 

(l) "Good Clinical Practices" means with respect to the Company, the then
current standards for clinical trials for pharmaceuticals (including all
applicable requirements relating to protection of human subjects), as set
forth in the FDCA and applicable regulations promulgated thereunder
(including, for example, 21 C.F.R. Parts 50, 54, and 56), as amended from
time to time, and such standards of good clinical practice (including all
applicable requirements relating to protection of human subjects) as are
required by other organizations and Governmental Entities in any other
countries, including applicable regulations or guidelines from the
International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, in which the products of the
Company, any Company Subsidiary or any Company Partner are sold or intended
to be sold, to the extent such standards are not less stringent than in the
United States.

 

 

 

 

 

 

 

 

 

65  

 

 

 

 

 

 

 

(m) "Good Laboratory Practices" means with respect to the Company, the then
current standards for pharmaceutical laboratories, as set forth in the FDCA
and applicable regulations and guidances promulgated thereunder, as amended
from time to time, and such standards of good laboratory practices as are
required by other organizations and Governmental Entities in any
other countries, including applicable regulations or guidelines from the
International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use in which the products of the
Company, any Company Subsidiary or any Company Partner are sold or intended
to be sold, to the extent such standards are not less stringent than in the
United States.

 

 

(n) "Good Manufacturing Practices" means (i) with respect to the
Company, the then current standards for the manufacture, processing,
packaging, testing, transportation, handling and holding of drug products, as
set forth in the FDCA and applicable regulations and guidances promulgated
thereunder, as amended from time to time, and such standards of good
manufacturing practices as are required by other organizations and
Governmental Entities in any other countries, including applicable
regulations or guidelines from the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for Human Use in
which the products of the Company, any Company Subsidiary or any Company
Partner are sold or intended to be sold, to the extent such standards are not
less stringent than in the United States.

 

 

(o) "Hazardous Substances" means any chemicals, materials or substances
defined as or included in the definition of "hazardous substances", "hazardous
wastes", "hazardous materials", "hazardous constituents", restricted
hazardous materials", "extremely hazardous substances", "toxic substances",
"contaminants", "pollutants", "toxic pollutants", or words of similar meaning
and regulatory effect under any applicable Environmental Law including,
without limitation, petroleum and asbestos.

 

 

(p) "Hydron Impeding Event" shall mean (1) any change, effect, event,
occurrence, state of facts or development which, individually or in
the aggregate, the effect of which shall be that an approved
prescription pharmaceutical product using the Hydron Technology is
voluntarily or involuntarily recalled from the market due to safety or
efficacy issues relating to the Hydron Technology or (2) any regulatory
occurrence or event that would reasonably be expected to materially and
negatively affect future sales of any Product utilizing the Hydron
Technology.

 

 

(q) "Hydron Technology" shall mean the Company\'s hydrogel implant technology
for subcutaneous drug delivery (currently known as "Hydron"), and any
products incorporating or utilizing such technology.

 

 

(r) "IND" means an investigational new drug application filed with the FDA,
including all documents, data and other information concerning the applicable
drug which are necessary for or filed with such application.

 

 

 

 

 

 

 

 

66  

 

 

 

 

 

 

(s) "Intellectual Property" shall mean trademarks, service marks, trade
names, brand names, certification marks, designs, logos, slogans, commercial
symbols, business name registrations, Internet domain names, trade dress and
other similar indications of source or origin and general intangibles of
like nature, the goodwill associated with the foregoing and registrations
and applications relating to the foregoing in any jurisdiction, including
any extension, modification or renewal of any such registration or
application; industrial designs, inventions, discoveries, ideas and
biological materials, whether patentable or not and whether or not reduced to
practice, in any jurisdiction; patents and patent applications (including
divisions, continuations, continuations-in-part, reissues and renewals,
and applications for any of the foregoing), and any renewals,
extensions, supplementary protection certificates or reissues thereof, in any
jurisdiction; research and development data (including the results of
research into and development of drug or biologic-based products and drug
delivery systems), formulae, know-how, proprietary processes, algorithms,
models and methodologies, technical information, designs, procedures,
laboratory notes, trade secrets and confidential information and rights in
any jurisdiction to limit the use or disclosure thereof by any Person;
writings and other works of authorship of any type (including the content
contained on any Web site), whether copyrightable or not, in any
jurisdiction; computer software (whether in source code or object code form),
databases, compilations and data; copyright registrations and applications in
any jurisdiction, and any renewals or extensions thereof; any other
intellectual property or proprietary rights and the right to sue for past
infringement, misappropriation, or other violation of any of the foregoing.

 

 

(t) "NDA" means a new drug application for a drug filed in accordance with 21
C.F.R. Part 314, and all supplements filed pursuant to the requirements of
the FDA, including all documents, data and other information concerning
the applicable drug which are necessary for FDA approval to market such drug
in the United States.

 

 

(u) "Nebido" means the long-acting intramuscular depot injection of
testosterone undecanoate currently under development for the treatment
of male hypogonadism and that is the subject of the NDA submitted by the
Company to the FDA on August 28, 2007.

 

 

(v) "Nebido Contingent Cash Consideration Payment " means the right to
receive one or more contingent cash consideration payments, subject to the
terms and conditions of a contingent cash consideration payment agreement
(the "Nebido Contingent Cash Consideration Payment Agreement") substantially
in the form attached hereto as Exhibit B.

 

 

(w) "Octreotide" means the octreotide implant currently under development for
the treatment of acromegaly and carcinoid syndrome, which development product
the Company acquired through its acquisition of Valera and which is a soft,
flexible 6-month hydrogel implant based on the patented HYDRON Polymer
Technology that delivers octreotide, a somatostatin analogue.

 

 

(x) "Octreotide Contingent Cash Consideration Payment " means the right to
receive a contingent cash consideration payment, subject to the terms and
conditions of a contingent cash consideration payment agreement (the
"Octreotide Contingent Cash Consideration Payment Agreement") substantially
in the form attached hereto as Exhibit C.

 

 

 

 

 

 

 

 

 

67  

 

 

 

 

 

 

(y) "Per Share Paid Value" shall mean, as of any Valuation Point, the sum of
(1) the per Share cash portion of the Merger Consideration and (2) the amount
per Share in cash previously paid or to be paid at such Valuation Point in
connection with the Contingent Cash Consideration Agreements.

 

 

(z) "Product IP" shall mean Company IP relating to any or all of
the Products.

 

 

(aa) "Products" shall mean all marketed and development products and services
of the Company and the Company Subsidiaries, including drugs and medical
devices and any services related thereto, and any line extensions, expansions
or other modifications thereof, including NEBIDO, Sanctura, Sanctura XR, the
Hydron Technology, VANTAS, Supprelin-LA, VP003 (Octreotide implant), VP004
(Naltrexone implant), VP005 (anti-inflammatory polymer
solution instillation), VP006 (rapid dissolve Desmopressin), Valrubicin
(including the products marketed as VALSTAR and Valtaxin), Delatestryl, PRO
2000, Pagoclone, and any other products and services marketed, sold,
manufactured, developed or distributed, including products and services
manufactured, developed or distributed by Company Partners, or in clinical or
preclinical development, by or for the Company, any Company Subsidiaries or
any Company Partner.

 

 

(bb) "Regulatory Authorizations" means all approvals, clearances,
authorizations, registrations, certifications, licenses and permits granted
by any Regulatory Authority, including all INDs and NDAs.

 

 

(cc) "Release" means any release, spill, emission, discharge, leaking,
pumping, injection, deposit, disposal, dispersal, leaching or migration into
the indoor or outdoor environment (including, without limitation,
ambient air, surface water, groundwater and surface or subsurface strata) or
into or out of any property, including the movement of Hazardous Substances
through or in the air, soil, surface water, groundwater or property.

 

 

(dd) "Representatives" shall mean the officers, directors, employees,
auditors, attorneys, financial advisors, lenders and other agents to each of
Parent and the Company.

 

 

(ee) "Supprelin" shall mean Supprelin-LA.

 

 

(ff)  "Valuation Point" shall mean each of (1) the Effective Time, (2) the
Approval With Label Milestone Date (as defined in the Nebido Contingent Cash
Consideration Agreement), (3) the Approval Without Label Milestone Date (as
defined in the Nebido Contingent Cash Consideration Agreement), (4) the Net
Sales Milestone Date (as defined in the Nebido Contingent Cash Consideration
Agreement) and (5) the Approval Milestone Date (as defined in the Octreotide
Contingent Cash Consideration Agreement).

 

 

(gg) For purposes of this Agreement, the terms "Associate" and "Affiliate"
shall have the same meaning as set forth in Rule 12b-2 promulgated under the
Exchange Act, and the term "Person" shall mean any individual,
corporation, partnership (general or limited), limited liability company,
limited liability partnership, trust, joint venture, joint-stock company,
syndicate, association, entity, unincorporated organization or government or
any political subdivision, agency or instrumentality thereof.

 

 

 

 

 

 

 

 

68  

 

 

 

 

 

 

(hh) For purposes of this Agreement, the phrase "Company Material Adverse
Effect" means (1) any change, effect, event, occurrence, state of facts or
development which individually or in the aggregate (i) results in any change
or effect that is materially adverse to the business, financial condition,
properties, assets, liabilities (contingent or otherwise) or results of
operations of the Company and its Subsidiaries, taken as a whole, or (ii)
prevents or materially impedes, interferes with, hinders or delays the
consummation by the Company of the Merger or the other transactions
contemplated by this Agreement; provided that none of the following shall be
deemed, either alone or in combination, to constitute a Company Material
Adverse Effect: (A) any change relating to the economy or securities markets
in general, (B) any adverse change, effect, event, occurrence, state of facts
or development attributable to conditions affecting the industry in which the
Company participates, including any changes to reimbursement rates related to
any Products, (C) any failure, in and of itself, by the Company to meet any
internal or published projections, forecasts or revenue or earnings
predictions for any period ending on or after the date of this
Agreement (provided, that the underlying causes of such failure may be
considered in determining whether a Company Material Adverse Effect has
occurred), (D) the effect of any change in any applicable Law or GAAP or (E)
any change, effect, event, occurrence, state of facts or development
resulting from any action required pursuant to the terms of this Agreement;
except, in the cases of clauses (A), (B) or (D) above, if such change, effect,
event, occurrence, state of facts or development disproportionately affects
the Company and its Subsidiaries as compared to other participants in the
industry in which the Company participates or (2) the occurrence of a
Hydron Impeding Event; provided, that any changes, effects and occurrences
as a result of either (X) the Company\'s receipt of notice from the FDA
that additional clinical trials with respect to Octreotide will be required
for approval by the FDA of Octreotide or (Y) the publication of the results
of the clinical trial relating to PRO 2000 sponsored by the National
Institutes of Health, shall not individually or in the aggregate, in and
of itself or themselves, constitute a Material Adverse Effect.

 

 

(ii) "Parent Material Adverse Effect" means any change, effect,
event, occurrence, state of facts or development which individually or in
the aggregate prevents or materially impedes, interferes with, hinders or
delays the consummation by Parent of the Merger or the other transactions
contemplated by this Agreement.

 

 

(jj) For purposes of this Agreement, a "Subsidiary" of any Person means
another Person, (i) an amount of the voting securities, other voting rights
or voting partnership interests of which that is sufficient to elect at least
a majority of its board of directors or other governing body is directly or
indirectly owned or controlled by such first Person or by any one or more of
its Subsidiaries, or by such first Person and one or more of its
Subsidiaries (or, if there are no such voting interests, 50% or more of the
equity interests of which is owned directly or indirectly by such first
Person) or (ii) of which such first Person or any other Subsidiary of such
first Person is a general partner (excluding partnerships, the general
partnership interests of which held by such first Person and any Subsidiary
of such first Person do not have a majority of the voting interests in such
partnership).

 

 

(kk) For purposes of this Agreement, the phrases "to the knowledge of the
Company," "known to Company," and similar formulations shall mean the actual
current knowledge, after reasonable investigation, of the people set forth in
Section 9.14(kk) of the Company Disclosure Letter.

 

 

 

 

 

 

 

 

 

69  

 

 

 

 

 

 

 

(ll) For purposes of this Agreement, the phrases "to the knowledge of
Parent", "known to Parent", and similar formulations shall mean the actual
current knowledge, after reasonable investigation, of the people set forth in
Section 9.14(ll) of the Company Disclosure Letter.

 

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

 

 

 

 

 

 

 

 

 

 

70  

 

 

 

 

 

 

 

 

IN WITNESS WHEREOF, Endo Pharmaceuticals Holdings Inc., BTB Purchaser Inc.
and Indevus Pharmaceuticals, Inc. have each caused this Agreement to be
executed as of the date first written above by their respective officers
thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

          |     |  

ENDO  PHARMACEUTICALS HOLDINGS INC.

    |     
---|---|---|--- 
        |     |     |     
        |     |     |     
        |     |     |     
        |     |  

By:

    | /s/  David P. Holveck   |     
        |     |     |  

Name:

    | David  P. Holveck   |     
        |     |     |  

Title

    | President  and Chief Executive Officer   |     
        |     |     |     |     |     
      |   |   |   |   |   
        |     |     |     |     |     
        |     |  

BTB  PURCHASER INC.

    |     
        |     |     |     |     |     
        |     |     |     |     |     
      |   |   |   |   |   
        |     |  

By:

    | /s/  David P. Holveck   |     
        |     |     |  

Name:

    | David  P. Holveck   |     
        |     |     |  

Title:

    | President  and Chief Executive Officer   |     
        |     |     |     |     |     
      |   |   |   |   |   
        |     |     |     |     |     
        |     |  

INDEVUS  PHARMACEUTICALS, INC.

    |     
        |     |     |     |     |     
      |   |   |   |   |   
        |     |     |     |     |     
        |     |  

By:

    | /s/  Glenn L. Cooper   |     
        |     |     |  

Name:

    | Glenn  L. Cooper   |     
        |     |     |  

Title:

    | Chairman  and CEO   |     
   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

EXHIBIT A

 



 



 

CONDITIONS OF THE OFFER

 



 

Notwithstanding any other provisions of the Offer, Merger Sub shall not be
required to, and Parent shall not be required to cause Merger Sub to, accept
for payment or, subject to any applicable rules and regulations of the SEC,
including Rule 14e-1(c) under the Exchange Act, pay for any tendered shares
of Company Common Stock unless:

 



 

       

 

    |  

(i)

    |  

there  shall have been validly tendered and not validly withdrawn prior to
the  expiration date for the Offer (as it may have been extended or re-
extended  pursuant to the Agreement, the "Expiration  Date") that number of
shares of Company Common Stock which, when  added to the shares of Company
Common Stock already owned by Parent and  its Subsidiaries, represents at
least a majority of the total number of  outstanding shares of Company Common
Stock on a "fully diluted basis"  (which assumes conversion or exercise of
all derivative securities  regardless of the conversion or exercise price,
the vesting schedule or  other terms and conditions thereof) on the
Expiration Date (the "Minimum  Tender Condition"),

    
---|---|--- 
   

 



 

       

 

    |  

(ii)

    |  

Any  waiting period (and any extension thereof) applicable to the
consummation  of the Offer under the HSR Act and any other applicable foreign
antitrust,  competition or similar Law shall have expired or been 
terminated;

    
---|---|--- 
   

 



 

       

 

    |  

(iii)

    |  

No  applicable Law and no permanent injunction or other judgment, order or 
decree entered, enacted, promulgated, enforced or issued by any court or 
other Governmental Entity of competent jurisdiction in the United States  or
any material foreign jurisdiction shall be and remain in effect which  has
the effect of prohibiting the consummation of the Offer, the Merger or  the
other transactions contemplated by the  Agreement

    
---|---|--- 
   

 



 

       

 

    |  

(iv)

    |  

There  shall not be existing any temporary restraining order, preliminary 
injunction, pending or threatened any suit, action or proceeding by any 
Governmental Entity which challenges or seeks to enjoin the Offer Closing, 
the Merger or the other transactions contemplated by the  Agreement;

    
---|---|--- 
   

 



 

       

 

    |  

(v)

    |  

(A)  The representations and warranties of the Company contained in the 
Agreement and in any certificate or other writing delivered by the Company 
pursuant thereto that are qualified by materiality or Company Material 
Adverse Effect shall be true and correct in all respects both as of the  date
of the Agreement and as of the Offer Closing Date as though made on  and as
of the Offer Closing Date (except to the extent such  representations and
warranties expressly relate to an earlier date, in  which case such
representations and warranties shall be true and correct  in all respects on
and as of such earlier date) and (B) the  representations and warranties of
the Company in the Agreement and in any  certificate or other writing
delivered by the Company pursuant thereto  that are not so qualified shall be

    
---|---|--- 
   

 

 

 

 

 

 

 

 

 

 

 

1  

 

 

 

 

 

 

 

 

 

       

 

    |  

    |  

true  and correct in all material respects both as of the date of the
Agreement  and as of the Offer Closing Date as though made on and as of the
Offer  Closing Date (except to the extent such representations and
warranties  expressly relate to an earlier date, in which case such
representations  and warranties shall be true and correct in all material
respects on and  as of such earlier date);

    
---|---|--- 
   

 

 

 

       

 

    |  

(vi)

    |  

The  Company shall have performed in all material respects all obligations 
required to be performed by it under the Agreement at or prior to the  Offer
Closing Date;

    
---|---|--- 
   

 



 

       

 

    |  

(vii)

    |  

The  Company shall have delivered to Parent a certificate, signed by the
chief  executive officer and chief financial officer of the Company, to the 
effect that each of the conditions specified in (vi) and (vii) above is 
satisfied;

    
---|---|--- 
   

 



 

       

 

    |  

(viii)

    |  

The  Company shall have delivered a duly executed FIRPTA  Certificate;

    
---|---|--- 
   

 



 

       

 

    |  

(ix)

    |  

There  shall not be pending any suit, action or proceeding by any
Governmental  Entity seeking to prohibit or impose any material limitations
on Parent\'s  ownership of the Company or the operation of all or a material
portion of  Parent\'s or the Company\'s businesses or assets (whether held
directly or  through Subsidiaries), or to compel Parent or the Company or any
of their  respective Subsidiaries to dispose of or hold separate any
material  portion of the business or assets of Parent or the Company (whether
held  directly or through Subsidiaries);

    
---|---|--- 
   

 



 

       

 

    |  

(x)

    |  

Since  the date of the Agreement there shall not have been any occurrence,
event,  change, effect or development that, individually or in the aggregate,
has  had or is reasonably expected to have a Company Material Adverse
Effect;  and

    
---|---|--- 
   

 



 

       

 

    |  

(xi)

    |  

the  Company and Parent shall not have reached an agreement that the Offer
or  the Agreement be terminated, and the Agreement shall not have been 
terminated in accordance with its terms.

    
---|---|--- 
   

 



 

The foregoing conditions shall be in addition to, and not a limitation of,
the rights of Parent and Merger Sub to extend, terminate and/or modify the
Offer pursuant to the terms of the Agreement.

 



 

The foregoing conditions are for the benefit of Parent and Merger Sub, may be
asserted by Parent or Merger Sub regardless of the circumstances giving rise
to any such conditions and may be waived by Parent or Merger Sub in whole or
in part at any time and from time to time in their sole discretion (except
for the Minimum Tender Condition), in each case, subject to the terms of the
Agreement and the applicable rules and regulations of the SEC. The failure by
Parent or Merger Sub at any time to exercise any of the foregoing rights
shall not be deemed a waiver of any such right and each such right shall be
deemed an ongoing right which may be asserted at any time and from time to
time.

 

 

 

 

 

 

 

 

 

 

 

       

2

    
--- 
   

 

       '

